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CHAPTER 1  
INTRODUCTION AND OBJECTIVES 
 
Freeze-drying, also termed “lyophilization”, is a low-temperature drying process employed 
to convert solutions of (heat-)labile materials into solids of sufficient stability for distribution 
and storage [1]. From a laboratory curiosity, freeze-drying has evolved to an industrial 
process in the 1930s, when there was a need to stabilize heat-labile antibiotics and blood 
products at high quantities [2]. During the last half of the twentieth century the freeze-
drying process became a well-established method not only employed to preserve 
biopharmaceuticals [3] but also to stabilize products in the food industry such as coffee, 
herbs and fruits. Nowadays, lyophilization is still the preferred stabilization method for 
biopharmaceuticals since approximately 46% of them are freeze-dried [4]. In the future, to 
overcome the poor solubility and bioavailability of new developed drugs [3], freeze-drying 
offers a promising alternative.  
Despite its wide use within the pharmaceutical industry, freeze-drying formulation and 
process development is still mainly accomplished empirically resulting in sub-optimal 
processes [5]. This is also certainly true for the freeze-drying process development of live 
virus vaccines for which the formulation is designed by trial-and-error [6]. The lack of 
analytical tools allowing the evaluation of live, attenuated viruses during the process is one 
reason for this lack of knowledge [7]. However, since 2004, pharmaceutical industries start 
to move from their traditional way of process development and product manufacturing 
towards a new approach, encouraged by the Food and Drug Administration’s (FDA) Process 
Analytical Technology (PAT) initiative [8]. The principal objective of PAT is a better 
fundamental scientific understanding and control of manufacturing processes. In order to 
achieve these objectives, several new process analytical technologies are now available or 
being developed. Among these PAT tools, process analyzers able to provide multivariate 
information related to biological, chemical and physical attributes of the materials being 
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processed coupled with multivariate data analysis offer new opportunities to increase the 
process understanding, formulation and process optimization, and hence process control. 
In collaboration with an industrial partner, Zoetis (formerly Pfizer Animal Health), this thesis 
examines the possibility to use fast and non-destructive spectroscopic tools (i.e., Raman, 
Near Infrared (NIR) and although being destructive, Fourier Transform Infrared (FTIR)) as 
process analytical techniques for the analysis of freeze-dried veterinary vaccines.  
 
The different objectives of this thesis are listed below: 
 Find out if process analytical techniques can be used to evaluate (and hence 
understand) live, attenuated viruses and their interactions with other compounds 
(i.e., stabilizers), in freeze-dried vaccine formulations;  
 Using process analytical techniques, increase the understanding of virus 
destabilization mechanisms during storage;  
 Develop and validate chemometric models allowing the prediction of the (or some) 
end product quality attributes making some traditional time-consuming off-line end 
product analyses superfluous. 
 
At the beginning of the thesis, both Raman and NIR spectroscopy were evaluated but 
systematically, the Raman spectra were not interpretable due to fluorescent interferences in 
the samples under investigation. Therefore, it was decided to mainly focus on NIR 
spectroscopy. Fourier Transform Infrared (FTIR) spectroscopy was also evaluated. Despite its 
longer analysis time and the need for sample preparation prior to measurement, FTIR 
spectroscopy offered advantages compared to NIR spectroscopy, mainly its more detailed 
level of spectral information (useful to study virus destabilization mechanisms or 
interactions with other formulation components e.g., during storage). 
The objectives of this thesis were elaborated in several chapters. In chapter 2, an overview 
of the freeze-drying process and used processing equipment is provided.  Chapter 3 reviews 
the current knowledge on the freeze-drying process of live, attenuated virus vaccines. The 
different stresses that viruses may encounter during the different freeze-drying process 
steps as well as the different formulation and processing strategies applied to withstand 
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these stresses are presented.  Chapter 4 summarizes the concept of PAT and discusses the 
process analytical tools used in this thesis. 
Chapters 5 to 9 present and discuss the experimental work performed for this PhD thesis. In 
chapter 5, the possibility to use NIR spectroscopy for the distinction between different 
freeze-dried live, attenuated virus formulations is evaluated. NIR spectra of freeze-dried 
samples prepared using different virus medium volumes or using different pre-freeze-drying 
virus treatments are collected and analyzed using principal component analysis (PCA). The 
possibility to classify new samples according to their pre-freeze-drying virus treatment using 
partial least squares discriminant analysis (PLSDA) is further assessed. Based on the same 
approach, chapter 6 evaluates the possibility to distinguish between freeze-dried samples 
varying in virus medium volume, pre-freeze-drying virus treatment or virus dose using FTIR 
spectroscopy. Three amide spectral regions are evaluated using PCA.  
By coupling both, process analytical spectroscopic techniques (NIR and FTIR spectroscopy) 
and traditional tools employed to evaluate freeze-dried vials, chapter 7 is dedicated to the 
study of a freeze-dried live, attenuated virus vaccine during an accelerated stability study. 
Freeze-dried samples stored during four weeks either at 4°C or at 37°C have been weekly 
analyzed by NIR and FTIR spectroscopy as well as potency assay, Karl Fischer and modulated 
differential scanning calorimetry (MDSC) and allow to better understand the virus 
destabilization mechanism upon storage. Chapters 8 and 9 aim at developing practical 
applications of NIR spectroscopy for the analysis of freeze-dried live, attenuated viruses in 
vaccine formulations. In chapter 8, a model able to classify freeze-dried samples according 
to their dose content is developed and validated using off-line collected NIR spectra. A soft 
independent modelling of class analogy (SIMCA) model is first built. Afterwards, using the 
developed model, new observations can be classified with a correct classification rate (CCR) 
above 95%. The model is further validated according to the European Medicines Agency 
(EMA) guideline. As second application (chapter 9), the possibility to predict the titer of new 
freeze-dried vials from off-line collected NIR spectra is evaluated.  
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CHAPTER 2 
FREEZE-DRYING AS PHARMACEUTICAL 
DRYING PROCESS 
 
2.1. THE CONCEPT OF FREEZE-DRYING 
Freeze-drying or lyophilization is defined as a low-temperature drying process, based on the 
principles of heat and mass transfer, employed to improve the stability and long-term 
storage of (heat-)labile drugs [1]. Although being a complex, costly, energy and time-
consuming (from 3-4 up to 7-10 days) multi-step process during which the starting material 
(solution) undergoes several transformations to yield the end product (dry cake), freeze-
drying has established itself as an important drying method in the (bio-)pharmaceutical 
industry. Accepted by the regulatory authorities as a suitable unit operation in the 
manufacture of therapeutic products [2], freeze-drying also offers several advantages over 
other drying techniques as: water is removed without excessive heating, the product sterility 
can be maintained during processing, the resulting porous cake has an extended shelf life 
and can be fast, easily reconstituted and handled (shipping and storage) [1, 3, 4].  
Freeze-drying starts by freezing the product. Afterwards, the solvent is removed first by 
sublimation of ice (primary drying) and then by desorption of unfrozen water (secondary 
drying). This very basic description of the lyophilization process hides a multitude of complex 
and interacting physical and chemical phenomena related to the formulation and the heat 
and mass transfers occurring during the process [2]. Formulation and process are 
interrelated: “A bad formulation can be nearly impossible to freeze-dry, and even with a well 
designed formulation, a poorly designed process may require more than a week to produce 
material of suboptimal quality” [1].  
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2.2. FREEZE-DRYING EQUIPMENT AND PROCESS 
A schematic diagram showing the main components of a freeze-dryer used for (bio-) 
pharmaceuticals is shown in Figure 2.1. The chamber contains temperature-controlled 
(coolable or heatable) shelves through which a heat transfer fluid is circulated. Hydraulically 
movable, the shelves can be compressed in order to fully insert the stoppers into the 
hexagonally packed vials at the end of the process (prior to aeration). The chamber is 
connected to the condenser via a valve. The condenser contains series of coils cooled down 
by a compressor, in order to collect the sublimed water. A vacuum pump is connected to the 
condenser in order to evacuate the system and provide the necessary pressures for 
conducting the primary and secondary drying steps [5].  
 
 
Figure 2.1: Schematic diagram of a typical freeze-dryer. 
 
A freeze-drying cycle consists in three main stages: freezing, primary drying and secondary 
drying. Three process settings can be varied (being the shelf temperature, the chamber 
pressure and the time) in a dynamic way in order to obtain a freeze-dried product. During 
the freezing stage, the shelf temperature is decreased (usually between -40°C to -50°C) in 
order to convert most of the water into ice. The conversion of liquid water into ice 
concentrates all solutes into regions between ice crystals. The solutes become more 
concentrated (i.e., freeze concentration) until they crystallize at the eutectic temperature 
Vacuum 
pump
Front 
door
Chamber
Condenser
Compressor Compressor
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(Teu) or until the viscosity sufficiently increases to transform into an amorphous system or 
glass [1]. The associated temperature with the latter phenomenon is the glass transition 
temperature Tg' of the maximally freeze-concentrated solution. In some cases, an annealing 
step is included in the freezing stage to overcome the freezing heterogeneity within a batch 
and to maximize crystallization of the bulking agent during freezing. The annealing 
temperature should be between the Tg’ of amorphous phase and Teu of bulking agent to 
give a high crystallization rate and complete crystallization. The optimum annealing time 
depends on the ratio and properties of the bulking agent used [3]. 
When the freezing stage is complete, the freeze-drying chamber pressure is decreased 
below the vapor pressure of ice at the temperature of the product and the shelf 
temperature is increased in order to provide the energy for ice to sublime. This is the 
primary drying step [5]. In order to avoid product collapse and maintain an elegant cake 
structure, the product temperature at the sublimation front must be kept at a temperature 
2-5°C below the product collapse temperature (Tc), which is generally a few degrees higher 
than Tg' [3,6,7]. The collapse temperature is the temperature above which the freeze-dried 
product loses macroscopic structure and collapse during freeze-drying [8]. Maintaining the 
temperature below Tg' makes the primary drying phase long (typically > 24 hours) and 
expensive but is necessary since any cake collapse may result in an inelegant cake (which is 
inacceptable from a commercial point of view), higher residual moisture content and 
prolonged reconstitution time. At the end of primary drying, there should be no more ice 
present in the vial and therefore, no more sublimation. Nevertheless, the amorphous 
product still contains some dissolved moisture (5-20%) which needs to be removed to values 
(usually less than 1-2%) allowing optimal product stability during distribution and storage. 
The objective of secondary drying is to further decrease the moisture by increasing the shelf 
temperature in order to facilitate the desorption. The product temperature increase from 
primary drying to secondary drying should be slow (and is in many cases performed 
gradually) preventing the product temperature exceeding the glass transition temperature 
(Tg) of the product, hence avoiding product collapse. As the water content of the amorphous 
phase decreases during secondary drying, the glass transition temperature sharply increases. 
Therefore, the secondary drying step is usually started at a low shelf temperature followed 
by a gradual increase to the final secondary drying shelf temperature [1]. At the end of 
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secondary drying, the water content must be low enough making sure that the glass 
transition temperature (Tg) is well above (approx. >30°C) the highest temperature relevant 
for product storage and distribution. The determination of the optimal end product residual 
moisture is performed empirically and is product dependent [1]. 
Figure 2.2 visualizes how the freeze-drying conditions are generally set. During most freeze-
drying processes, the process settings (e.g., shelf temperature, chamber pressure and time) 
are rather fixed during each process phase (e.g., constant shelf temperature during primary 
drying, see Figure 2.2).  
 
 
Figure 2.2: Example of traditional temperature and pressure settings of a freeze-drying process 
 
To increase process efficiency, product temperature during primary drying should be as high 
as possible without inducing collapse. Therefore, the process settings, shelf temperature and 
chamber pressure, should not be chosen too conservative. During the sublimation phase, 
the thickness of the dried product layer increases which simultaneously leads to an increase 
of the dried product mass transfer resistance and product temperature at the sublimation 
interface. Therefore, the process conditions of an optimal freeze-drying cycle should be 
modified as primary drying proceeds [9]. Mechanistic modelling, describing the energy and 
mass transfer during freeze-drying leading to a dried product, can be used to determine the 
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optimal combination of shelf temperature and chamber pressure in order to keep the 
product temperature at the sublimation front below the critical temperature during primary 
drying. Based on mechanistic modelling, the evolution of the optimal chamber pressure and 
shelf temperature shows a different profile during primary drying compared to a traditional 
freeze-drying cycle and is presented in Figure 2.3. The high shelf temperature is calculated 
by the model in order to provide energy for sublimation while keeping the product 
temperature at the sublimation interface below the critical temperature. As the dry layer 
thickness increases with the progression of primary drying, the shelf temperature is 
decreased and adapted accordingly. 
 
 
Figure 2.3: Example of temperature and pressure settings based on mechanistic modelling of the 
primary drying step of a freeze-drying process.  
 
Some years ago, a SMART freeze-drying system was developed [10]. Depending on the input 
parameters (physical and chemical product properties, vial properties, etc.) for the material 
to be freeze-dried, the SMART system produces an optimized recipe for freeze-drying. 
Furthermore, during primary drying the recipe is adjusted in real-time for shelf temperature 
and chamber pressure based on water vapor content measurements in the freeze-dryer 
chamber, hence guaranteeing the required product temperature and optimizing the drying 
step efficiency. However, the SMART system does not allow to control the annealing process 
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during the freezing step, the product solid state, the dehydration during secondary drying 
and the residual moisture content.   
Therefore, continuous in-line information of the product itself is needed. Critical product 
information can be continuously monitored using process analyzers (e.g., Raman or NIR 
spectroscopy) [11-15]. In order to ensure that the process settings are adjusted based on the 
real-time product behaviour, control algorithms need to be developed (if it is proven that 
these product characteristics can be linked to the process settings), thereby leading to a fully 
automatic controlled process based on advanced in-line monitored critical process and 
formulation information.  
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ABSTRACT 
Freeze-drying is the preferred method for stabilizing live, attenuated virus vaccines. After 
decades of research on several aspects of the process like the stabilization and 
destabilization mechanisms of the live, attenuated viruses during freeze-drying, the optimal 
formulation components and process settings are still matter of research. The molecular 
complexity of live, attenuated viruses, the multiple destabilization pathways and the lack of 
analytical techniques allowing the measurement of physicochemical changes in the antigen’s 
structure during and after freeze-drying mean that they form a particular lyophilization 
challenge. The purpose of this chapter is to overview the available information on the 
development of the freeze-drying process of live, attenuated virus vaccines, herewith 
focusing on the freezing and drying stresses the viruses can undergo during processing as 
well as on the mechanisms and strategies (formulation and process) that are used to 
stabilize them during freeze-drying. 
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CHAPTER 3 
FREEZE-DRYING OF LIVE VIRUS VACCINES: A 
REVIEW 
 
3.1. INTRODUCTION 
Since its discovery over 200 years ago by Edward Jenner, vaccination can be considered as 
one of the major steps in the fight against infectious diseases. Vaccination aims at 
controlling and ultimately eliminating infectious agents. The latter objective was obtained 
for smallpox, which was in 1980 certified as eradicated by the World Health Assembly [1]. 
Today, vaccines are estimated to avert approximately 2.5 million deaths from diphtheria, 
tetanus, pertussis (whooping cough), and measles every year and in all age groups. However, 
millions of people still die from vaccine preventable diseases [2]. This unfortunate finding 
can directly be linked to the difficulty to distribute vaccines in poorly-served remote rural 
areas, fragile states and strife-torn regions [3], but also to the often weak thermostability of 
vaccines [4]. Increasing the stability of vaccines has been at the forefront for decades. 
Vaccine development scientists aim to provide products preserving adequate quality 
(potency, titer, activity, and immunogenicity) during storage and after accidental exposure 
to exceptional conditions, until the vaccines are administered [5]. 
There are several factors (temperature, pH, suspension medium, exposure to light, freezing, 
thawing, anti-microbials and inactivating agents) influencing the stability of vaccines. 
However, the most important factor is the antigen itself as its antigenicity and infectivity are 
affected differently depending on the antigen’s intrinsic stability [5]. According to the U.S. 
National Institute of Allergy and Infectious Diseases (NIAD), there are seven different types 
of vaccines, based on their antigen type: live, attenuated vaccines, inactivated vaccines, 
subunit vaccines, toxoid vaccines, conjugate vaccines, DNA vaccines and recombinant vector 
vaccines [6].  
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Live, attenuated vaccines generate both humoral (antibody) and cellular immune responses 
and are the most successful of all human vaccines because they are able to confer long-term 
immunity after one or two immunizations [7].  The antigens of such vaccines are bacteria 
(tuberculosis (BCG), typhoid) or most often viruses (measles, mumps, rubella, polio, yellow 
fever, varicella and rotavirus) [8]. Live, attenuated virus vaccines consist of viruses that have 
lost their virulence but that are still able to confer a protective immunity against a virulent 
virus. Compared to inactivated vaccines, live, attenuated viruses are easier to produce, do 
not require the use of adjuvants in the formulation and only need minimal downstream 
processing [9].  
The production process of virus vaccines is very complex because it uses living cells that 
make standardization difficult [9]. Live, attenuated vaccines also form a formulation 
challenge because of the macromolecular complexity of viruses and bacteria. Viruses can be 
enveloped or non-enveloped, and have a size ranging (diameter) from 30 (poliovirus) to 
300nm (vaccinia (smallpox) virus) [7]. 
Protected in an adequate cryoprotection medium (e.g., buffer to avoid pH changes, non 
reducing sugars as cryoprotectants, non ionic surfactants to avoid adsorption and 
aggregation), most viruses are stable below -60°C. Other viruses are stable at higher 
temperatures but a temperature above 8°C is always harmful for any virus [5]. To maintain 
the vaccine temperature between safe margins, from the manufacturing location to the 
vaccine administration (patient), a cold chain is required.  
The cold chain concept is applicable in several industrial fields (e.g., food and pharmaceutical 
industry) which require to maintain temperature-sensitive products at a protective 
temperature during processing, storage and distribution. The first significant efforts to 
ensure a continuous cold chain in the pharmaceutical field were deployed at the beginning 
of the 1980s with the development of insulated packages, temperature recorders and the 
improvement in training of the various parties involved in the distribution system [10]. 
Despite these numerous improvements, keeping the temperature between 2 and 8°C (the 
temperatures specified by the World Health Organization (WHO), the FDA and other 
governmental agencies in order to ensure an optimal quality of the vaccines) is not always 
feasible, even in industrialized countries: breakage of the cold chain due to handling errors 
occurs frequently [11-14] as well as equipment power failures [10, 15]. However, 
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maintaining a well-controlled cold chain is of major importance since a disturbance in it can 
lead to a decrease of the vaccine’s therapeutic efficiency. In addition to the presented risks 
of disturbances, certain vaccines can’t be delivered via the cold chain system as the 
requirements in term of minimal acceptable temperature are not met. This is the case for 
the oral vaccines against poliomyelitis [16] and the smallpox vaccine in dry form [17], which 
require a storage at -20°C. Therefore, reducing the dependency on the cold chain of the 
products would be very useful [18]. 
The limited stability of viruses in aqueous media above 8°C is well known [5]. This instability 
results from several types of water-mediated destabilization and degradation pathways. 
Therefore, as is the case for proteins [19], the removal of the bulk water (to 1-2% total 
weight) can significantly increase the stability of viruses by inhibiting or sufficiently 
decelerating the degradation and destabilization pathways that can occur in aqueous media 
[7, 8, 9]. Except the oral polio vaccine (OPV), which is a stable vaccine in aqueous 
formulation [20], all live, attenuated viral vaccines are freeze-dried [4, 21].  
Freeze-drying offers many advantages over other drying processes: the low temperatures 
used during this process allow avoiding high destabilizing drying temperatures, the shelf life 
of the freeze-dried product is significantly enhanced, the dried product (cake) can be easily 
reconstituted and the aseptic processing operation meets the finished product sterility 
requirements without the stress of a terminal sterilization step.  
Despite the numerous studies performed, the destabilization mechanisms as well as the 
protection mechanisms for live, attenuated virus vaccines during lyophilization are not well 
known. This is attributed to the already mentioned complex structure of viruses, the 
multiple degradation routes and the lack of analytical techniques allowing the measurement 
of physicochemical changes in the antigen’s structure during and after freeze-drying. 
Because the destabilization pathways always result in a loss of bioactivity, potency assays 
are typically used during formulation development [22]. Unfortunately, such assays are 
characterized by weak accuracy and precision [23], and don’t provide direct information to 
elucidate the mechanisms of destabilization and inactivation.  
This chapter focuses on the freeze-drying of live, attenuated virus vaccines. The purpose is to 
review the available information on the development of the freeze-drying process of live, 
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attenuated virus vaccines, herewith focusing on the stresses the viruses undergo during 
processing as well as on the mechanisms and strategies (process and formulation) to 
stabilize them during freeze-drying. 
 
3.2. LIVE, ATTENUATED VACCINE STRESS AND STABILIZATION 
MECHANISMS DURING FREEZE-DRYING 
To provide solutions for improving the stability of freeze-dried live, attenuated vaccines, 
understanding of the mechanisms of degradation and destabilization during freeze-drying is 
needed. A huge amount of information is available on the stress mechanisms and 
stabilization strategies of pharmaceutical peptides, proteins and DNA during freeze-drying 
[24-29]. This contrasts to the lack of detailed knowledge on viral-based vaccines. During the 
past decades, reported improvements of the freeze-drying of live, attenuated virus vaccines 
(formulation and process) have resulted mainly from empirical discoveries rather than from 
rational approaches [7]. This chapter aims at providing an overview of the available 
information.  
Firstly, the stresses that can occur during the freezing as well as the drying steps and the 
strategies that are used to avoid these stresses will be described.  
Afterwards, this chapter will focus in more detail on the formulation and more precisely, on 
the most often used buffers and stabilizers. Finally, the process development strategy will 
shortly be discussed. 
 
3.2.1. Virus structure 
Most live, attenuated viruses possess a lipid bilayer which is considered as the less stable 
virus component because of its high fragility. The enveloped viruses also have glycosylated 
or non glycosylated proteins that are essential to infect their host and must be protected 
[30]. Finally, the viral genome consists either of RNA or DNA and is considered as more 
stable, but is still subject to both physical and chemical stresses. Considering only this 
simplified structural description, loss of potency during freeze-drying can be due to protein 
destabilization (e.g., unfolding, degradation, aggregation), nucleic acid degradation, lipid 
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layer alteration (e.g., phase transition, mechanical damage) and stresses related to changes 
in the internal (ice formation, osmolarity change) and external (pH and osmolarity change) 
virus environment. A schematic overview of the virus and the factors possibly affecting its 
potency is presented in Figure 3.1. 
 
 
Figure 3.1: Schematic overview of the virus and the factors possibly affecting its potency. 
 
3.2.2. Freezing and associated stresses 
During the freezing step, the liquid formulation to be freeze-dried is cooled until ice 
nucleation starts, which is followed by ice crystal growth. Many biological structures and bio 
reactions are temperature dependent. Consequently, cooling creates conditions deviating 
from the normal physiological conditions [31] that might have detrimental effects on the 
viruses. Freezing can damage the individual virus components (viral coated proteins, viral 
lipid membrane), change the formulation buffer and osmolarity, all impacting the virus 
stability. Finally, based on cells cryopreservation knowledge, freezing could also cause intra-
virus ice formation. The following paragraphs overviews these possible stresses. 
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3.2.2.1. Intra-virus ice formation  
Compared with viruses, the impact of freezing on cells has been more widely studied [31, 
32]. Freezing might damage cells for several reasons (e.g., solution effects, extracellular ice 
formation, and dehydration), but intracellular ice formation is the most important one [31-
33]. Ice formation inside the cells increases the intracellular concentration of electrolytes 
which in turn affects ionic interactions that can be involved in the stabilization of the native 
state of intracellular enzymes [31, 32]. Intracellular ice formation occurs when the cell 
cannot maintain its osmotic equilibrium with the environment, typically at high cooling rate 
[34]. At low cooling rate, providing water can leave the cells rapidly to maintain 
thermodynamic equilibrium across the cell membrane, the cytoplasm will not cool below its 
freezing point [34]. The effect of the cooling rate on cells is well illustrated in [32]. 
In addition, the interaction of water and ice with the hydrophilic surfaces of intracellular 
enzymes is different. This is potentially important because the surface tension of water is 
involved in maintaining the enzymes native state (=hydrophobic effect). If this water is 
replaced by ice, the stabilizing interaction via the hydrophobic effect can be lost [31]. 
Intracellular ice crystals can also directly cause mechanical damages to the cellular ultra-
structure or the cells can also be affected by the volumetric expansion induced by ice 
formation [31].  
Hence, it can be expected that ice formation within the live, attenuated virus might also 
result in significant loss of potency for similar reasons under fast cooling. To our best 
knowledge, there are no publications describing intra-virus ice formation or the 
consequences of intra-virus ice formation.  
3.2.2.2. Changes in osmolarity 
Changes in ionic strength as well as in uncharged molecule concentration must be carefully 
evaluated, especially for vaccines containing antigens with semipermeable membranes like 
enveloped viruses because of the potential osmotic effects (contraction or swelling) [35]. 
Marek’s disease vaccine can be dramatically affected by the osmolarity. Values of 
745mOsm/kg and higher have been proven to markedly reduce the virus survival [36].  
The vaccine integrity can be affected by osmotic changes. When grown in culture medium at 
specific ionic strengths, the virus must reequilibrate when introduced in solutions of 
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different ionic strengths (e.g. during formulation). This results in osmotic swelling or 
contraction hence potentially damaging the virus.  
When herpes simplex viruses are in a low osmotic pressure (50 mOsm/kg) medium, a 
dramatic potency decrease (only 26% recovery) is observed, whereas a high osmotic 
pressure (840 mOsm/kg) medium gives a recovery of 80-92% [37]. The reason for this is that 
in a hyper-osmotic medium, the internal water of the virus escapes and the protein 
concentration in the tegument (that anchors the lipid membrane and the capsid) increases. 
This lowers the nucleation temperature inside the virus membrane and prevents ice crystals 
formation and growth [37].  
Both reported cases were not observed under freezing conditions. However, the freezing 
step implies the conversion of water into ice and hence might affect the ionic strength of the 
formulation. Such change could impact the virus integrity but it has, to our best knowledge, 
never been demonstrated.  
3.2.2.3. Effect of the freezing step on pH  
During freezing, pH shifts by crystallization of buffer components can occur [38]. This 
possibility must be properly investigated as both chemical and physical degradations are 
strongly pH dependent [35]. 
Brandau and coworkers illustrated the importance of pH on virus activity for several live, 
attenuated vaccines [35]. The storage stability of the cold-adapted influenza virus liquid is 
dependent on the pH. At pH 7.1 the formulation retained its titer for 1 month upon storage 
at 4°C, whereas the same formulation stored at higher or lower pHs showed a significant 
titer decrease [39]. A pH change can affect viruses by activating or inhibiting certain enzymes 
(e.g., viral RNA polymerase) and/or by affecting the overall charge of the coated proteins 
leading to conformational changes of these proteins. The viral RNA polymerase of the live, 
attenuated oral polio vaccine (OPV) degrades RNA upon storage. However, keeping the 
formulation at a pH near 5-6 results in a lower enzyme activity [40].  The secondary and 
tertiary structure of the glycoprotein haemagglutinin (HA) of the influenza subunit virus has 
been shown to be sensitive to pH drops during freezing [41]. In the study, the magnitude of 
pH change of a phosphate-buffered solution (PBS) and a Hepes-buffered solution (HBS) was 
compared and the effects on the glycoproteins were evaluated.  The pH change was higher 
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when using PBS (because of the higher tendency of PBS to crystallize) and led to HA 
structural changes. The reversibility of HA changes upon acidification and subsequent 
neutralization is however an indication that structural change isn’t caused by pH change 
(alone) [42, 43] (see next paragraph). 
Measles viruses are more stable at neutral pH. In an acidic environment, the physical 
stability of this virus is highly compromised. Light scattering and circular dichroism (CD) 
spectroscopy have shown evidence of aggregation at low temperature and precipitation in 
acidic environments [44].  
Numerous studies have revealed that the optimal pH range to limit the loss of activity is 
generally between 6 and 8 [7, 45, 46] which is a convenient result regarding the needs for 
parenteral preparations which require a pH close to the physiological pH and confirms the 
conclusion by Peetermans that most viruses are affected by pH values outside the 
physiological limits [5]. In most cases, the glycoproteins are affected by a pH shift. Changes 
in their conformation can be reversible but can also lead to aggregation and precipitation of 
the viral particles. It is therefore highly recommended to examine with care the impact of pH 
changes and to select an appropriate buffer system.  
3.2.2.4. Effects of the freezing step on the viral coated proteins  
The necessity to protect viral coated proteins during freeze-drying was already understood 
in 1968 in a study evaluating the stability of suspensions of influenza viruses dried to 
different residual moisture contents [47]. One year later, it was claimed that the surfaces of 
virus particles, containing coated proteins, were the first exposed to the phasic changes 
during freezing [48].  The kinds of changes occurring to the viral proteins during freezing, 
freeze-drying and long term storage are determinant for the activity of the re-hydrated virus 
particles [48].  
Today, it is well known that proteins, in general, are subjected to different freezing stresses 
[49, 50] during a freeze-drying process. There are three main stress factors: cold 
denaturation, ice formation and freeze concentration [50].  
Change in osmolarity, pH and solute concentration have already been described in the 
previous paragraphs and are caused by the same stress factor, freeze concentration [24, 25]. 
This stress factor (freeze concentration) can also lead to liquid-liquid phase separation [50, 
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51] between incompatible excipients within the freeze concentrate and could negatively 
influence the preservation of virus by separating the virus from at least one of the protective 
excipients [50].  
A second important stress factor is the formation of large ice-water interfaces due to ice 
crystallization that can promote surface-induced denaturation of surface-sensitive proteins 
[28]. High cooling rates result in small ice crystals and large ice-water interface [28]. Even if 
large ice-water interface has already been demonstrated to result in protein structure 
change and protein aggregation [24, 52], such a destabilization mechanism has, to the best 
of our knowledge, never been demonstrated for viruses. The mechanism of protein 
denaturation at the ice surface is still under discussion [50]. 
Finally, cold denaturation has been reported for a large number of proteins. This mechanism 
states that the protein’s free energy of unfolding becomes negative at low temperature and 
may induce spontaneous unfolding of the protein [49]. However the contribution of this 
stress is frequently considered as negligible in lyophilization because the estimated cold 
denaturation temperatures are far below the lyophilization temperature especially in the 
presence of saccharides and polyols [50]. 
The freezing stresses inducing (possibly irreversible) protein conformation changes have 
been demonstrated in many case-studies performed on different model proteins [25, 49, 53, 
54]. In contrast, only a few studies provide information on the influence of freezing-stress 
upon viral proteins [41, 55]. 
For herpes simplex viruses, a lipid-enveloped virus, immunogold labeling experiments have 
shown that the structural integrity of membrane glycoproteins can be lost during freezing 
[55]. 
But the most studied virus glycoprotein is the influenza haemagglutinin (HA). This protein 
can be found at the surface of several live, attenuated virus vaccines, but can also be used as 
antigen in the influenza subunit vaccine [41] as well as in influenza virosomes [56]. The 
secondary and tertiary structures of this viral protein are susceptible to freezing stresses 
[41]. Demonstrated by a proteolitic assay, the HA conformation might change because of pH 
change (acid-induced conformation change), but HA structural changes (exposed trypsin 
cleavage site) can also be observed despite moderate pH shift [41] and can be caused by a 
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change of the ionic strength resulting from an increase in solute concentration in the non-
frozen fraction, recognized as a protein destabilization factor [28].  
Fluorescence and CD-spectroscopy of HA after freeze-thawing experiments also confirm that 
HA conformational changes after freezing are not only caused by a pH shift, but also by 
freezing-related stress [41]. Finally, haemagglutinin conformation change upon acidification 
was found to be reversible after subsequent neutralization [42, 43]. 
3.2.2.5. Effect of the freezing step on the lipid membrane 
The lipid membrane is very fragile and an important consideration since the loss of the viral 
lipid layer automatically results in viral inactivation [57]. 
Liposomes are considered as model for cell membranes and are extensively studied to 
understand the effects of lyophilization on the stability of the cell membrane. During the 
freezing step, the lipid layer must mainly be protected against ice crystal damage [58], fusion 
and thermotropic phase transitions [59].  
More than fifty years ago, Greiff and co-workers observed a titer decrease of influenza A 
virus during freeze-thawing experiments [60]. According to the authors, the titer decrease 
was due to mechanical injuries caused by small ice crystals during freezing [60]. The first 
freeze-thawing cycles caused a relatively limited titer loss, but after the fifth freeze-thawing 
cycle a marked loss in infectivity titer was observed. These observations were linked to the 
ice crystal size. Large ice crystals and therefore large interstices (safety zones for the viruses) 
caused limited damage, whereas the formation of more but smaller ice crystals resulted in 
more mechanical injury and caused substantial titer decrease. 
Conversely, in 2010, Chen and co-workers in their review about liposome lyophilization 
affirm that fast freezing results in smaller ice crystals which induce little damage to lipid 
bilayers [58]. In contrast, slow freezing generates bigger ice crystals which are detrimental to 
the membrane integrity. Other studies confirm the importance to avoid too large ice crystals 
[61, 62].  
However, aiming for the smallest ice crystals can also lead to virus destabilization. Zhai and 
co-workers compared the effect of three different cooling rates on the retention of the viral 
infectivity after freeze-drying of a herpes simplex virus [37]. The fastest cooled samples 
(cooled in melting propane) surprisingly generated the highest virus loss. This loss was 
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explained by recrystallization of the small ice crystals occurring when the rapidly frozen 
samples were warmed to a temperature at which lyophilization was practical. Ice 
recrystallization disrupted the virus, hence resulting in more loss of viral infectivity.  
Although there are only a few studies available, it can be concluded that mechanical 
damages caused by ice crystals leading to viral inactivation can occur. Demonstration of the 
mechanism of action is lacking, but mechanical degradation is the most often proposed 
mechanism.  
The mechanism of two other effects (fusion and thermotropic phase transitions) during the 
freezing step is less extensively explained in literature. Both results in an increase of 
membrane permeability, hence water-soluble molecules that were internally isolated are 
often leaked to the external medium. Furthermore, thermotropic phase transitions can lead 
to lateral phase separations of phospholipids and other constituents such as membrane 
proteins [59]. 
 
3.2.3. Formulation and process strategies to protect live, attenuated 
viruses during freezing 
This section overviews the strategies described in literature to protect live, attenuated 
viruses from the freezing stresses and their consequences discussed above (intra-virus ice 
formation, change in osmolarity, pH changes, glycoprotein structural changes, lipid 
membrane mechanical damages and fusion). To avoid these stresses, two protective actions 
are systematically taken: the use of cryoprotectants and an appropriate cooling rate. The 
effects of both parameters, especially the cooling rate, must be carefully studied as it might 
have a positive influence against a determined stress (e.g., a high cooling rate results in small 
ice crystals that are less detrimental to the membrane [58]) combined with a negative effect 
on another stress (ice recrystallization of the small ice crystals upon drying [37], larger ice-
water interface leading to a larger extent of surface-induced denaturation of surface-
sensitive proteins [28] or intra virus ice formation [34]). 
Selecting a good cryoprotectant is also very important since this formulation component can 
protect live, attenuated viruses against: coated protein structural changes,  
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fusion/aggregation, membrane damages caused by ice crystals, intracellular ice formation 
and pH shift. However, it should be emphasized that a good cryoprotectant does not 
necessarily act as a good lyoprotectant. Polyethylene glycol (PEG) is an excellent lactate 
dehydrogenase and phosphofructokinase protectant during freeze-thawing experiments, 
however, PEG failed to protect both proteins during freeze-drying unless associated with a 
supplemental stabilizer (i.e., glucose or trehalose) [63].  
Sugars have been demonstrated to protect the HA glycoproteins against changes in 
secondary and tertiary structure caused by freezing [41]. Currently, in literature, two 
mechanisms are proposed to explain the stabilization of proteins: thermodynamic and 
kinetic [49]. 
The thermodynamic mechanism is related to the ability of the cryoprotectant to 
thermodynamically shift the equilibrium from the unstable, unfolded conformation toward a 
stable, native state [49]. The solute exclusion hypothesis is the most widely supported 
thermodynamic mechanism [49]. It suggests that during freeze concentration, the stabilizer 
is preferentially excluded from the surface of the protein, i.e., the vicinity of the protein 
contains a higher amount of water molecules that thermodynamically stabilize the native 
state of the protein. However, the validity of this solute exclusion hypothesis is questioned 
[29] in particular because of the low mobility in the glassy state. Thermodynamic 
stabilization requires a rapid equilibrium between native and unfolded states which isn’t 
possible in the glassy state or even close to the glass transition temperature of the 
maximally freeze concentrate (Tg’) [49]. 
The kinetic mechanism is rather related to the ability of the cryoprotectant to slow down the 
rate of inactivation. The vitrification hypothesis is the most widely invoked. During freezing, 
the solutes concentrate until the freeze-concentrate reaches a maximum and forms a glass 
at Tg’, specific for each formulation.  
The exact stabilization mechanism of protein is still under investigation and a subject of 
research.  
In addition to the protection of the coated proteins, other virus structures must be 
preserved during the freezing step. The vitrification hypothesis during freezing, can also 
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explain the protection of the viruses against other freezing stresses like aggregation, 
damages caused by ice crystals and pH shift. 
It has been shown that the high viscosity and the limited molecular mobility in a glassy 
matrix prevents liposomes fusion/aggregation [58, 64, 65] and protects lipid membranes 
from damage by ice crystals [58].  
In addition, cryoprotectants could also prevent aggregation and fusion of live, attenuated 
viruses by isolating the virus particles in the unfrozen fraction, i.e., the particle isolation 
hypothesis. When frozen in low sucrose/DNA ratio, aggregation of lipid/DNA complexes was 
observed despite the glassy state of the sucrose under the experimental conditions. 
However, when frozen in high sucrose/DNA ratio, aggregation was prevented. The same 
protection was observed when glucose was used as stabilizer. Whereas a low glucose/DNA 
ratio did not prevented aggregation, a high glucose/DNA ratio provided particles comparable 
to unfrozen controls. Nevertheless, in contrast to the sucrose samples, no vitrification was 
observed when using glucose indicating that the immobilization of particles in a glassy 
matrix cannot explain the lipid/DNA complexes stabilization and that spatial separation of 
particles in the unfrozen fraction is sufficient to prevent aggregation [66].    Intra virus ice 
formation would also be a major concern during freezing of live, attenuated vaccines. Based 
on freezing studies of cells and liposomes, the use of non-penetrating cryoprotectants such 
as hydroxyethyl starch (HES) or dextran can inhibit intracellular ice formation [31]. The 
stabilizers increase the osmotic potential of the extracellular liquid, leading to an escape of 
water from the cells and thus preventing any intracellular ice formation [67].  
To avoid pH shifts during freezing, crystallization of the buffer components in the 
formulation must be inhibited. This can be done by choosing optimal buffer salts, by keeping 
the buffer concentration at a minimum, by adding further solutes to maintain all buffer 
species in the amorphous state or by selecting an appropriate cooling rate [50]. 
Crystallization of buffer species can also be inhibited by agents, such as sucrose and 
mannitol [38, 68].  Finally, each buffer salt is characterized by a critical cooling rate, above 
which crystallization is inhibited and will not result in a pH shift [69]. 
In cellular cryobiology, the cooling rate is also important in order to manage the volumetric 
contraction due to the osmotic effect [70]. A slow cooling rate results in a high volumetric 
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contraction caused by the escape of water from the cell [70]. A fast cooling rate allows little 
volumetric contraction because the intracellular water has no time to leave the cell rapidly 
[70]. Water inside the cell implies a less likely vitrification and intracellular ice formation 
[31]. Slow and high cooling rates depend on the cell and cytoplasm properties. By using a 
moderate cooling rate, it is possible to allow vitrification with a moderate volume 
contraction [31].  
 
3.2.4. The drying step and the associated stresses 
The lyophilization drying step leads to dehydration of the sample. The consequences on live, 
attenuated viruses of ice sublimation (primary drying) and water desorption (secondary 
drying) have not been well studied and are even less described than the effects of freezing 
upon live, attenuated viruses. Therefore, reviewing the known drying stresses that proteins 
and liposomes face is the best option to reflect on the potential stresses that coat proteins 
and the lipid layer of the virus can undergo during the drying steps of freeze-drying.  
3.2.4.1. Effects of drying on the viral coated proteins 
Proteins in aqueous solution are fully hydrated and are surrounded by a monolayer of water 
which is termed the hydration shell [71]. Drying removes part of the hydration shell which 
can disrupt the native state of the protein and lead to denaturation [28]. During 
dehydration, exposure to a water-poor environment will cause a decrease of the charge 
density that may facilitate protein-protein hydrophobic interaction and cause aggregation 
[28] (during dehydration, the hydrated protein tends to transfer protons to the ionized 
carboxyl groups and thus abolishes as many charges as possible [71]). Water can also play a 
functional role in the active site of the protein. Removal of these water molecules can 
inactivate proteins [28]. 
Even if these stresses are not described in literature for viruses, they could destabilize the 
proteins in the virus coat, hence affecting the vaccine potency. 
3.2.4.2. Effect of drying on the lipid membrane 
Similar to proteins, liposomes are also surrounded by a water layer (hydration shell) which is 
removed during drying and can cause fusion/aggregation of liposomes [58, 72].  
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Another degradation caused by drying that might lead to viral inactivation is linked to the 
melting point (Tm) of the lipid layer. Above Tm lipids are in the liquid crystalline phase, while 
below its melting points, lipids are in the gel phase. During dehydration, water from the lipid 
headgroup region is removed which causes an increase in van der Waals forces between 
lipids and results in a higher melting point [41]. When fully hydrated, egg 
phosphatidylcholine has a Tm of 0°C, but upon dehydration its Tm is 70°C [73, 74]. The 
changes in Tm between the hydrated and dehydrated state determine whether or not a 
phase transition will occur during lyophilization and rehydration [58]. The use of 
carbohydrates can prevent this phase transition which is explained in the next chapter.  
If a phase transition from gel to liquid crystalline occurs, it can result in the release of the 
vesicle content in the environment. This phenomenon has been observed for liposomes, 
baker’s yeast and cells. 
 
3.2.5. Strategies to protect live, attenuated vaccines during drying 
The stabilizing capacity of sugars during drying is well known for viruses (see Tables 3.1 and 
3.2). However, as for freezing protection, hypotheses related to the protection mechanism 
of live, attenuated vaccines during drying are not available as such and must be derived from 
the freeze-drying protection mechanisms of sugars used for liposomes, cells or proteins.  
There exist two sugar based drying stabilizing hypotheses: (i) the water-substitution 
hypothesis and (ii) the kinetic stabilization mechanism (vitrification theory). These two 
hypotheses can be invoked to explain protein stabilization as well as liposome stabilization. 
The water-substitute hypothesis states that the sugar replaces the water molecules (that are 
removed in the hydration shell) in the hydrogen bonding interactions with the protein and 
offers a thermodynamic stabilization [75]. This hypothesis is also valid for liposomes and has 
the effect of reducing Tm of the membrane. By interacting with the phospholipid head 
group, carbohydrates maintain the spacing and reduce the van der Waals interactions 
among the acyl chains of the phospholipids. It reduces the interaction between water and 
phospholipids, replaces water and finally decreases the transition melting temperature [58, 
76].  
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This hypothesis could be relevant for viruses, as a sugar can be hydrogen bonded to the viral 
coated proteins (providing thermodynamic stabilization) and to the head group of the 
membrane phospholipids to protect the membrane from phase transition.  
The vitrification hypothesis has the same mode of action as during the freezing step. For 
proteins the isolation into a glassy matrix lowers the molecular mobility needed for the 
degradation pathways like bimolecular interactions, unfolding and chemical degradation 
[26]. Similarly, drying can facilitate the aggregation of viral particles by removing the 
hydration shell surrounding them [77]. The dispersion of the viruses into a glassy matrix can 
also contribute to the protection by lowering the probability of aggregation.  
The viruses appear to be protected by lyoprotectant in three different ways: (a) the 
dispersion of the virus in a glassy matrix reduces the probability of aggregation and the 
molecular mobility needed for the degradation pathways, the stabilization of (b) coated 
proteins and (c) lipid membrane by hydrogen bonding (i.e., water substitution) with the 
lyoprotectant.  
3.3. FORMULATIONS 
Freeze-dried live attenuated viruses often require complex formulations existing of 
numerous excipients [78]. Generally, such freeze-dried vaccines contains one or several 
antigens, a bulking agent to provide a satisfactory product appearance, a buffer to maintain 
the pH at a specific value, tonicity modifiers and stabilizers to provide protection to the 
organism against chemical and physical degradation during processing and storage [75].  
Freeze-drying is performed to increase the stability of the vaccine but the freezing and the 
dehydration steps themselves can be stressful for the product, as described in the first part 
of this review.  
To reduce the negative impact caused by the process, the use of an optimized formulation 
and process is essential. Optimizing the formulation means finding the best combination of 
excipients that will have a specific function related either to the process or to the protection 
of the active component during and after lyophilization. 
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Several compounds have been used in order to stabilize freeze-dried live, attenuated 
vaccines. Information gained from databases of licensed vaccines (Table 3.1) as well as from 
published studies (Table 3.2) reveal some trends and will further be exposed. 
Table 3.1: Example of freeze-dried vaccine formulations. Compiled from Physicians Desk Reference 
and the list of vaccines licensed for immunization and distribution in the U.S. (FDA) 
Vaccine 
Description Virus characteristics 
Excipients (not 
necessarily complete) Sponsor 
ACAM2000 Live, smallpox (vaccinia) 
Vaccine 
DNA viruses. Envelopped Mannitol, human serum 
albumin 
Sanofi Pasteur 
Biologics Co 
Attenuvax Live attenuated measles virus RNA viruses. Envelopped Sorbitol, sucrose, gelatin, 
human albumin, fetal 
bovine serum Merck 
Biavax II Live attenuated rubella and 
mumps viruses 
mumps: RNA viruses. 
Envelopped 
Sorbitol, gelatin 
Merck 
rubella: RNA viruses. 
Envelopped 
MMR-II Live attenuated measles, 
mumps and rubella  viruses 
measles: RNA viruses. 
Envelopped 
Sorbitol, gelatin 
Merck 
mumps: RNA viruses. 
Envelopped 
 rubella: RNA viruses. 
Envelopped 
M-M-VAX Live attenuated measles and 
mumps  viruses 
measles: RNA viruses. 
Envelopped 
Sucrose, glutamate, human 
albumin 
Merck 
mumps: RNA viruses. 
Envelopped 
M-R-VAX 
Live attenuated measles and 
rubella  viruses 
measles: RNA viruses. 
Envelopped 
Sorbitol, gelatin 
Merck 
rubella: RNA viruses. 
Envelopped 
Meruvax II Live attenuated rubella virus RNA viruses. Envelopped Sorbitol, gelatin 
Merck 
Mumpsvax Live attenuated mumps virus RNA viruses. Envelopped Sorbitol, gelatin 
Merck 
Nasovac 
Live influenza attenuated 
virus 
RNA viruses. Envelopped Sorbitol, gelatin, phosphate 
buffer 
Serum institute of 
India Ltd. 
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Table 3.1: Example of freeze-dried vaccine formulations. Compiled from Physicians Desk Reference 
and the list of vaccines licensed for immunization and distribution in the U.S. (FDA) (continued). 
ProQuad 
Live attenuated measles, 
mumps, rubella and varicella 
viruses 
measles: RNA viruses. 
Envelopped 
Sorbitol, sucrose, gelatin, 
human albumin 
Merck 
mumps: RNA viruses. 
Envelopped 
  
rubella: RNA viruses. 
Envelopped 
  
varicella: DNA viruses. 
Envelopped 
Varivax Live attenuated varicella virus DNA viruses. Envelopped Sucrose, gelatin, glutamate 
Merck 
YF-Vax Yellow Fever Vaccine RNA viruses. Envelopped Sorbitol, gelatin 
Sanofi Pasteur 
Biologics Co 
Zostavax Live attenuated varicella-
zoster virus 
DNA viruses. Envelopped  Sucrose, gelatin, glutamate 
Merck 
 
Table 3.2: Compilation of the formulation composition of published studies on virus vaccines 
stabilization. 
Vaccine Formulations 
Respiratory syncytial viruses (RSV) SPGA (Sucrose phosphate glutamate albumin) 
Human vaccine Sucrose 
[79] Potassium phosphate buffer 
  Na glutamate 
  Bovine  albumin 
Rinderpest (RP) LGS 
Veterinary vaccine Lactobionic acid 
[80] Hydrolysed gelatin 
  Sorbitol 
  Hepes buffer 
  BUGS 
  Potassium phosphate buffer 
  Hydrolysed gelatin 
  Sorbitol 
  LS 
  Lactalbumine hydrolysate 
  Sucrose 
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Table 3.2: Compilation of the formulation composition of published studies on virus vaccines 
stabilization (continued). 
Live, attenuated peste des petits ruminants  LS 
(PPR) vaccine Lactalbumine hydrolysate 
Veterinary vaccine Sucrose 
[81] HBSS (Hank's balanced salt solution, used to maintain 
pH and osmotic balance) 
  WBM (Weybridge medium) 
  Lactalbumine hydrolysate 
  Sucrose 
  Na glutamate 
  
HBSS (Hank's balanced salt solution, used to maintain 
pH and osmotic balance) 
  BUGS 
  Potassium phosphate buffer 
  Hydrolysed gelatin 
  Sorbitol 
  TD 
  Trehalose dihydrate 
Duck viral hapatitis virus (DHV) vaccines SPGA (Sucrose phosphate glutamate albumin) 
Veterinary vaccine Sucrose 
[82] Potassium phosphate buffer 
  Na glutamate 
  Bovine albumin 
  LPGG (Lactose phosphate glutamate gelatin) 
  Lactose 
  Potassium phosphate buffer 
  Na glutamate 
  Gelatin 
  TPGG (Trehalose phosphate glutamate gelatin) 
  Trehalose 
  Potassium phosphate buffer 
  Na glutamate 
  Gelatin 
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Table 3.2: Compilation of the formulation composition of published studies on virus vaccines 
stabilization (continued). 
  SPGG (Sorbitol phosphate glutamate gelatin) 
  Sorbitol 
  Potassium phosphate buffer 
  Na glutamate 
  Gelatin 
Influenza virus SPG (Sucrose phosphate glutamate) 
[39] Sucrose 
  Potassium phosphate buffer 
  Glutamate 
  Casitone 
Respiratory syncytial viruses (RSV) Sucrose 
Human parainfluenza 3 (hPIV3) Phosphate buffer 
Human vaccine Pluronic F68 
[83]   
Herpes simplex virus (HSV) Tris-HCL buffer 
[37] Sucrose 
  Na glutamate 
Camelpox virus (CMLV) LS (Lactalbumine hydrolysate and sucrose) 
[85] Lactalbumine hydrolysate 
 
Sucrose 
 
HBSS (Hank's balanced salt solution, used to maintain 
pH and osmotic balance) 
 
BUGS 
 
Potassium phosphate buffer 
 
Hydrolysed gelatin 
 
Sorbitol 
 
TAA (Trehalose with amino acids and divalent 
cations) 
 
Trehalose 
 
L-Alanine and L-Histidine 
 
Ca
++ 
and Mg
++
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Table 3.2: Compilation of the formulation composition of published studies on virus vaccines 
stabilization (continued). 
Mumps virus Trehalose 
[86] Potassium phosphate buffer 
 
Na glutamate 
 
Gelatin 
 
Sucrose 
 
Sorbitol 
 
Na glutamate 
 
Human serum albumin 
 
Gelatin 
 
Among the different excipients, the buffer and the stabilizers are intended to play a critical 
role in the protection of the active ingredient and will be the main focus.  
 Formulation pH - Buffer 
In order to stabilize the pH of a vaccine formulation at a specific value (which guarantees an 
optimal stability of the antigens), buffers are added to the formulation. The buffer choice 
when developing a formulation to be freeze-dried is critical.  
In protein formulation, the most commonly used buffers are phosphate salts [38]. For virus 
formulations, limited information is available. However, from Table 3.2, it appears that 
potassium phosphate is the most frequently used buffer. The reason is the pH range of the 
buffer (6-8) which is particularly suitable to maintain satisfactory virus activity [7, 45, 46], 
and it is close to physiological pH. 
Depending on the salt used, the crystallization tendency and the pH shift magnitude (see 
paragraph 3.2.2.3, effect of the freezing step on pH) of phosphate buffer will vary. Sodium 
phosphate buffer demonstrated significant pH changes (increase  4 pH units) during 
freezing, as a result of crystallization of the buffer component, disodium hydrogen 
phosphate dodecahydrate, recognized to precipitate at low temperature [84, 87, 88]. The 
potassium phosphate buffer system was subjected to a smaller pH change due to the 
crystallization of the monobasic salt which is less soluble than the dibasic form [87].  
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However, the presence of a phosphate buffer in the formulation will not necessary result in 
a pH shift. This phenomenon appears to be concentration and freezing-rate dependent. 
Lower concentrations will result in smaller pH shift [41, 89]. This has been illustrated with a 
Hepes buffered solution (pH 7.4) in an influenza formulation frozen at -20°C. A drop of 1.4 
pH units has been determined for a concentration of 20mM [84], whereas at a concentration 
of 2mM the pH was reduced by less than 1 unit [41]. Variation in pH for a phosphate 
buffered saline depended also on the cooling rate with fast cooling (quenching) resulting in a 
more pronounced pH change compared to slow freezing [41, 88, 91]. 
Finally, crystallization of buffer species can also be inhibited by agents such as sucrose and 
mannitol [38, 68]. For sodium phosphate buffer, sucrose and mannitol act by inhibiting the 
crystallization of dibasic sodium phosphate [92]. 
Several other buffers (tartrate, succinate, malate and citrate) present interesting properties 
for lyophilization purposes but are not used for freeze-drying of viruses because of their pH 
range, which is not appropriate for viruses. 
 Stabilizer 
Stabilizers are added to the formulation to provide protection to the active ingredient 
against process-induced stress [75]. Because neither the impact of each freeze-drying step 
on the live, attenuated vaccine, nor the stabilization mechanisms needed to protect the live 
viruses are fully understood or known, stabilizers are selected by trial-and-error screenings 
[8, 49].  
However, the large variability (size, shape, composition) in nature of antigens can make the 
optimal lyo- and cryoprotectant formulation difficult. Several classes of compounds 
(disaccharides, polyols, animal derived compounds, etc) have been used to stabilize freeze-
dried live, attenuated vaccines. Information gained from published studies (Table 3.2) as well 
as from databases of licensed vaccines (Table 3.1) reveal some trends. 
Disaccharides (i.e., sucrose and trehalose) are generally good stabilizers and are frequently 
used. In addition, sorbitol and animal-derived components (gelatin or albumin) seem to 
provide a satisfactory stability and are also frequently used.  
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- Sucrose and trehalose 
Disaccharides like sucrose and trehalose have the capacity to remain amorphous during 
freeze-drying and are referred to in many publications as good stabilizers [75], with high Tg 
[90] and higher Tc than monosaccharides [93].  
Even if never demonstrated, sucrose and trehalose probably protect the live viruses during 
freeze-drying by forming a glass (vitrification) and/or hydrogen bonds (water-substitution), 
hence avoiding several stresses. During the freezing step, dispersion of the antigen into a 
glass could prevent membrane fusion/aggregation and membrane damage caused by ice 
crystals. The stabilizers can also protect the viruses indirectly by inhibiting buffer 
crystallization. During the drying steps, the sugars can act as a water substitution agent by 
forming hydrogen bonds with the coated proteins or the lipid membrane, hence stabilizing 
the viruses. By lowering the melting temperature of the lipid membrane, the sugars can also 
prevent the membrane from phase transition during rehydration of the lyophilized product.  
Only two formulations shown in Table 3.2 mention the use of trehalose as a stabilizer 
despite its more favorable properties. Sucrose is one of the best stabilizers but compared to 
trehalose, sucrose has been reported to undergo hydrolysis at low pH [75, 94-96], forming 
reducing monosaccharides whereas no similar report is found for trehalose. Moreover, the 
viscosity of trehalose in solution has been determined to be nearly 2.5-fold higher than 
sucrose for all concentrations tested [97]. The viscosity increase during freezing restricts 
diffusion of reacting molecules [28], minimizing the rate of chemical degradation [29]. The 
glass transition temperature of trehalose is superior (118°C) [90] to sucrose (75°C) [90] 
which is particularly important for the long-term stability at ambient temperature. The glass 
transition temperature of maximally concentrated solutions (Tg’) is higher for trehalose (-
40°C) in comparison with sucrose (-46°C) [98] allowing a higher primary drying temperature 
and therefore a shorter primary drying time. For a detailed review on trehalose, readers are 
referred to [98].   
Despite the favorable properties of trehalose, its limited occurrence in vaccine formulation is 
linked to the following aspects. Firstly, the superiority of trehalose as stabilizer is not 
universal. Better shelf-stability has been sometimes observed with formulations containing 
sucrose compared to similar formulations containing trehalose [26, 81, 93]. A combination of 
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lactalbumin hydrolysate-sucrose was found to be a better thermal protectant of the live, 
attenuated peste des petits ruminants (PPR) vaccine than trehalose alone [78]. Conversely, in 
a stability study at various temperatures (i.e., 4°C, 25°C, 37°C and 40°C) trehalose, in 
combination with amino acids and divalent cations has been demonstrated to better protect 
a camelpox virus vaccine than a combination of sucrose and lactalbumine hydrolysate [85]. 
Similarly, trehalose in combination with gelatin was demonstrated to be a better stabilizer 
than sucrose combined with sorbitol for the protection of a live-attenuated mumps vaccine 
[86]. Using Design of Experiments (DOE), sucrose, in combination with raffinose and 
compounds frequently observed to accumulate in developing seeds, demonstrated 
promising long-term stabilization of adenovirus (Ad5) in liquid and freeze-dried formulation 
stored at various temperatures [99]. Although the use of trehalose in commercial products 
has been subjected for approval by several governing bodies, this compound has only 
recently been listed as a pharmaceutical reagent in the United States National Formulary (in 
2010), European Pharmacopoeia (in 2010) and the Japanese Pharmacopoeia (in 2011) [98]. 
These approvals combined with the fact that the use of trehalose to stabilize live attenuated 
vaccines is recently off-patent, will undoubtedly increase the use of this stabilizer in vaccine 
formulations.  
- Sorbitol 
Sorbitol is a sugar alcohol which does not easily crystallize [81] despite being an isomer of 
mannitol (the most commonly used bulking agent) and has been demonstrated, when 
formulated together with gelatin, to be an effective stabilizer for measles virus [100], 
rinderpest virus [80], duck viral hepatitis virus [82] and others commercialized vaccines listed 
in Table 3.1. Different sugars (lactose, sucrose and trehalose) and sorbitol were compared to 
stabilize duck viral hepatitis virus (DHV). The only formulations able to confer an acceptable 
stability were the sorbitol-containing formulations [89]. For measles virus, a sorbitol:gelatin 
ratio of 2:1 is sufficient to preserve the potency of the virus [100]. For DHV, higher sorbitol 
concentrations (sorbitol:gelatin ratio of 4:1, 8:1 and 16:1) reduce the stability [82]. This 
could be due to the low Tg of sorbitol (-1.6°C) [101] which implies that sorbitol cannot be 
used as a main formulation component. The low Tg of sorbitol limits its use, but is probably 
at the origin of its stabilizing success. Chang and co-workers studied the effect of sorbitol on 
the stability of lyophilized antibodies [102]. When added to a sucrose formulation, due to its 
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low Tg, sorbitol acts as plasticizer, increasing the molecular mobility but improving the 
stability upon storage of an IgG1 (according to Chang, this surprising observation is due to 
the fact that “mobility” does not control protein stability at storage temperature well below 
the formulation Tg). In this same study, FTIR results showed that the sucrose formulation 
containing sorbitol produces a more “native-like structure” than the sucrose formulation 
without sorbitol [102].   
- Animal-derived components 
 Animal-derived components such as gelatin and albumin have also been used as stabilizer in 
freeze-dried live, attenuated vaccines. Albumin, in combination with sucrose, was employed 
in 1950 by Bovarnick and coworkers to stabilize rickettsiae [103]. The gelling characteristics 
of gelatin are frequently used in vaccine formulation (Tables 3.1 and 3.2) to prevent 
inactivation due to environmental changes such as temperature [82].  However, animal-
derived compounds like gelatin represent a potential danger due to the possible 
contamination with the scarpie-prion-protein (PrPSC) and the new variant of the Creutzefeld-
Jakob disease (vCJD) [104] and are therefore more and more requested to be replaced by 
stabilizers of non-animal origin. In an attempt to substitute gelatin as a stabilizer for a 
varicella virus liquid vaccine, other components including κ-Carrageenan and different plant 
proteins have been investigated [105]. Carrageenan, a polysugar synthesized by red algae, 
was the best choice regarding its capacity to retain the activity of the virus compared to a 
control formulation with gelatin as stabilizer [105].  
A novel promising excipient, silk fibroin, a biologically-derived protein polymer purified from 
domesticated silkworm (Bombys mori) cocoons has recently shown interesting stabilizing 
properties on a MMR (measles, mumps, rubella) vaccine [106]. The encapsulation of 
measles, mumps and rubella viral particles in silk film enhanced their storage stability at 25, 
37 and 45°C. The mechanism of stabilization seems to act by reducing residual moisture 
increase during storage at elevated temperatures and by increasing the denaturation 
temperature of the viral proteins [106]. 
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3.4. PROCESS DEVELOPMENT STRATEGY 
The development of a freeze-dying process is very important because of the impact the 
chosen parameters have on the final product (product appearance, virus potency/stability, 
residual moisture and freeze-drying cycle duration). 
Several studies describing the freeze-drying of virus-based vaccines do not pay attention to 
the freeze-drying process optimization (process settings) [39, 79-82,107-112]. These studies 
mainly focus on the formulation optimization by comparing different stabilizers and their 
effect upon virus titer under different storage conditions and on residual moisture of the 
finished product. The effects of the process conditions used are often unknown and the 
rationale behind their settings is almost never described. The choice for a specific set of 
parameters is often based on previous experience [83], or because it corresponds to a gentle 
cycle that allows the preservation of a large range of bacteria (for a bacterial vaccine) [113]. 
Table 3.3 presents some vaccine studies and their freeze-drying process parameters used. 
Comparing the different process conditions (temperature, pressure and time) between the 
different studies is impossible because critical product parameters like Tg’, Tc, filling volume 
or filling depth, are formulation dependent. However, Table 3.3 shows a high variability of 
freeze-drying approach like the use of pre-cooled shelves and the cooling rate, which have a 
direct effect on the virus.  
The use of pre-cooled shelves is conventional when freeze-drying vaccines [83]. However, 
based on Table 3.3, it is not systematically used (e.g., quench freezing) or when loading on 
pre-cooled shelves is not desired. The placement of the vials on the shelves that have 
already been cooled to the desired freezing temperature (typically -40 or -45°C) results in 
higher nucleation temperature (i.e., low degree of supercooling, -9.5°C), compared to the 
conventional shelf-ramped freezing (-13.4°C) [114].  With this pre-cooled shelf method, a 
large heterogeneity in supercooling between vials is observed [114], but this is also the case 
with the shelf-ramped freezing with differences up to 3°C resulting in important variability in 
product quality and process performance [115]. 
In order to obtain a more homogeneous freezing and avoid any ice formation on shelves 
prior loading, vials can be equilibrated at low shelf temperature (5-10°C) for 15-30min 
before linearly decreasing the shelf temperature [116].  
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A thorough study of both shelf-ramp and shelf pre-cooling freezing methods on virus 
potency could provide valuable process information and is, to our best knowledge, lacking. 
As sufficiently demonstrated, the cooling rate is of major importance for virus protection. 
Two studies [37, 41] listed in Table 3.3 compared different cooling rates and demonstrated 
the significant effect of this parameter on virus stabilization. Structural integrity of 
haemagglutinin of an influenza subunit vaccine is better preserved when the solution is 
rapidly frozen in liquid nitrogen [37]. Fast freezing allows the system to rapidly vitrify which 
may prevent the conformational change [37]. 
Herpes simplex virus-2 was better preserved when frozen in slush nitrogen [41]. In this case, 
the high cooling rate has a positive impact on the viruses by promoting the formation of 
small ice crystals.  
From the two presented studies [37, 41], it seems that quench freezing offers better 
preservation of viruses than slow freezing. Another emerging technique during freezing is 
the use of controlled nucleation, allowing the control of the nucleation temperature [50]. 
This method results in a more uniform ice crystal structure and maybe virus titer. This 
method is subjected to investigational studies in the pharmaceutical industry. To date, no 
study evaluating the impact of controlled ice nucleation on live attenuated viruses has been 
published. 
Finally, Table 3.3 reveals that while the effect of cooling rate on viruses receives limited 
attention, the impact of primary and secondary drying parameters (temperature, time and 
pressure) on viruses receives almost no attention. These parameters can be easily calculated 
to obtain a freeze-drying cycle that promises an elegant product in the shortest time 
possible [117]. Rules and advice to select appropriate drying steps conditions for protein 
formulation are largely available in literature [28, 92, 115, 116] and can be applied to 
viruses.  
Primary drying is however very important as demonstrated by Schneid and co-workers on a 
bacterial vaccine formulation [117]. Whereas conservative primary drying conditions 
resulted after 28 days storage at 40°C in 50.106 living bacteria cells in the product, an 
increase of the primary drying temperature of 2 and 5°C resulted in 28.106 and 20.106 living 
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bacteria cells, respectively [117]. This study highlights the importance of carefully selecting 
the primary drying temperature as a difference of 2°C can result in a 44% loss.  
Residual moisture of the end product can impact vaccine stability and is dictated by the 
temperature, pressure and duration of secondary drying that are established via empirical 
studies [75]. Staying within a specified range of residual moisture levels can be vital for 
product integrity [4]. Whereas overdrying is to be avoided, too high residual moisture levels 
can cause structural collapse during storage [75] and can increase the product degradation 
rate as the sorbed water provides molecular mobility [4,75] that can induce chemical 
degradation (methionine oxidation of human growth hormone [118]) and aggregation 
(human serum albumin [119]).  
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Table 3.3:  Process parameters of some vaccine studies. 
Pre-
cooled 
shelves 
Cooling rate 
Freezing                   
(Temperature 
/ Time) 
Annealing 
(Temperat
ure / 
Time) 
Primary drying                      
(Temperature / 
Pressure / Time) 
Secondary drying                      
(Temperature / 
Pressure / Time) 
Organism Remarks Reference 
-45°C Unk -45°C / 90min  -15°C / 33h -30°C / 0.1mbar / 48h 
2 steps: 
Medi 534                            
Live 
attenuated 
virus vaccine 
Annealing step not for 
all samples 
  
[83] 
1) 0°C / 0.1mbar / 
30min 
2) 10°C / 0.1mbar / 
280min 
 
No Unk 
-20°C / 24h 
(refrigerator) 
No 
-35°C / 0.220mbar / 
24h 
20°C / 0.060mbar / 
24h 
Influenza 
subunit 
vaccine  
Transferred to a 
vacuum dessicator at 
RT for 2 days 
  
[41] 
Liquid nitrogen 
/ 5 - 10min 
 
No Unk 
-75°C / unk.       
(cold air 
chamber) 
No 
-10°C / 0.15mbar / 
18h 
20°C / 0.15mbar / 15h Bacteria   [113] 
-50°C 10°C.sec
-1
 -50°C / ~25sec No 
 -50°C / 0.067mBar / 
1000min 
5°C / 0.067mBar / 
120min 
HSV-2 virus 
  
  
  
  
  
[37] 
No 20-50°C.sec
-1
 
Slush nitrogen 
/ ~25sec 
No 
                -180 to 20°C / 1.10
-5
mBar / 14h 
 
No 
200-
400°C.sec
-1
 
Melting 
propane / 
~25sec 
No 
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Table 3.3: Process parameters of some vaccine studies (continued). 
No Unk 
Liquid nitrogen 
/ 5 - 10min 
No 
-35°C / 0.220mbar / 
24h 
20°C / 0.060mbar / 
24h 
Virosomes 
Same research group 
as [41] 
[56] 
No 1°C/min -50°C / 3h No 
2 Steps: 
20°C / 3Pa / 8h Adenovirus 
  [119] 
1) -50°C / 3Pa / 60h                               
2) 0°C / 3Pa / 4h   
 
No 1°C/min -40°C / 3h 
No 
2 Steps: 
20°C / 0.045mbar / 
10h 
Virus like 
particles 
  [120] 
1) -35°C / 0.045mbar / 
25h  
2) -20°C / 0.045mbar / 
10h   
 
No 
-15°C / 0.045mbar / 
20h 
40°C / 0.007mbar / 
10h   
 
-15°C / 2h 
-15°C / 0.045mbar / 
20h 
40°C / 0.007mbar / 
10h   
 
No Unk -40°C / 3h No 
-40 to 37°C / 60mTorr 
/ 40h  
 Duck viral 
hepatitis 
vaccine 
 
[82] 
Unk= unknown. 
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3.5. CONCLUSION 
Despite the high dependence on freeze-drying to stabilize live virus vaccines, their 
lyophilization process and especially their (de)stabilization mechanisms are still not well 
elucidated. The complexity of these formulations as well as the lack of techniques to 
evaluate the different virus degradation pathways are responsible for this gap [4, 7, 83]. 
Moreover, the large financial issues behind vaccine development and stabilization make that 
the available information is rarely published. However, other biopharmaceuticals like 
proteins, liposomes and cells have been well studied and provide valuable knowledge. 
Knowing the different stresses that can occur during freeze-drying is essential to provide 
stabilization solutions. 
During the freezing step, the stresses that viruses can face are numerous and summarized in 
Table 3.4. Although the stresses and their causes are different, there are two strategies that 
can be used to protect the virus: an appropriate cooling rate and the use of a cryoprotectant 
that acts via the solid exclusion hypothesis and/or the vitrification hypothesis.  
Table 3.4: Summary of the possible virus stresses during the freezing step, their cause and the 
strategy that can be used to avoid the stress.  
Stress Cause Strategy to protect 
Intra-virus ice formation Fast freezing Cryoprotectant and adequate cooling rate 
Osmolarity change Conversion of water into ice Cryoprotectant and adequate cooling rate 
pH shift Buffer crystallization 
Cryoprotectant 
Low buffer concentration 
Adequate cooling rate 
Coated proteins destabilization  Freeze concentration Cryoprotectant 
Lipid destabilization 
     -mechanical damage 
     -fusion and phase transition 
 Ice formation Cryoprotectant 
 
Information related to the destabilization mechanisms during the drying steps are less 
numerous. The lipid membrane and the coated viral proteins are the main attributes 
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susceptible to degradation. Both can be protected by the use of a stabilizer via the 
vitrification hypothesis and the water replacement hypothesis. A typical property of lipids is 
their melting temperature (Tm) that must be taken into account in order to avoid phase 
transition. Disaccharides, via the water substitute hypothesis, can decrease the Tm and 
avoid such phase transition [73, 74]. 
Examination of the formulations used to stabilize viruses reveals a relatively constant use of 
sorbitol, sucrose and animal-derived components such as gelatin. However, other 
compounds (like trehalose and silk fibroin) are gaining interest in the freeze-drying field 
because of their superior stabilizing properties.  
Finally, process parameters, despite being of high importance (cooling rate, primary and 
secondary drying temperatures) are not subjected to extensive studies. During optimization 
studies, the formulation parameters often receive priority over the process settings while 
they however should be considered together.   
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CHAPTER 4 
PROCESS ANALYTICAL TECHNOLOGY FOR 
FREEZE-DRYING 
 
4.1. PROCESS ANALYTICAL TECHNOLOGY 
4.1.1. Introduction 
In September 2003, the Wall Street Journal stated: ‘The pharmaceutical industry has a little 
secret: even as it invents futuristic new drugs, its manufacturing techniques lag far behind 
those of potato-chip and laundry-soap makers’ [1]. Still partially applicable today, 
conventional pharmaceutical manufacturing is generally accomplished using batch 
processing. Often considered as uncomprehended inefficient black-boxes, the batch 
processes are monitored with univariate sensors measuring e.g., pH, temperature and 
pressure. At the end of the process, end product quality is assessed off-line with time-
consuming and less efficient laboratory testing conducted on randomly collected samples. 
However, significant opportunities exist to improve pharmaceutical development, 
manufacturing, and quality assurance. In many other industries (e.g., chemical, food, 
agricultural, etc), real time fast and non-destructive process analyzers have replaced 
traditional off-line laboratory techniques [2]. The low analysis time (seconds or minutes) of 
the process analyzers compared to the traditional laboratory techniques (hours or days) 
offers the opportunity of live feedback (i.e., during processing). In addition, by eliminating 
the manual sampling handling, the sample integrity is retained and the risk of operator error 
is reduced [3].   
Unfortunately, the pharmaceutical manufacturing industry has been hesitant to introduce 
such innovative systems. The highly regulated environment of the pharmaceutical industry 
was considered as rigid and unfavorable to innovation [4]. Therefore, in 2002, in order to 
eliminate the hesitancy to innovate, the Food and Drug Administration (FDA) launched a 
new initiative entitled “Pharmaceutical Current Good Manufacturing Practices (CGMPs) for 
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the 21st Century: A Risk-Based Approach” [5]. Aiming to a global improvement and the 
modernization of pharmaceutical manufacturing, this initiative was followed by the launch 
of several other guidelines written by the FDA [4, 6] and the International Conference of 
Harmonization (ICH) [7-9]. Process Analytical Technology (PAT) is a key element of the 
CGMPs for the 21st Century initiative [10] and is intended to encourage the development and 
implementation of effective and efficient innovative approaches in pharmaceutical 
development, manufacturing and quality assurance.  
 
4.1.2. The PAT framework 
The FDA has defined PAT as a system for designing, analyzing and controlling manufacturing 
through timely measurements (i.e., during processing) of critical quality and performance 
attributes of raw and in-process materials and processes, with the goal of ensuring final 
product quality. The term analytical in PAT is viewed broadly to include chemical, physical, 
microbiological, mathematical and risk analysis conducted in an integrated manner. One of 
the most important statements within the PAT concept is that ‘quality cannot be tested into 
products; it should be built-in’ [4]. By using the approach of building quality into products, 
the PAT guidance highlights the necessity to fundamentally understand the process. The 
design and development of well understood processes that will consistently ensure a 
predefined quality at the end of the manufacturing process is a desired goal of the PAT 
framework [4]. Several criteria must be fulfilled to consider a process well understood: (i) all 
critical sources of variability are identified and explained, (ii) variability is managed by the 
process, and (iii) product quality attributes can be accurately and reliably predicted over the 
design space established for materials used, process parameters, manufacturing, 
environmental and other conditions. 
Several PAT tools are available to enable process understanding for scientific, risk-managed 
pharmaceutical development, manufacture, and quality assurance. An appropriate 
combination of some, or all, of these tools may be applicable to a single-unit operation, or to 
an entire manufacturing process and its quality assurance. These tools are subdivided in four 
categories [4]. 
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 Multivariate tools for design, data acquisition and analysis 
Pharmaceutical products and processes are complex multi-factorial systems. Structured 
experiments conducted during product and process development can provide scientific 
understanding of the relevant multi-factorial relationships and serve as building blocks of 
knowledge. Together with other development projects, they can become part of an overall 
institutional knowledge system for a particular product and its processes and support the 
development of process simulation models. An appropriate use of these tools enables 
identification and evaluation of product and process variables that may be critical to product 
quality and performance. The identification of potential failure modes and the evaluation of 
their effects may also be possible. 
 Process analyzers 
From univariate process measurement tools (e.g., pH, temperature, and pressure) to 
multivariate tools able to measure (sometimes non-destructively) biological, chemical and 
physical attributes, process analysis has advanced significantly during the past several 
decades. The measurement can be performed at-line (the sample is removed, isolated from 
and analyzed close to the process stream), on-line (the sample is removed for analysis from 
process stream and returned to process stream again), in-line (the sample is not removed 
but analyzed in the process stream), and off-line (the sample is removed and analyzed away 
from process stream) (Figure 4.1). In the context of freeze-drying, several in-line monitoring 
analytical techniques are available (Table 4.1). Some of these tools are applicable at the 
production scale but some of them are restricted to the laboratory scale. Moreover, within 
the group of PAT tools, one can distinguish between process analyzers measuring directly 
the product or measuring the entire batch progress (based on gas composition in the 
chamber). 
In order to be implemented, the process analyzers should be compatible with the extreme 
conditions of the freeze-drying process (vacuum, low temperature, and sterility) [11]. It is 
also possible to extract samples out of the freeze-dryer during the process via a sampling 
thief and perform at-line measurements [11, 12]. Conversely, on-line monitoring appears to 
be incompatible with the freeze-drying process as performed today.  
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Figure 4.1: Schematic overview of a freeze-dryer chamber illustrating the difference between in-line, 
at-line, on-line and off-line measurements.  
 
 Process control tools 
Based on the (critical) material attributes of the input materials and the continuously 
obtained critical process and product information, process monitoring and control tools 
enable to steer the process settings, hence guiding the freeze-drying process towards it’s 
desired state, providing a consistent end product quality. As already described in chapter 2, 
a SMART system has been developed some years ago [13]. Based on water vapor content 
measurements in the freeze-dryer chamber (during primary drying) the recipe is adjusted in 
real-time for shelf temperature and chamber pressure, hence guaranteeing the required 
product temperature and optimizing the primary drying step efficiency. However, the 
SMART system does not allow to control all aspects of the freeze-drying process (e.g., the 
annealing process during the freezing step, the product solid state, the dehydration during 
secondary drying and the residual moisture content) and is not yet applied at production 
scale. 
 Continuous improvement and knowledge management tools  
Over the life cycle of a product, data collection and analysis contribute to continuous 
learning and can be used to justify proposals for post-approval changes. 
Freeze drier chamber
Probe
In-line
On-lineAt-line
Sample thief 
system
Off-line
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Table 4.1: Available in-line freeze-drying process monitoring tools compiled from [11]. 
In-line tools 
Application to  
production 
freeze-dryer 
Measured parameter(s) Advantages Disadvantages 
Product monitoring tools 
Thermocouples Yes - Product temperature   
- Invasive 
- Influence product behaviour 
- Measurement depends on position 
Resistance temperature 
detectors (RTD) 
Yes - Product temperature   
- Invasive 
- Influence product behaviour 
Temperature Remote 
Interrogation System 
(TEMPRIS) 
Yes - Product temperature 
- Wireless and battery-free 
- Compatible with automatic 
loading system 
- Can be placed anywhere on the 
shelf 
- Invasive 
- Huge size of the probe 
- Influence product behaviour 
- Practically difficult to implement 
The Microbalance technique No - Sublimation rate 
- Suitable to study effect of 
cooling rate on sublimation rate 
- Interruption of heat transfer during 
measurement 
- Measurement heavily depends on vial 
location 
Near Infrared (NIR) 
spectroscopy 
No 
- Residual moisture 
determination 
- Primary drying endpoint 
- Product monitoring (protein) 
- Non-destructive 
- Non invasive 
- Fast 
- Single vial technique (except if use NIR 
with multiprobe) 
- Difficult or impossible to implement at 
production scale (conventional batch 
process) 
- Only a fraction of vial is analyzed 
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Table 4.1: Available in-line freeze-drying process monitoring tools compiled from [11] (continued). 
Raman spectroscopy No 
- Product monitoring (physical 
phenomena, protein behaviour) 
- Freezing and primary drying end 
point 
- Non-destructive 
- Non invasive 
- Fast 
- Single vial technique 
- Difficult or impossible to implement at 
production scale (conventional batch 
process) 
- Only a fraction of vial is analyzed 
Batch monitoring tools 
Capacitance manometer (CM) Yes 
- Pressure 
- Primary drying end point (when 
combined to Pirani) 
- Wide pressure range 
- Withstand steam sterilization 
  
Pirani Yes 
- Pressure 
- Primary drying end point (when 
combined to CM) 
- Withstand steam sterilization 
- Inaccurate pressure measurement when 
gas composition change (end of Primary 
drying) 
Gas Plasma Spectroscopy 
(Lyotrack) 
Yes 
- Primary drying endpoint 
- Withstand steam sterilization 
- Potential risk to product stability (via 
free radical oxidation) 
Manometric Temperature 
Measurement (MTM) 
Yes 
- Product temperature 
- Ice sublimation interface 
temperature 
- Primary drying end point 
- Vial heat transfer coefficient 
- Sublimation rate 
- Product resistance 
- Provides parameters useful for 
process monitoring and control  
- Require a minimum ice sublimation area 
- Briefly impact the process (when closing 
the valve) 
- Does not work for formulations with 
high amorphous solid content 
- Temperature biased towards colder 
running vials 
- Require a fast closing valve (may be 
difficult for production scale) 
 
 
 
Chapter 4 – Process analytical technology for freeze-drying 
77 
 
Table 4.1: Available in-line freeze-drying process monitoring tools compiled from [11] (continued). 
Tunable Diode Laser 
Absorption Spectroscopy 
(TDLAS) 
Yes 
- Sublimation rate 
- Potential to measure primary 
and secondary drying end point 
- Potential to measure product 
temperature 
- Potential to determine residual 
moisture 
  
- Applicability depends on duct length 
between the chamber and the condenser 
- Needs further improvement in both the 
hardware and the analysis (for residual 
moisture determination) 
Residual Gas Analyzer (RGA) Yes 
- End of primary and secondary 
drying 
- Residual moisture (Calibration) 
- Detection of leaks and 
contaminants 
  
- Cannot withstand steam sterilization 
- Can be applied in sterile environment 
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4.2. PROCESS ANALYTICAL TECHNOLOGY FOR BIOPHARMACEUTICAL 
PROCESSES 
Compared to the implementation of PAT in the chemical and pharmaceutical industries, 
some unique considerations come into play with biotechnological processes and products 
[10, 14, 15]. 
 
1) Biopharmaceutical products (e.g., proteins, viruses) are large, complex and 
heterogeneous molecules [10]. 
2) Biotechnological processes are more complex than typical chemical or small-molecule 
drug-manufacturing processes (with regard to number of batch records, number of 
product quality tests, number of critical process steps, and the amount and complexity 
of process data generated) [10]. 
3) Biopharmaceutical products are extremely sensitive to the manufacturing process 
(batch to batch variability is commonly observed in product quality) [14, 16]. 
4) Raw materials can be complex and often variable [14, 17] 
5) The function/clinical significance of product variants, small changes in molecular 
structure in the product or profile of impurities is often incompletely understood [14].  
6) In-process intermediates can be complex mixtures where the desired product may be a 
small fraction of the bulk liquid [14] 
All these differences make the implementation of PAT in biopharmaceutical manufacturing 
more challenging than in chemical or pharmaceutical processes.  
Biotechnological manufacturing can be divided into four segments being upstream (e.g., 
microbial fermentation, mammalian cell culture), harvest, downstream (e.g., refolding, 
precipitation, filtration) and drug product processing (e.g., formulation, filling, lyophilization) 
[10]. The monitoring of critical quality attributes (CQAs) and critical process parameters 
(CPPs) with PAT tools is possible in each segment. Upstream unit operations can be 
monitored with PAT tools (e.g., FTIR spectroscopy, NIR spectroscopy, conductance and 
capacitance-based biomass probe, gas sensors, and many others) providing information on 
substrate, biomass, product and metabolite concentrations [18, 19]. The harvest step is less 
investigated from a PAT point of view, because of its limited effect on final product quality 
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[10]. Relatively under-explored compared to the possible opportunities [10], PAT 
implementation in downstream processes and particularly in process chromatography, 
might present a lot of gain (e.g., to facilitate the pooling of the chromatography columns) 
[20, 21]. Freeze-drying is a commonly used unit operation in biotechnological drug products 
processing. Several freeze-drying PAT applications have been developed for small molecules 
and can easily be extended to their biotechnological counterparts. Today, PAT sensors can 
be used to monitor several quality attributes during freeze-drying (e.g., residual moisture 
[22-25], protein unfolding [26-28], mannitol phase [29], lipid content [30], virus state [31, 
32]) as well as process attributes (e.g., step endpoint [33-35], heat and mass transfer [36], 
product layer resistance [37], sublimation rate [38]).  
 
4.3. MEASUREMENT PRINCIPLES OF THE APPLIED PROCESS ANALYZERS 
4.3.1. NIR spectroscopy 
Near infrared (NIR) spectroscopy is a fast, non-destructive and non-invasive analytical tool 
that can be implemented during pharmaceutical development, in production processes for 
monitoring or in quality control laboratories [39]. The possibility to measure samples fast 
and directly through transparent containers (e.g., glass vials [40]) enables the monitoring of 
large numbers of samples in the production line, without affecting the throughput of the 
production. This advantage contributed to the wide acceptance of this spectroscopic tool in 
the pharmaceutical industry [41].  A single NIR spectrum may contain qualitative and 
quantitative physical and chemical information [42]. Therefore, when associated with 
chemometrics, NIR spectroscopy becomes a powerful tool to analyze solid, liquid and 
biotechnological pharmaceutical forms. 
NIR spectroscopy studies the absorption of electromagnetic radiation in the NIR region (i.e., 
800-2500nm or 4000-12 500cm-1) [43, 44]. All NIR absorption bands result from overtones 
and combinations of fundamental vibrations from the mid-infrared (Figure 4.2). 
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Figure 4.2: Electromagnetic spectrum. 
 
When a sample is measured by NIR spectroscopy, the sample is irradiated by NIR light. Some 
of this NIR light is absorbed by the molecules, bringing them to a higher vibrational state 
(Figure 4.3) [42]. 
 
 
Figure 4.3: Schematic overview of the energy level transition associated with IR and NIR absorption, 
the Raman effect and fluorescence [42] 
 
UV
Visible
Infrared Microwave Radio
Overtones and combination 
bands
Fundamental
Near-infrared spectroscopy
(NIR)
800nm
-
12.500cm-1
2500nm
-
4000cm-1
25.000nm
-
400cm-1
mid-infrared spectroscopy
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Molecules that absorb NIR energy vibrate in two modes: stretching and bending. Stretching 
is defined as a continuous change in the interatomic distance along the axis of the bond 
between two atoms. Bending corresponds to a change in bond angle. Only vibrations 
resulting in changes in molecule dipole moment can absorb NIR radiation. A dipole is the 
product of charge (positive and negative) and distance. While no change in dipole moment 
occurs during the stretch vibration of an X2 molecule, a change in dipole moment can be 
observed during the stretch vibration of an XY molecule (Figure 4.4). Consequently, R-H, O-H, 
N-H, C-H and S-H bonds are strong NIR absorbers whereas diatomic molecules like H2 do not 
absorb NIR radiation. 
 
Figure 4.4: Schematic overview of the possible changes in dipole moment during the stretch 
vibration of an X2 (a) and a XY (b) molecule, respectively. Adapted from [42] 
 
The NIR spectrum contains overtones and combinations of the fundamental mid-infrared 
bands. The overtones occur at about two and three times the frequency of the fundamental 
vibration. For example, the absorption band of the C-H stretch fundamental vibration occurs 
at a frequency of 2960cm-1, the first overtone at 5920cm-1 and the second overtone at 
8880cm-1. Combination bands are the sum of several fundamentals from different vibrations. 
Therefore, a C-H combination band, which is the sum of a C-H stretch (2960cm-1) and a C-H 
bend (1460cm-1) will occur near 4420cm-1. 
 NIR spectra are difficult to interpret due to their complexity [43]. NIR absorption bands are 
broad, overlapping and weaker than the corresponding mid-infrared band [43, 45]. 
Therefore, direct interpretation of the NIR raw spectra is difficult and might require 
chemometrics in order to relate the NIR spectral information to the sample properties [39, 
43]. Besides the different sample properties, undesired sample variation (e.g., particle size, 
a b
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sample density, sample-to-sample measurement variations, etc.) can also be reflected in 
spectral differences. Therefore, spectral preprocessing methods are commonly used to 
reduce the effect of this interfering variance sources, thereby increasing the part of the 
variance due to the parameters of interest [46].    
4.3.1.1. Integrating sphere 
The integrating sphere is a powerful, fast and easy-to-use tool for diffuse-reflection sampling 
of solids and powders (Figure 4.5). When directed onto a surface, the infrared radiation will 
interact with the surface by alternately passing through it and reflecting. This causes the 
light to scatter, or “diffuse”, as it makes its way through the sample. 
The integrating sphere allows to measure extended sample area (depending on the sample 
port size) and provide uniform light collection independent of the sample orientation [47]. 
Diffuse-reflection measurements are simplified by using an integrating sphere. The NIR 
beam is directed onto the sphere and travels directly through the center of the sphere, 
through the optical window, and into the sample. The beam scatters off of the sample and 
the reflected light beams re-enter the sphere. The inside of the sphere is coated with diffuse 
gold, which collects the light beams and directs them into the detector (Figure 4.5).  
 
 
Figure 4.5: Integrating sphere sample interface picture (a) and schematic overview (b). 1: sample. 2: 
sapphire window. 3: Internal gold reference flag, computer controlled. 4: detector. 5: Gold coated 
sphere. 6: Infrared radiation. 
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2
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4.3.1.2. NIR application in freeze-drying 
Since the demonstration of the suitability of NIR spectroscopy to determine the residual 
moisture content in lyophilized sucrose through the glass vial [40], several studies of freeze-
dried products monitored with NIR spectroscopy have been published and are presented in 
Table 4.2.  The first studies were performed off-line and focused on the residual moisture 
content determination [22, 23, 48-50]. Fifteen years later, a study aiming to detect and 
evaluate the protein conformation was published [26] and several other off-line studies 
conducted to study biopharmaceutical products followed [31, 51, 52]. The possibility to 
monitor a freeze-dried mannitol formulation in-line was demonstrated in 2009 [35] and 
allowed to evaluate the mannitol behaviour during the different freeze-drying steps. Other 
in line experiments were performed and studied the protein stabilization mechanisms during 
the freeze-drying process [27] or monitored the residual moisture content at different 
positions of the freeze-dryer shelves [25]. 
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Table 4.2: Applications of NIR spectroscopy for the freeze-drying process 
In-process 
interfacing 
Monitored critical information Formulation type Reference 
Off-line Moisture content Pharmaceutical - sucrose [40] 
Off-line Moisture content Undisclosed [48] 
Off-line Moisture content: method transfer Undisclosed [49] 
Off-line Moisture content determination Pharmaceutical - mannitol [22] 
Off-line 
Moisture content: comparison between LOD and 
NIR 
Biopharmaceutical - hepatitis A virus, porcine parvovirus and 
pseudorabies virus 
[50] 
Off-line Distinction between surface and hydrate water Pharmaceutical - mannitol [23] 
Off-line Protein conformation 
Biopharmaceutical - Bovine chymotrypsinogen A and horse 
cytochrome C 
[26] 
Off-line Protein secondary structure analysis Biopharmaceutical - Various proteins [51] 
In-line 
Product monitoring and process step endpoint 
determination 
Pharmaceutical - mannitol [35, 53] 
Off-line 
Moisture content determination with different 
stabilizer ratios 
Pharmaceutical - mannitol/sucrose [54] 
Off-line Hydrogen bond between protein and stabilzer Biopharmaceutical – Ribonuclease A (RNase A) [52] 
Off-line Trehalose crystallization monitoring Pharmaceutical - Trehalose [55] 
Off-line 
Classification of freeze-dried products according 
to composition, water content and solid-state 
properties 
Pharmaceutical - mannitol/sucrose [24] 
Off-line Solid state analysis of protein formulation Biopharmaceutical - Insulin and human growth hormone [56] 
Off-line Phenol quantification Biopharmaceutical - Phenol/Insulin formulation [57] 
Off-line Moisture content determination Pharmaceutical - mannitol [58] 
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Table 4.2: Applications of NIR spectroscopy for the freeze-drying process (continued) 
 
In-line Product monitoring: protein unfolding Biopharmaceutical - imunoglobuline G (IgG) [27] 
Off-line Virus evaluation Biopharmaceutical - Trehalose/live, attenuated virus [31] 
In-line, multipoint Moisture content monitoring Pharmaceutical - sucrose [25] 
In-line Monitoring of a multicomponent formulation Pharmaceutical - Mannitol, fenofibrate and tertiary-butyl alcohol [59] 
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4.3.2. FTIR spectroscopy 
Fourier Transform Infrared (FTIR) spectroscopy has been successfully used in several 
scientific and technical applications [60]. The expansion of the use of this technique (since 
2001) can be in part explained by the Fast Fourier Transform algorithm [61]. The idea is to 
split the light into two beams and measure the interference of their radiation. The detector 
measures a signal that is a function of the change in path length between these two beams. 
This obtained signal will finally be converted by a mathematical method, called Fourier 
Transformation (FT), to the normal output, i.e., frequencies [62]. In addition, the use of 
chemometric tools and the versatility of the spectroscopic technique which allows to analyze 
different types of samples (liquids, pastes, polymers, gases) contributed to the popularity of 
this technique [60, 61].  
FTIR spectroscopy studies the absorption of the electromagnetic radiation in the mid IR 
region (i.e., 2500-25.000nm or 4000-400cm-1) [60, 61].  Similarly to NIR spectroscopy, FTIR 
spectroscopy measures molecular vibrations (which vibrate in two modes: stretching and 
bending). The selection rule for molecules to be FTIR active is identical to NIR, being a 
change in dipole moment during their normal modes [60]. The principal difference between 
FTIR and NIR spectroscopy is that, FTIR spectroscopy mainly measures the fundamental 
vibrations of molecules (Figure 4.3) whereas NIR spectroscopy measures overtones and 
combinations of the fundamental vibrations [44, 61]. Fundamental vibrations are 
significantly higher in absorption than overtones and combination bands [44]. Therefore, the 
ability of FTIR spectroscopy to detect low levels of analyte is higher. Higher absorption also 
confers an advantage for the identification of molecules via their “fingerprint” region. 
Indeed, all mid-infrared fundamental absorptions bands in the FTIR fingerprint region 
(roughly below 1700cm-1), are already in their second or third overtone above 4000cm-1 and 
hence too weak to significantly contribute in the NIR [44]. 
4.3.2.1. Attenuated Total Reflectance (ATR) 
A wide range of sample interfaces (sampling accessories) have been developed for infrared 
spectroscopy over the past 20 to 30 years [60]. The attenuated total reflectance (ATR) unit 
allows to measure samples in different conditions (liquid, pastes, polymers, dehydrated 
samples) and also offers the advantage to require little or no sample preparation [61]. 
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In ATR, the sample is placed onto an optically dense crystal of relatively higher refractive 
index. When light transits between materials with different refractive indices, refraction 
occurs (Figure 4.6). If the transition is from a high refractive index material (crystal) to a low 
refractive index material (sample), the incident angle is smaller than the transmitted angle. 
When the internal angle reaches a critical level, the external angle is 90 degrees and the 
propagation of light is parallel to the surface of the interface between the materials and 
constitutes the critical angle. With ATR, the infrared beam enters the crystal at an angle 
greater than the critical angle of the crystal. This causes the IR energy to internally reflect off 
the parallel surfaces of the crystal.  
 
 
Figure 4.6: Light pathways between a crystal of high refractive index (nc) and a sample of lower 
refractive index (ns) in function of the incident angle [63].  
 
In ATR measurement, the IR beam reflects from the internal surface of the crystal and 
creates a small amount of radiation, an evanescent wave, which extends beyond the surface 
of the crystal and interacts with the sample in close contact with the ATR crystal (Figure 4.7). 
Some of the energy of the evanescent wave is absorbed by the sample and the reflected 
radiation is passed to the detector in the IR spectrometer as it exits the crystal [61]. 
Penetration depth at each reflection point (~ 2.0µm for a ZnSe crystal) depends on many 
factors and is wavelength-dependant. Longer wavelength waves penetrate deeper than 
shorter wavelength waves. 
Ɵ critical
Total reflexion
Crystal, nc
Sample, ns
Refraction
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Figure 4.7: ATR sample measurement [64]. 
 
4.3.2.2. FTIR applications in freeze-drying 
FTIR spectroscopy is recognized to be a tool of choice for the study of protein secondary 
structure [65]. It is therefore not surprising to find this tool in several studies dedicated to 
the freeze-drying process of proteins (Table 4.3). FTIR spectroscopy is a sensitive tool but the 
in-line measurements are not straightforward [66]. Indeed, in all cited studies of Table 4.3 
(except [67]), the FTIR spectra collection was performed off-line. As can also be observed in 
Table 4.3, the amide I band is the most often used to assess different proteins secondary 
structure. The amide I band is a characteristic band for proteins and polypeptides. The band 
arises from the amide bonds linking the different amino acids and is associated to stretching 
vibrations of the C=O bond of the amide with minor contributions from the out-of-phase CN 
stretching vibration [65]. Since the C=O is involved in the hydrogen bonds responsible for the 
protein secondary structure, frequency shifts of this amide I is associated to protein 
secondary structure changes and is therefore used in the different studies as a reference to 
assess the stability/conformation of proteins. 
Crystal, nc
Sample, ns
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Table 4.3: Applications of FTIR spectroscopy in the freeze-drying process. 
In process 
interfacing 
Monitored critical 
information 
Used as reference 
technique? 
Formulation type Reference 
In-line Amide I monitoring No Biopharmaceutical - Lysozyme/sucrose [67] 
Off-line Amide I evaluation Yes Biopharmaceutical - Actin [68] 
Off-line Amide I evaluation Yes 
Biopharmaceutical - Bovine chymotrypsinogen A and horse 
cytochrome C [26] 
Off-line Amide I evaluation Yes 
Biopharmaceutical - Imunoglobuline G (IgG) and 
recombinant human serum albumin [69] 
Off-line Amide I evaluation Yes Biopharmaceutical - Imunoglobuline G (IgG) [70] 
Off-line Amide I evaluation Yes Biopharmaceutical -  Various proteins [51] 
Off-line Amide I evaluation Yes Biopharmaceutical -  Imunoglobuline G (IgG) [71] 
Off-line Amide I evaluation Yes Biopharmaceutical - Human growth hormone (hGH) [72] 
Off-line 
Asparagine side chain 
(Amide I) No Biopharmaceutical - Ribonuclease A (RNase A) [52] 
Off-line Phenol quantification No Biopharmaceutical - Phenol/Insulin formulation [57] 
Off-line Amide I and II evaluation Yes Biopharmaceutical - β-galactosidase [73] 
Off-line Amide I evaluation Yes Biopharmaceutical - Imunoglobuline G (IgG) [27] 
Off-line Amide I evaluation Yes Biopharmaceutical - Imunoglobuline G (IgG) [74] 
Off-line Amide I evaluation Yes Biopharmaceutical - Lactic Dehydrogenase (LDH) [28] 
Off-line Amide I, II & III No Biopharmaceutical - Live, attenuated virus vaccine [32] 
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ABSTRACT 
This chapter examines the applicability of NIR spectroscopy to evaluate the virus state in a 
freeze-dried live, attenuated vaccine formulation. Therefore, this formulation was freeze-
dried using different virus volumes and after applying different pre-freeze-drying virus 
treatments (resulting in different virus states): (i) as used in the commercial formulation; (ii) 
without antigen (placebo); (iii) concentrated via a centrifugal filter device; and (iv) stressed 
by 96h exposure to room temperature. Each freeze-dried product was measured directly 
after freeze-drying with NIR spectroscopy and the spectra were analyzed using principal 
component analysis (PCA). Herewith, two NIR spectral regions were evaluated: (i) the 7300-
4000cm-1 region containing the amide A/II band which might reflect information on the 
coated proteins of freeze-dried live, attenuated viruses; and (ii) the C-H vibration overtone 
regions (10,000-7500 and 6340-5500cm-1) which might supply information on the lipid layer 
surrounding the freeze-dried live, attenuated viruses. The different pre-freeze-drying treated 
live, attenuated virus formulations (different virus states and virus volumes) resulted in 
different groups in the scores plots resulting from the PCA of the collected NIR spectra. 
Secondly, partial least squares discriminant analysis models (PLSDA) were developed and 
evaluated, allowing classification of the freeze-dried formulations according to virus pre-
freeze-drying treatment. The results of this chapter suggest the applicability of NIR 
spectroscopy for evaluating live, attenuated vaccine formulations with respect to their virus 
pre-freeze-drying treatment and virus volume. 
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CHAPTER 5 
NEAR-INFRARED SPECTROSCOPIC 
EVALUATION OF LYOPHILIZED VIRAL 
VACCINE FORMULATIONS 
 
5.1. INTRODUCTION 
The limited stability of many biopharmaceutical products in aqueous solutions is a well-
known problem. Drying these formulations prior to storage is a solution to overcome this 
instability issue. 
Therefore, freeze-drying has become a well-established and preferred technique in the 
pharmaceutical industry (despite the disadvantages of cost and process time) since 
approximately 46% of biopharmaceuticals are freeze-dried [1]. The freeze-drying process 
consists of 3 main consecutive steps: freezing, primary drying and secondary drying. During 
the freezing step, the temperature is decreased in order to convert most of the water into 
ice. Herewith, the solutes are crystallized or transformed into an amorphous system. During 
primary drying, vacuum is introduced in the freeze-drying chamber and the ice is removed 
by sublimation. The secondary drying step, occurring under deep vacuum, ends the process 
by removing the unfrozen water by desorption [2]. 
Although freeze-drying is performed to stabilize a product for long term storage and 
distribution, the freezing and dehydration steps themselves can be stressful and damaging 
for the biopharmaceutical product, hence reducing the therapeutic activity. Therefore, 
understanding the product behaviour and the mechanisms of stabilization and 
destabilization during freeze-drying are of crucial importance for optimal product and 
process design.  
According to the National Institute of Allergy and Infectious Diseases (NIAID), there are up to 
seven different types of vaccines: live attenuated vaccines, inactivated vaccines, subunit 
vaccines, toxoid vaccines, conjugate vaccines, DNA vaccines and recombinant vector 
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vaccines [3]. Because of their manufacturing simplicity and the strong immune response 
they generate, live, attenuated vaccines have been favored in many cases. The organisms of 
such vaccines can be bacteria (Tuberculosis (BCG), typhoid) or - most often - viruses 
(measles, mumps, rubella, polio, yellow fever, varicella and rotavirus) [4]. Due to their low 
stability in aqueous solution, most of the live, attenuated vaccines are freeze-dried. 
Studies elucidating the (de)stabilization mechanisms of live, attenuated viruses in vaccine 
formulations during freeze-drying are lacking. This lack of knowledge is a major barrier to the 
development of more thermally stable vaccines [5] and can be attributed to two main 
reasons: (i) measuring the destabilization mechanisms is complex because of the multiple 
destabilization pathways (such as oxidation, light-catalyzed reaction, change in ionic 
strength, pH shift due to buffer crystallization and possibly mechanical membrane damage 
due to ice crystal growth)[6,7], and (ii) the analytical tools allowing the evaluation of live, 
attenuated viruses during freeze-drying are lacking.  
As a consequence, biological potency assays after processing are the currently applied 
methods to evaluate whether the activity of the viruses is maintained [6, 8, 9]. 
Today, the stabilization strategies applied for live, attenuated viruses, their coated proteins 
and their surrounding lipid bilayer during freeze-drying are derived from the stabilizing 
actions taken for other biopharmaceutical products like proteins, cells and liposomes.  
However, the stabilization mechanisms during freeze-drying of proteins and biologicals in 
general, are currently still a matter of research and debate. Several hypotheses have been 
proposed but no full satisfactory explanation has yet been demonstrated [10-12]. The 
vitrification hypothesis states that the protein is molecularly dispersed into a glassy matrix 
which limits the molecular mobility needed for unfolding and other destabilization 
mechanisms [13]. This vitrification stabilization mechanism can also be helpful during freeze-
drying of live, attenuated virus formulations since the isolation of viruses into a glassy matrix 
can contribute to its protection by reducing the probability of unfolding and, as a 
consequence, aggregation of its coated proteins. The water-substitute hypothesis states that 
water removed from the environment of proteins (i.e., water shell) during drying is replaced 
by a lyoprotectant, which is hydrogen bonded to the protein hence thermodynamically 
stabilizing the protein. It is hypothesized that a lyoprotectant can also be hydrogen bonded 
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to the viral coated proteins hence stabilizing the live, attenuated virus. Furthermore, studies 
have also demonstrated that multiple hydrogen bonds can be formed between 
lyoprotectants and lipids [14, 15] via the phospholipid polar group at the surface of lipid 
bilayer vesicles [16] and liposomes [17]. This interaction might also be formed between 
lyoprotectants and the lipid layer of live, attenuated viruses.  
Furthermore, because of the more complex structure of live, attenuated viruses compared 
to e.g., proteins and liposomes, other  destabilization sources must be avoided during 
freeze-drying e.g., mechanical damages due to ice crystals and intra-cellular ice formation. 
As for cells and bacteria, the freezing step might destroy viruses via mechanical damage to 
the membrane, and via ice formation in the virus particle which may lead to its destruction. 
Compared to viruses, the impact of freezing on cells is much more studied [18, 19]. 
Freezing can damage cells for several reasons but intracellular ice formation is mostly fatal 
[18, 19]. Ice formation inside the cell (under fast cooling [19]) increases the concentration of 
electrolytes which affects the ionic interactions that can be involved to stabilize cellular 
enzymes. It can also change the osmotic potential of the cell or directly cause mechanical 
damages to the cellular ultra-structure [18, 19].  
De Beer et al., [20, 21] and Pieters et al., [22] recently proposed the first process analytical 
techniques (NIR and Raman spectroscopy) allowing the monitoring and evaluation of the 
product behaviour itself (excipients and proteins) during the entire freeze-drying process. 
These non-invasive analytical tools allow fast and non-destructive analysis of samples 
before, during and after freeze-drying. Determination of the residual moisture content 
through intact glass vials was the first application of NIR analysis of freeze-dried 
formulations [23-26]. Afterwards, focus has moved to the real time monitoring of product 
behaviour (APIs and excipients) during freeze-drying [20-22, 27, 28]. Protein dehydration and 
denaturation has been monitored using NIR spectroscopy by evaluating the amide A/II 
frequency (near 4850cm-1) which represents the strength of the hydrogen bonds of the 
amide group of proteins [22, 29, 30]. Liposomes were monitored by looking at the lipid layer 
via the analysis of the C-H overtones in NIR spectra [28]. Finally, FTIR spectroscopy has been 
used off-line to study the effect of different protectants on the membrane phase behaviour 
and the overall protein secondary structure of air-dried Lactobacillus bulgaricus by 
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evaluating the C-H stretching region (3000-2800cm-1) and the amide I and II bands (1655 and 
1545cm-1, respectively) [31]. 
To our best knowledge, it has never been demonstrated whether NIR spectroscopy can 
evaluate viruses in vaccine formulations and distinguish intact from non-intact live, 
attenuated viruses. The aim of this chapter is to examine the applicability of NIR 
spectroscopy to evaluate the virus in a freeze-dried live, attenuated vaccine formulation. 
Therefore, this formulation was freeze-dried using different virus volumes and after applying 
different pre-freeze-drying virus treatments (resulting in different virus states): (i) as used in 
the commercial formulation; (ii) without antigen (placebo); (iii) concentrated via a 
centrifugal filter device; and (iv) stressed by 96h exposure to room temperature. 
 
5.2. MATERIALS AND METHODS 
5.2.1. Materials  
The live, attenuated virus used as vaccine in this chapter was obtained from Zoetis.   
For the first experiments performed to study the capability of NIR to evaluate the virus state, 
the live, attenuated viruses were differently pre-freeze-drying treated. Depending on the 
applied pre-freeze-drying treatment (further termed ‘pretreatment’), the virus quality, 
integrity or state might vary. The resulting formulations were named after their 
pretreatment:  'normal' (i.e., as used in the commercial formulations), 'absent' (i.e., placebo 
formulations), 'concentrated' via a centrifugal filter device (Millipore, Amicon® Ultra) and 
'stressed' (by storage at room temperature for 96hours). For clarity, the 'concentrated' virus 
samples were prepared using a similar virus culture medium volume as the 'normal' virus 
samples, but because of the centrifugation pretreatment process they contain more viral 
particles in that volume. The other formulation components (stabilizers and buffer) were 
similar as in the commercial formulation and thus kept constant for these four classes. 
Detailed information on the composition of the commercial formulation cannot be given 
because of confidentiality reasons.  
For a second series of experiments, the stabilizers from the commercial formulation were 
replaced by trehalose (Cargill, Krefeld, Germany) in order to make the formulation less 
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complex for the NIR spectral interpretation (see results section). Trehalose is a well-known 
cryo-/lyoprotectant used in many freeze-dried formulations. Its ability to maintain a 
satisfying titer (i.e., similar to the commercial formulation) after lyophilization and to provide 
a freeze-dried cake with sufficient elegance was investigated and confirmed in preliminary 
experiments. The same four classes (normal, concentrated, placebo, stressed) as for the 
commercial formulation were freeze-dried and an additional placebo formulation which only 
contained the culture medium of the virus was also freeze-dried. This placebo formulation is 
further called 'flow through' formulation since the culture medium, free from virus, is 
obtained by collecting the flow through after the centrifugation.  
An overview of all formulations used for this study is given in Table 5.1a.  
Besides examining whether NIR spectroscopy is able to evaluate viruses differently 
pretreated, also its ability to detect differences in added volume of virus culture medium to 
the formulations was studied. This study was only done for the trehalose formulation. Four 
virus formulations varying in virus volume were prepared (Table 5.1b). Stabilizer and buffer 
were kept constant (concentration and volume).  
An overview of all formulations used in this chapter is presented in Figure 5.1. 
 
Table 5.1: Overview of the studied live, attenuated virus formulations. 
 
Virus 
pretreatment 
Virus 
medium (µl) 
Buffer 
(µl) 
Stabilizer (µl) 
qsp filling 
volume (µl) 
Total 
volume (µl)  If commercial 
formulation 
If  Trehalose 
formulation 
a Normal x y z 9% w/v j 800 
Stressed x y z 9% w/v j 800 
Concentrated x y z 9% w/v j 800 
Without 0 y z 9% w/v j + x 800 
Flow through x y NA 9% w/v j 800 
b Normal 0 y NA 9% w/v i + 400 800 
Normal 30 y NA 9% w/v i + 370 800 
Normal 100 y NA 9% w/v i + 300 800 
Normal 400 y NA 9% w/v i + 0 800 
a) Virus pretreatment study. b) Virus volume study.  
All symbols (x, y, z and j) represent  absolute values in µl. 
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Figure 5.1: Overview of the formulations used in the (a) virus pretreatment study and (b) virus 
volume study. 
 
The virus pretreatment study was performed independently from the virus volume study. 
The difference between both studies is the volume of virus culture medium that has been 
used. A constant volume was used for the virus pretreatment study (Table 5.1a) whereas 
different virus volumes were used for the virus volume study (Table 5.1b).  
The studied formulations (Table 5.1) were freeze-dried multiple times, resulting in several 
batches (Table 5.2). 
 
 
 
 
 
(a) Virus pretreatment study
(b) Virus volume study
Virus medium
Water
20min
4000g
Filter
10.000M
96h @ RT before 
freeze-drying
Stressed
0µl 30µl 100µl 400µl
Concentrated Flow throughNormalAbsent
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Table 5.2: Overview of the freeze-dried batches of each used live, attenuated virus formulation.  
Batches Batch ID Formulation Study 
Sample types per 
batch & number of 
samples per type 
Number of 
titrated 
samples  
Analyzed spectral 
regions  
7300-
4000 cm-1 
10,000-
7500 & 
6340-
5500cm-1 
Commercial 
formulation 
1 
Com1 Table 5.1a 
Virus 
pretreatment 
Normal: 20 samples Normal: 6/20 
X X 
Stressed: 20 samples 
Stressed: 
8/20 
Concentrated: 20 
samples 
Concentrated: 
6/20 
Without: 20 samples Without: 0/20 
Total: 80 samples 
Total: 20 
samples 
Commercial 
formulation 
2 
Com2 Table 5.1a 
Virus 
pretreatment 
Normal: 19 samples Normal: 5/19 
X 
  
Stressed: 19 samples 
Stressed: 
0/19 
Concentrated: 20 
samples 
Concentrated: 
5/20 
Without: 20 samples Without: 0/20 
Total: 78 samples 
Total: 10 
samples 
Trehalose 
formulation 
1 
Treha1 Table 5.1a 
Virus 
pretreatment 
Normal: 20 samples Normal: 0/20 
  X 
Concentrated: 20 
samples 
Concentrated: 
0/20 
Without: 19 samples Without: 0/19 
Total: 59 samples 
Total: 0 
sample 
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Table 5.2: Overview of the freeze-dried batches of each used live, attenuated virus formulation 
(continued).  
Trehalose 
formulation 
2 
Treha2 Table 5.1b Virus volume 
0µl: 10 samples 
0µl: 0 
samples 
X X 
30µl: 10 samples 
30µl: 4 
samples 
100µl: 10 samples 
100µl: 4 
samples 
400µl: 10 samples 
400µl: 4 
samples 
Total: 40 samples 
Total: 12 
samples 
Trehalose 
formulation 
3 
Treha3 Table 5.1a 
Virus 
pretreatment 
Normal: 10 samples Normal: 6/10 
X X 
Concentrated 1min: 
10 samples 
Concentrated 
1min: 8/10  
Concentrated 10min: 
10 samples 
Concentrated 
10min: 8/10 
Concentrated 20min: 
10 samples 
Concentrated 
20min: 8/10  
Flow through: 10 
samples 
Flow through: 
0/10  
Without: 10 samples Without: 0/10  
Total: 60 samples 
Total: 30 
samples 
Trehalose 
formulation 
4 
Treha4 Table 5.1a 
Virus 
pretreatment 
Normal: 29 samples 
Normal: 
17/29 
  X 
Concentrated: 27 
samples 
Concentrated: 
7/27 
Flow through: 30 
samples 
Flow through: 
0/30 
Without: 30 samples Without: 0/30 
Total: 116 samples 
Total: 24 
samples 
Trehalose 
formulation 
5 
Treha5 Table 5.1a 
Virus 
pretreatment 
Normal: 30 samples Normal: 0/30 
  
X 
Concentrated: 30 
samples 
Concentrated: 
14/30 
Flow through: 30 
samples 
Flow through: 
0/30 
Without: 30 samples Without: 0/30 
Total: 120 samples 
Total: 14 
samples 
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Table 5.2: Overview of the freeze-dried batches of each used live, attenuated virus formulation 
(continued).  
Trehalose 
formulation 
6 
Treha6 Table 5.1a 
Virus 
pretreatment 
Normal: 20 samples 
Normal: 
12/20 
  
X 
Concentrated: 20 
samples 
Concentrated: 
12/20 
Flow through: 20 
samples 
Flow through: 
0/20 
Without: 20 samples Without: 0/20 
Total: 80 samples 
Total: 24 
samples 
 
5.2.2. Freeze-Drying 
Freeze-drying experiments were performed using an Amsco FINN-AQUA GT4 freeze-dryer 
(GEA, Köln, Germany). 
Different freeze-drying process settings were used depending on the formulation. For 
confidentiality reason, these freeze-drying cycle settings are not detailed. All freeze-dried 
cakes had an elegant appearance without signs of collapse. 
 
5.2.3. NIR spectroscopy 
NIR spectra of all freeze-dried samples from each batch were collected off-line using a 
Fourier-Transform NIR spectrometer (Thermo Fisher Scientific, Nicolet Antaris II near-IR 
analyzer) equipped with an InGaAs detector and a quartz halogen lamp. One NIR spectrum 
per freeze-dried sample was recorded in the 10000-4000cm-1 region with a resolution of 
8cm-1 and averaged over 16 scans through the bottom of the glass vial in random order with 
the integrating sphere device. The NIR spectra were collected immediately after freeze-
drying. 
5.2.4. Data analysis 
NIR spectral data analysis was done using SIMCA P+ v.12.0.1 (Umetrics, Umeå, Sweden). Two 
spectral regions were evaluated: (i) the amide A/II band (7300-4000cm-1) which might reflect 
information on the coated proteins (Haemagglutinin and Neuraminidase) from the studied 
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freeze-dried live, attenuated viruses; and (ii) the C-H vibration overtone regions (10,000-
7500 and 6340-5500cm-1) which might supply information on the lipid layer surrounding the 
freeze-dried live, attenuated viruses. In order to avoid the influence of water in the 7300-
4000cm-1 region, this spectral range has also been reduced to 5029-4000cm-1. The 10000-
7500 & 6340-5500cm-1 spectral ranges were selected based on the work from Christensen et 
al., [28] and contains the 1st and 2nd overtone of the CH- group. This spectral range has the 
advantage not to be influenced by water. Table 5.2 overviews the analyzed spectral ranges 
for each freeze-dried batch. All collected NIR spectra were preprocessed using standard 
normal variate (SNV) and second derivatives with Savitzky-Golay smoothing (37 points) (the 
latter only for the 7300-4000cm-1 spectral region). The use of SNV preprocessing eliminates 
the additive baseline offset variations and multiplicative scaling effects in the spectra which 
may be caused by possible differences in sample density and different-sample-to-sample 
measurement variations. Second derivatives have been selected for (a) spectral 
discrimination, as a qualitative fingerprinting technique to accentuate small structural 
differences between similar spectra; and for (b) spectral resolution enhancement, as a 
technique for increasing the apparent resolution of overlapping spectral bands in order to 
more easily determine the number of bands and their wavelengths. 
All collected NIR spectra per batch were analyzed as one data matrix (D) using principal 
component analysis (PCA), allowing to examine the spectral differences between the 
different sample types per batch (Table 5.2). PCA produces an orthogonal bilinear data 
matrix (D) decomposition, where principal components (PCs) are obtained in a sequential 
way to explain maximum variance:  
D=TPT + E 
= t1p’1 + t2p’2 +…+tQp’Q + E 
 
Where T is the M x Q score matrix, P is the N x Q loading matrix, E is the M x N model 
residual matrix, i.e., the residual variation of the data set that it is not related to any 
chemical contribution. Q is the selected number of PCs, each describing a non-correlated 
physical phenomenon in the data set, and N is the number of collected spectra at M 
wavelengths [32]. Each principal component consists of two vectors, the score vector t and 
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the loading vector p. The score vector contains a score value for each spectrum, and this 
score value informs how the spectrum is related to the other spectra in that particular 
component. The loading vector indicates which spectral features in the original spectra are 
captured by the component studied. These abstract, unique, and orthogonal PCs are helpful 
in deducing the number of different sources of variation present in the data. However, these 
PCs do not necessarily correspond to the true underlying factors causing the data variation, 
but are orthogonal linear combinations of them, since each PC is obtained by maximizing the 
amount of variance it can explain [33]. 
Furthermore, partial least square discriminant analysis (PLSDA) models were developed 
based on the NIR spectra from the different sample types (normal, placebo, concentrated 
and stressed). PLSDA models are able to accomplish a rotation of the projection to give 
latent variables a focus on class separation (“discrimination”). This model takes into account 
the class membership of observations and is developed from a training set of observations of 
known classes (sample pretreatments) [34]. The aim was to use the PLSDA models to predict 
the class membership of future samples. To evaluate the well known risk that the PLSDA 
model is spurious, i.e., the model just fits the training set well but doesn’t predict the new 
observations correctly, a permutation test was used. The idea of this validation is to 
compare the goodness of fit and the goodness of prediction (R2 and Q2, respectively) of the 
original model with the goodness of fit and the goodness of prediction of several models 
based on data where the class membership has been randomly permuted, while the X-
matrix has been kept intact. The ability of each created PLSDA model to classify observations 
was evaluated using a misclassification table. Such table shows the proportion of correct 
classification of the tested new observation set. The calculated misclassification rates are 
considered as good indicators of model performance [35]. 
 
5.2.5. Titration 
Titration was done according the company internal SOP. Each titer is the average of triplicate 
measurements and is expressed in log10 CCID50 (Cell Culture Infection Dose 50 – Inverse of 
the highest dilution which produces a cytopathogenic effect in 50% of the cells). Titration 
provides information regarding the number of viral particles contained in each vial.  
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Statistical analysis for comparing the significant titer differences between the different 
pretreated samples was performed using the non-parametric Kruskal-Wallis analysis of 
variance test (Minitab (R) 15.1.1.0 software). In addition, in order to determine which group 
of pretreated samples differs significantly, Dunn’s test was performed using a Matlab m-file 
[41] as follow-up test (Matlab 7.12, The Mathworks, Natick, MA). For practical reason, only 
some samples from each batch could be titrated and are presented in Table 5.2.  
 
5.2.6. Karl Fischer  
The residual moisture content was determined on 24 samples from batch Treha2 (Table 5.2) 
using Karl Fischer titration. A Mettler Toledo V30 volumetric Karl Fischer titrator 
(Schwerzenbach, Switzerland) with Hydranal® titration solvent from Sigma Chemical 
Company was used. A known volume of dried methanol was added to the sampled vial, and 
left to equilibrate for a few minutes. From the solution, a known volume was then removed 
volumetrically using a syringe and injected into the titration cell. The water content of pure 
methanol was determined in duplicate prior to the measurement and subtracted from the 
result. All titrated vials were measured in duplicate. 
 
5.3. RESULTS AND DISCUSSION 
The discussion of the results is divided into two parts, based on the column 'study' in Table 
5.2: (i) virus pretreatment; (ii) virus volume. Furthermore, each study is subdivided into two 
parts being the results obtained by analyzing the spectral region (7300-4000cm-1) 
corresponding to the coated proteins and the results obtained by analyzing the spectral 
region (10000-7500 & 6340-5500 cm-1) corresponding to the lipid layer covering the live, 
attenuated viruses.  
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5.3.1. Virus pretreatment study 
5.3.1.1. Spectral region 7300-4000cm-1  
 Principal component analysis (PCA) 
Principal component analysis was performed on all collected spectra from batch Com1 
(Table 5.2) (i.e., 80 spectra, 1 spectrum per sample, 20 samples per virus pretreatment 
class). All preprocessed NIR spectra were decomposed into four principal components (PCs) 
explaining 80.9% of the spectral variance, where PC1 accounted for 30.5%, PC2 28.8%, PC3 
13.1% and PC4 8.5% of the spectral variance, respectively.  The PC1 versus PC2 scores plot 
(Figure 5.2a) showed no separation along PC1 according to the sample pretreatment. A peak 
around 5280cm-1, representing water [36] in the PC1 loadings (Figure 5.2b), indicated that 
PC1 differentiates between the samples according to moisture content. The residual 
moisture variability in the samples was hence independent from the sample pretreatment 
since the spectra from the samples differently pre-treated were randomly spread along PC1. 
Interestingly, the PC2 versus PC3 scores plot (Figure 5.2c) distinguished the samples 
according the pretreatment. Examination of the PC2 and PC3 loadings to identify the 
spectral variability responsible for this separation revealed that many NIR signals (except 
water bands since these were captured by PC1) contributed to this separation (data not 
shown). This is most probably due to the complexity of the commercial formulation which 
contains e.g., more than three stabilizers. However, the excipients were similar in each 
differently pretreated sample from batch Com1. The only difference between the samples 
types from batch Com1 (Table 5.2) was the pretreatment. Although the spectra were 
separated according to pretreatment, it was not possible to explain this from the spectral 
contributions because of the complexity of the loadings and the formulation. 
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Figure 5.2: Scores plots obtained after PCA of the spectra collected from batch Com1 (7300-4000cm-1 
spectral region) a) PC1 versus PC2 scores plot b) PC1 loadings line plot c) PC2  versus PC3 scores plot. 
Each point represents one different vial and each symbol represents a different sample 
pretreatment. 
 
To ensure that the observed groups in the PC2 versus PC3 scores plot was related to the 
sample pretreatment, several verifications were done.  
Undoubtedly, examination of the virus itself gained the first attention. As mentioned in the 
introduction, only biological potency assays after freeze-drying were possible. These assays 
are not of high precision [8] and only result in a titer (quantitative information) without 
qualitative information.  
Titration of the samples revealed that the ‘stressed’ samples having a mean titer of 5.46±0.2 
(n=8), were significantly different from the mean titer (6.91±0.09, n=6) of the ‘concentrated’ 
samples (Kruskal-Wallis, p<0.05). Having a titer of 6.56±0.14 (n=6), the 'normal' samples 
Normal
Without
Concentrated
Stressed
a c
b
5280cm-1
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were not significantly different from the 'stressed' or the ‘concentrated’ samples even if the 
‘normal’ samples were distinguished from the other samples by NIR spectroscopy. This can 
be a confirmation of the low precision of the assay [8] to detect the differences between 
pretreated samples. 
Fourteen weeks after freeze-drying of batch Com1, NIR spectra were collected again. PCA 
was done combining these spectra and the spectra collected directly after freeze-drying, 
resulting in a four components PCA model explaining 94.3% of the spectral variance. The PC1 
versus PC4 scores plot is presented in Figure 5.3a. In this scores plot, PC1 (explaining 82.9% 
of the spectral variance) showed a separation according to storage time while PC4 (2.4% of 
the spectral variance) showed a separation according virus pretreatment. PC2 and PC3 
explained respectively 6% and 2.9% of the spectral variance and did not show any separation 
anymore. The examination of the PC1 and PC4 loadings (Figure 5.3b) revealed that the 
clustering according storage time along PC1 was attributed to differences in water content 
whereas the separation according virus pretreatment along PC4 was due to many NIR 
signals, which were difficult to interpret because of the complexity of the commercial 
formulation. Increase in residual moisture content during storage can be observed and was 
most probably caused by moisture release from the stopper [37]. 
When analyzing by PCA the spectra collected after 14 weeks of storage individually,  the PC2 
versus PC3 scores plot (model explaining 83.4% of the total spectral variance, PC2= 15.4% 
and PC3=13.6%) also showed clustering according virus pretreatment (Figure  5.3c), although 
less clear compared to the scores plot from the spectra collected before storage (Figure 
5.2c). 
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Figure 5.3: Impact of storage time. a) PC1 versus PC4 scores plot obtained after PCA of the spectra 
collected before and after storage. b) Corresponding PC1 (black dotted) and PC4 (red) loadings line 
plot c) PC2 versus PC3 scores plot obtained after PCA on the spectra collected only after storage. 
Each point represents one sample and each symbol represents a different virus pretreatment. 
 
Finally, as it can be seen in Table 5.1a, the viruses are contained in a culture medium 
(inherent to virus production, culture). The viruses and the culture medium hence form the 
virus medium (Table 5.1a). In order to ensure that the observed NIR spectral differentiation 
according to pretreatment (Figure 5.2c) were not due to culture medium changes but due to 
viruses changes, a batch identical to batch Com1 but only containing  culture medium was 
differently pretreated (normal, stressed, concentrated) and then freeze-dried. These 
samples were then measured using NIR spectroscopy and analyzed by PCA. The obtained 
scores plots did not show any spectral differentiation among these differently pretreated 
samples of this 'culture medium' batch (data not shown). This confirmed that the higher 
Normal
Without
Concentrated
Stressed
a c
b
14 weeks storage No storage
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observed NIR spectral differences according to virus medium pretreatment were due to virus 
modifications and not culture medium changes.  
Exploratory analysis with PCA suggests that NIR spectroscopy is able to distinguish between 
the four different 'virus pretreatments' in the commercial vaccine formulations. However, it 
was not possible to interpret the spectral variability (from the loadings) which is responsible 
for the clustering in the scores plots. Therefore, in new experiments less complex 
formulations, (i.e., formulations having less different excipients) were used (see further).  
 Partial least square discriminant analysis (PLSDA)  
Since the formulations subjected to different pretreatments could be distinguished from the 
NIR data, the possibility to classify future freeze-dried samples according to their 
pretreatment was evaluated. Therefore, a PLSDA model was built using batch Com1 (Table 
5.2), excluding the placebo samples (without viruses). The 60 collected spectra (20 normal, 
20 concentrated and 20 stressed) were divided into a training and a test set. The training set 
contained 39 spectra (13 spectra per sample pretreatment) and was used to develop the 
model. The test set was then used to evaluate the model. The developed PLSDA model 
existed of five components (R2Y= 0.963 and Q2Y= 0.938). The Q2 parameter expresses the 
predictive ability of the model and is obtained by cross validation [34]. Special attention 
should be paid to the validation of PLSDA models. The Q2 value can provide over-optimistic 
results [35]. Therefore, combination with other model evaluation techniques such as 
permutation tests [35, 39], and model performance evaluation via misclassification tables 
are advised [35] and have been used in this study.  
For the permutation test, a total of 20 permutations of the class membership (Y-block) was 
done while the spectra in the X-block were not permutated. For each permutation, a PLSDA 
model was fitted and the new estimates of R2Y and Q2Y values were computed. These values 
were afterwards plotted in a permutation plot and compared to the original Q2Y and R2Y 
values (Figure 5.4). If the original values are outside the distribution of the permuted values, 
a high validity of the original model may be assumed [40]. Analysis of the permutation plot 
(Figure 5.4) hence contributed to validating the original model since all the permuted Q2 
values were clearly lower than the original Q2 value (top right Figure 5.4) and since the 
regression line of the Q2 values intersected the vertical axis below zero [34]. Moreover, 
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when all permuted R2 values are lower to the original R2 value, this is also an indication for 
the validity of the original model [34]. 
 
Figure 5.4: Validation plot obtained by performing a permutation test. The plot shows, for a selected 
y-variable (‘normal’ variable), on the vertical axis the values of R2 (green triangle) and Q2 (blue 
square) for the original model (far to the right) and of the Y-permuted models further to the left. The 
horizontal axis shows the correlation between the permuted y-vectors and the original y-vector for 
the selected y (‘normal’ variable). Two regression lines have been fitted, one among the R2Y points 
and another one among the Q2Y points (Intercepts: R2 = (0.0, 0.163) and Q2 = (0.0, - 0.361)). 
 
The predictability of the PLSDA model was finally evaluated using a misclassification table in 
which the spectra from the test set - spectra not used for the model development - were 
classified by the model and in which the proportion of misclassification of the test set 
samples is given. As can be seen from the misclassification table (Table 5.3), the prediction 
of the test set was 100% correct. The test set samples were from the same batch as the 
training set samples (batch Com1). The number of correct classifications is presented for 
each class. 
Table 5.3: Misclassification table overviewing the predictions of the test samples using the PLSDA 
model.  
  Members  Correct classification rate (CCR, %) Normal Stressed Concentrated 
Normal 7 100% 7 0 0 
Stressed 7 100% 0 7 0 
Concentrated 7 100% 0 0 7 
No class 0  0 0 0 
Total 21 100% 7 7 7 
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In a next step, the classification ability of the PLSDA model was evaluated using samples 
from another freeze-dried batch; i.e., batch Com2 (Table 5.2) containing similar formulations 
as batch Com1: 19 'normal ' samples, 19 'stressed' samples and 20 'concentrated' samples.  
Table 5.4: Misclassification table overviewing the predictions of the external test set (batch Com2) 
using the PLSDA model.  
 Members Correct classification rate (CCR, %) Normal Stressed Concentrated 
Normal 19 100% 19 0 0 
Stressed 19 0% 19 0 0 
Concentrated 20 65% 7 0 13 
No class 0  0 0 0 
Total 58 55.17% 45  13 
 
The misclassification table (Table 5.4) showed that all 'normal' samples were correctly 
classified. The stressed samples were all wrongly classified as normal. There is a possibility 
that these samples were not enough stressed to be classified as stressed viruses and that 
they were therefore classified as normal samples. In order to stress the viruses, they were 
exposed 96hours at room temperature. However, this stressing condition is subject to 
variation of the surrounding environment resulting in uncontrolled stressing and hence 
possibly not enough stressed viruses in case of batch Com2. Unfortunately, due to a titration 
problem, no titers were obtained for these stressed samples. It was therefore impossible to 
confirm that the viruses exposed to stressing conditions had similar titers as the unstressed 
samples. The PLSDA model claimed that there was no difference between the stressed and 
normal samples from batch Com2. Finally, 65% of the ‘concentrated’ samples were correctly 
classified. The other 35% were classified as 'normal'.  
Five concentrated samples were titrated from batch Com2. Among these, samples C4 and C5 
were misclassified by the model (i.e., as normal samples). However, from the titration results 
(Figure 5.5) it can be seen that concentrated samples C4 and C5 had a titer similar to the 
titers of the 'normal' samples (N1-N5) whereas the titers of the correctly classified 
'concentrated' samples (C1, C2 and C3) were higher. 
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Figure 5.5: Titration results of batch Com2. In gray, normal samples and in white, concentrated 
samples. Titers are expressed as log10 CCID50 (Cell Culture Infection Dose 50). Each titer is the mean of 
3 determinations ± standard deviation. 
 
5.3.1.2. Spectral region 10000-7500 & 6340-5500cm-1 
To evaluate the live, attenuated virus samples via the surrounding lipid bilayer, another NIR 
spectral region (10000-7500 & 6340-5500cm-1) was selected. Compared to the above 
analyzed protein region, this spectral region offers the advantage that it does not include the 
NIR spectral water band regions [28]. PCA using this spectral region of the NIR spectra 
collected from batch Com1 (Table 5.2) did not allow to distinguish between the samples 
according virus pretreatment (PCA scores plot not shown).  
To simplify the NIR spectral analysis (i.e., to avoid disturbing NIR spectral signals from the 
different excipients in the commercial formulation in the NIR spectral ranges used to 
evaluate the virus pretreatment), and based on the fact that Christensen and co-workers 
[28] were able to detect liposomes in a trehalose formulation using the spectral ranges 
10000-7500 & 6340-5500cm-1, trehalose 9% w/v was used to replace the stabilizers from the 
commercial formulation (Table 5.1a).   
 Principal component analysis (PCA) 
Principal component analysis was performed on the NIR spectra from all samples of batch 
Treha1 (Table 5.2) and allowed clear distinction between the different virus pretreatments 
(data not shown). This was more extensively studied using batch Treha3 (Table 5.2). This 
batch contained 60 samples in total having 6 different virus pretreatments (10 samples per 
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virus pretreatment): normal, absent (i.e., placebo formulations), concentrated via a 
centrifugal filter device using different centrifugation times (1 minute, 10 minutes or 20 
minutes) and the flow through pretreatment (see materials and methods).  
Within batch Treha3, different PCA were performed using the two spectral ranges (10000-
7500 & 6340-5500cm-1) individually and combined. The PCA of the NIR spectra from the 
samples 'normal', 'concentrated 20min', 'flow through', and 'without' using the 10,000-
7500cm-1 spectral region consisted of 2 PCs explaining 95.3% of the spectral variability. The 
first PC explained 89.4% of the spectral variability and was responsible for the separation 
according virus pretreatment (Figure 5.6a). PCA using the 6340-5500 cm-1 NIR spectral region 
also resulted in separation according to virus pretreatment (Figure 5.6b). These 2 PCs 
explained 96.5% of the spectral variability, where the first principal component accounted 
for 93.4% and allowed differentiation according to the virus pretreatment (Figure 5.6b). 
Separation was also seen along the second component, where the placebo samples were 
isolated from the samples containing virus medium.  The groups in both scores plots in 
Figure 5.6 are explained in their corresponding PC1 loadings in Figures 5.6c and 5.6d. For 
both spectral regions, the NIR signal responsible for the separation corresponded to the 1st 
and 2nd C-H overtones from the lipids surrounding the live, attenuated viruses.  
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Figure 5.6: Scores and loadings plots obtained after PCA of the NIR spectra from the samples normal, 
concentrated 20min, flow through and without of batch Treha3 using the 10,000-7500cm-1 and 6340-
5500 cm-1 spectral regions. a) PC1 versus PC2 scores plot (10,000-7500cm-1) b) PC1 versus PC2 scores 
plot (6340-5500cm-1). c) PC1 loadings plot (10,000-7500cm-1) d) PC1 loadings plot (6340-5500cm-1). 
 
Another PCA was performed for evaluating the differently concentrated samples from batch 
Treha3 (Table 5.2), prepared using different centrifugation times (i.e., 1 minute, 10 minutes 
and 20 minutes). The titration results of these differently concentrated samples showed that 
the highest centrifugation time (20 minutes) resulted in the highest titer (Figure 5.7d). PCA 
analysis was performed to evaluate whether these concentration differences could also be 
derived from the NIR spectra. 
Normal
Concentrated
Without
Flow through
a b
c d2nd C-H overtone (10,000-7500cm-1) 1st C-H overtone (6340-5500cm-1)
2nd C-H overtone (10,000-7500cm-1) 1st C-H overtone (6340-5500cm-1)
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Figure 5.7: PC1 versus PC2 and PC2 versus PC3 scores plots obtained after PCA of the NIR spectra 
from the samples obtained after applying different centrifugation times. (Normal = no centrifugation, 
concentrated 1min, concentrated 10min and concentrated 20min = centrifugation times of 1 minute, 
10 and 20 minutes respectively. Each color in the scores plots represents the samples subjected to a 
different centrifugation time. a) PC1 versus PC2 scores plot. b) PC 1 loadings plot. c) PC2 versus PC3 
scores plot. d) Titration results. 
 
The PCA of the NIR spectra collected from the differently concentrated samples in batch 
Treha3 consisted of 3 PCs explaining 93.6% of the spectral variance. The first principal 
component accounted for 77% of the spectral variability and did not distinguish between the 
differently concentrated samples (Figure 5.7a). The analysis of the loadings of this 
component showed the C-H overtone corresponding to the lipid layer (Figure 5.7b). The PC2 
versus PC3 scores plot (Figure 5.7c) clearly differentiated between the viruses centrifugated 
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for 20 minutes and the other samples. The differences in titration results might explain this 
clustering (Figure 5.7d). The 20 minutes concentrated samples had a titer (6.88±0.29, n=8) 
which was significantly higher (Kruskal-Wallis, p<0.05) than the 10 minutes and 1 minute 
concentrated samples and the normal samples (6.52±0.31 n=8, 6.45±0.31 n=8 and 6.45±0.33 
n=6), respectively. 
 Partial least square discriminant analysis (PLSDA).  
Using different independent trehalose batches (Treha 1-4-5-6, Table 5.2), a PLSDA model 
was built to evaluate the possibility to classify the different virus pretreatment samples using 
the lipid spectral range.  
The training set to develop the PLSDA model consisted of the NIR spectra from 375 samples 
of batches Treha 1-4-5-6, representing 4 different virus pretreatments (normal, 
concentrated, flow through and without). The developed PLSDA model consisted of five 
components (R2Y= 0.778 and Q2Y= 0.682). Similarly to the PLSDA model built for batch 
Com1, a permutation test was performed. A total of 20 permutations of the class 
membership were done and the analysis of the permutation plot validated the model (data 
not shown). The PLSDA model was further evaluated using the Treha3 batch (as independent 
test batch) containing 10 normal, 10 concentrated for 20 minutes, 10 flow through and 10 
without samples. 
 
Table 5.5: Misclassification table overviewing the predictions of the external test set (batch Treha3) 
using the PLSDA model.  
 Members  
Correct 
classification 
rate (CCR, %)  
Normal  Concentrated  FT  Without  
Normal  10 50% 5 5 0 0 
Concentrated 10 90% 0 9 1 0 
FT  10 90% 0 1 9 0 
Without  10 100% 0 0 0 10 
No class  0  0 0 0 0 
Total 40 82,50% 5 10 15 10 
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In total, 82.5% of the samples from the test batch were well classified (Table 5.5). The 
without samples were 100% correctly attributed, the concentrated and flow through 
samples had a score of 90%. The normal samples were less correctly classified: 50% were 
classified as normal but 50% were wrongly classified as concentrated. However, the titration 
results of the samples from batch Treha3 revealed that several normal samples had a high 
titer (N1 and N2) (Figure 5.8). This might be the reason why they were classified as 
concentrated samples by the model. Moreover, several concentrated samples from the 
batches used to build the model were probably not enough concentrated which can also 
explain that normal samples with high titers were misclassified and considered as 
concentrated samples. 
 
 
Figure 5.8: Titration results of the normal and 20 minutes concentrated samples from the 
independent test batch (Treha3).  
 
5.3.2. Virus volume study 
This part of the study evaluates the ability of NIR spectroscopy to distinguish differences in 
applied virus volume in freeze-dried live, attenuated vaccine formulations. Four trehalose 
formulations varying in virus volume were prepared as described in Table 5.1b. The stabilizer 
and buffer were kept constant (concentration and volume) as well as the virus pretreatment 
(normal). The added water volume was varied depending on the applied virus volume in 
order to guarantee an equal total volume in each formulation. One batch (Treha2, Table 5.2) 
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was freeze-dried for this study. The residual moisture and titer of some samples from each 
volume class were determined. The vials containing 0µl of virus were not titrated as they did 
not contain the antigen. The 30µl virus volume vials had a titer of 6.56±0.1 (n=4), which 
differed significantly from the 400µl virus volume samples which had a titer of 8.3±0.5 (n=4) 
(Kruskal-Wallis, p<0.05) (Figure 5.9a). The 100µl virus volume samples had a titer of 
7.52±0.35 (n=4) which did not significantly differ from the 30µl and 400µl virus volume 
samples.  
The Karl Fischer analysis revealed an increase of the residual moisture with the virus volume 
(Figure 5.9b). The 0µl vials had a residual moisture of 1.22±0.1% (n=6), the 30µl, 100µl and 
400µl had a residual moisture content of 1.49±0.1% (n=6), 2.31±0.3% (n=6) and 4.92±0.3% 
(n=6), respectively. 
 
Figure 5.9: Titration and residual moisture results of the Treha2 batch. a) Titration results. b) Residual 
moisture results. 
 
After freeze-drying, NIR spectra were collected from each sample (i.e., 40 spectra) of batch 
Treha2. The NIR spectra were analyzed using PCA for both the 7300-4000cm-1 and the 
10,000-7500 cm-1 spectral ranges. 
5.3.2.1. Spectral region 7300-4000cm-1 
The PCA performed on the 40 spectra described 97.7% of the spectral variability (composed 
by 2 PCs). The PC1 versus PC2 scores plot showed that the first PC (explaining 95.3% of the 
spectral variability) distinguished the samples according to their virus volume (Figure 5.10a). 
Analysis of the PC1 loadings plot clearly revealed two major contributions : the water bands 
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(~7000cm-1 and ~5200cm-1) and the amide A/II band (4850cm-1) (Figure 5.10b). These two 
involved spectral contributions were confirmed by the titration results as well as by the 
residual moisture analysis: the higher the virus volume, the higher the titer and residual 
moisture. To avoid the contribution of the water bands, the spectral region was reduced to 
5029-4000cm-1. The new 2-components PCA model explained 98.3% of the spectral variance. 
The PC1 versus PC2 scores plot revealed again that the first PC (explaining 93.5% of the 
spectral variability) distinguished the samples according to their virus volume (Figure 5.10c). 
Analysis of the PC1 loadings plot showed that the NIR signal at 4850cm-1 was responsible for 
this separation. This NIR signal corresponded to the amide A/II band (Figure 5.10d) [22].  
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Figure 5.10: Scores and loadings plots a) PC1 versus PC2 scores plot obtained after PCA of the NIR 
spectra from the virus volume samples using the 7300-4000cm-1 spectral region. b) Corresponding 
PC1 loadings plot (7300-4000cm-1 spectral region) the blue dashed arrows represent water and the 
black solid arrow represents the amide A/II band c) PC1 versus PC2 scores plot obtained after PCA of 
the NIR spectra from the virus volume samples using the 5029-4000cm-1 spectral region. d) 
Corresponding PC1 loadings plot (5029-4000cm-1 spectral region). Each symbol represents a different 
virus volume sample. 
 
5.3.2.2. Spectral region 10,000-7500cm-1 
The 40 NIR spectra from the Treha2 batch were further analyzed using the 10,000-7500cm-1 
spectral region. This spectral range has the advantage not to be influenced by water [28]. 
The PCA consisted of 2PCs, explaining 87.6% of the overall spectral variability. The PC1 
versus PC2 scores plot indicated that PC1, describing 76.9% of the spectra variability, 
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distinguished between the samples according to virus volume (Figure 5.11a). The PC1 
loadings plot confirmed that the 2nd C-H overtone was responsible for the separation along 
PC1 in the scores plot (Figure 5.11b). 
 
Figure 5.11: Scores and loadings plots obtained after PCA on the NIR spectra of the virus volume 
samples using the 10,000-7500cm-1 spectral range a) PC 1 versus PC2 scores plot, each color 
represents a different virus volume. b) PC1 loadings plot. 
 
In addition to the ability of NIR spectroscopy to distinguish between different virus 
pretreatments, these results suggest that NIR is also able to distinguish differences in virus 
volume. The distance between the different classes within the scores plot (Figure 5.10c and 
5.11a) corresponded to the virus volume increase but also to the water volume increase 
(Figure 5.9b). However, the absence of water band within the analyzed spectral region 
prevents the possibility that the clustering was due to residual moisture differences between 
the different virus volume samples [28] and ensure that the clustering was rather due to the 
virus volume. 
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5.4. CONCLUSION 
This study is - to our best knowledge - the first one evaluating and demonstrating the 
suitability of NIR spectroscopy to detect live, attenuated viruses in a freeze-dried 
formulation. NIR spectroscopy was able to distinguish between formulations varying in 
terms of 'virus pretreatment' as well as 'virus volume'. This was possible using two specific 
spectral ranges; (1) 7300-4000cm-1 containing the amide A/II region (2) 10,000-7500 and 
6340-5500cm-1 containing the first and second overtones of CH vibrations. 
In order to evaluate the possibility to classify the freeze-dried vaccine formulations 
according to their virus pretreatment, two PLSDA models were built, each model based on 
one of the two different studied spectral regions. Both models were validated using a 
permutation test and the models were systematically evaluated with an internal and an 
external independent test set using misclassification tables. The prediction of the internal 
data set was successful whereas the prediction of the external independent batch was not 
optimal. However, the pretreatment variability could explain the misclassifications as well as 
the batch-to-batch variability. By in the future increasing the number of batches to update 
the models, it should be possible to better cover the batch-to-batch variability.   
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ABSTRACT 
This chapter examines the applicability of Fourier Transform Infrared (FTIR) spectroscopy to 
detect the applied virus medium volume (i.e., during sample filling), to evaluate the virus 
state and to distinguish between different vaccine doses in a freeze-dried live, attenuated 
vaccine formulation. Therefore, different formulations were freeze-dried after preparing 
them with different virus medium volumes (i.e., 30µl, 100µl and 400µl) or after applying 
different pre-freeze-drying sample treatments (resulting in different virus states); i.e., (i) as 
done for the commercial formulation; (ii) samples without virus medium (placebo); (iii) 
samples with virus medium but free from antigen; (iv) concentrated samples obtained via a 
centrifugal filter device; and (v) samples stressed by 96h exposure to room temperature; or 
by using different doses (placebo, 25-dose vials, 50-dose vials and 125-dose vials). Each 
freeze-dried product was measured directly after freeze-drying with FTIR spectroscopy. The 
collected spectra were analyzed using principal component analysis (PCA) and evaluated at 
three spectral regions which might provide information on the coated proteins of freeze-
dried live, attenuated viruses: (i) 1700-1600cm-1 (amide I band), 1600-1500cm-1 (amide II 
band) and  1200-1350cm-1 (amide III band). The latter spectral band does not overlap with 
water signals and is hence not influenced by residual moisture in the samples. It was proven 
that FTIR could distinguish between the freeze-dried samples prepared using different virus 
medium volumes, containing different doses and using different pre-freeze-drying sample 
treatments in the amide III region.  
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CHAPTER 6 
FTIR SPECTROSCOPY FOR THE DETECTION 
AND EVALUATION OF LIVE ATTENUATED 
VIRUSES IN FREEZE-DRIED VACCINE 
FORMULATIONS 
 
6.1. INTRODUCTION 
Live, attenuated viruses are used in many vaccines because of the strong immune response 
they generate [1]. However, their potency is severely compromised by their low stability in 
aqueous solutions. To overcome this, most live, attenuated virus formulations are freeze-
dried [2]. 
After freeze-drying, the potency of live, attenuated viruses measured by titration is generally 
evaluated in a few randomly collected samples by assays measuring their biological response 
in vitro (i.e., cell-based assays). These tests are often considered imprecise, labor-intensive 
and time-consuming [3-5]. 
Near infrared (NIR) and Raman spectroscopy are frequently used as non-invasive, non-
destructive and fast analytical techniques for pharmaceutical products [6-8]. One of the first 
freeze-drying related applications of NIR spectroscopy was the determination of residual 
moisture content in the end products (i.e., through the glass vials) [9-12]. Afterwards, NIR 
and Raman in-process monitoring of excipient [13-15] and protein [16] behaviour during 
freeze-drying was performed. 
Recently, also the possibility of NIR spectroscopy to evaluate live, attenuated virus vaccine 
formulations has been examinated [17]. For a freeze-dried live, attenuated virus vaccine 
formulation, NIR spectroscopy was able to distinguish between samples prepared using 
different virus medium volumes or using different pre-freeze-drying treatments. This 
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distinction could be made by evaluating two NIR spectral regions: (i) the 7300-4000cm-1 
region containing the amide A/II band which might reflect information on the coated 
proteins of the freeze-dried live, attenuated viruses; and (ii) the C-H vibration overtone 
regions (10,000-7500 and 6340-5500cm-1) which might supply information on the lipid layer 
surrounding the freeze-dried live, attenuated viruses.  
Fourier transform infrared (FTIR) spectroscopy is a reference technique frequently used to 
obtain information about the secondary structure of proteins [18]. The amide I and amide II 
bands are two characteristic bands for proteins and polypeptides. Both arise from the amide 
bonds linking the different amino acids. The amide I (~ 1650cm-1) is associated to stretching 
vibrations of the C=O bond of the amide with minor contributions from the out-of-phase CN 
stretching vibration, whereas the amide II (~ 1550cm-1) is associated to bending vibrations of 
the N-H bond and stretching vibrations of the C-N bond [18]. Since both, the C=O and N-H 
bonds, are involved in the hydrogen bonds responsible for the protein secondary structure, 
frequency shifts of these amide I and II bands are associated to protein secondary structure 
changes. The amide III band (1400 to 1200cm-1) is the combination of the N-H bending and 
the C-N stretching vibration [18, 19]. The amide III is also influenced by side-chain vibrations 
that vary considerably making this band less suited for secondary structure analysis [18]. 
However, in contrast to the amide I and II bands the amide III band offers the advantage not 
to show overlap with water signals, which is important when analyzing freeze-dried samples 
[20-22]. 
Several studies have evaluated freeze-dried proteins secondary structure [16, 23-25] and 
bacteria (lactic acid bacteria protein secondary structure and lipid CH2 vibration) [26] using 
FTIR spectroscopy. However, to our best knowledge, there is no paper demonstrating the 
possibility of FTIR spectroscopy to evaluate live, attenuated viruses in freeze-dried 
formulations. 
The selection rule for molecules to be FTIR and NIR active is identical, being a change in 
dipole moment during their normal modes. However, FTIR spectroscopy mainly measures 
the fundamental vibrations of molecules, whereas NIR spectroscopy mainly measures 
overtones and combinations of fundamental vibrations. Overtones and combinations bands 
have a lower intensity than fundamental bands, resulting in detection sensitivity differences 
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at low levels of analyte (FTIR being more sensitive). Because of the anharmonicity of the 
atomic vibrations, the NIR bands related to particular functional groups of an analyte are 
often broad and overlapping [27] making their analysis complex and requiring 
chemometrics.   
The aim of this study was to examine the suitability of FTIR spectroscopy to evaluate live, 
attenuated viruses in freeze-dried vaccine formulations. Two different formulations provided 
by a pharmaceutical company were studied.  Being available in large quantities, product 1 
was freeze-dried after preparing it with different virus medium volumes (i.e., 30µl, 100µl and 
400µl) or after applying different pre-freeze-drying sample treatments (resulting in different 
virus states); i.e., (i) as done for the commercial formulation; (ii) samples without virus 
medium (placebo); (iii) samples with virus medium but free from antigen; (iv) concentrated 
samples obtained via a centrifugal filter device; and (v) samples stressed by 96h exposure to 
room temperature. Product 2, containing another live attenuated virus, was provided by the 
company in its freeze-dried form. These freeze-dried samples varied in the number of viral 
particles present in the virus medium, resulting in different multidose vials (i.e., placebo, 25-
dose vials, 50-dose vials and 125-dose vials). 
 
6.2. MATERIALS AND METHODS 
6.2.1. Materials  
The live, attenuated viral vaccines were provided by Zoetis.  
Trehalose (Cargill, Krefeld, Germany), a well-known cryo-/lyoprotectant used in many freeze-
dried formulations, was used as stabilizer at a concentration of 9% (w/v) in product 1. 
To study the capability of FTIR spectroscopy to evaluate the virus state, live, attenuated 
viruses were differently pre-treated (Table 6.1b). Depending on the applied pre-freeze-
drying-treatment (further termed ‘pretreatment’), the virus quality, integrity or state might 
vary. The resulting formulations were named after their pretreatment:  'normal' (i.e., as used 
in the commercial formulations,), 'absent' (i.e., placebo formulations without virus medium), 
'concentrated' via a centrifugal filter device (Millipore, Amicon® Ultra), ‘medium’ (i.e., 
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placebo formulations where virus medium without viruses was used) and 'stressed' (by 
storage at room temperature for 96hours). For clarity, the 'concentrated' virus samples were 
prepared using a similar virus culture medium volume as the 'normal' virus samples. 
However due to the centrifugation pretreatment process, the 'concentrated' samples 
contain more viral particles in that volume. The other formulation components (stabilizers 
and buffer) were kept constant (Table 6.1b).  
Besides investigating whether FT-IR is able to evaluate the differently pretreated viruses, its 
ability to detect differences in added virus culture medium volume was studied as well. 
Three virus formulations varying in virus medium volume were prepared (Table 6.1a). 
Stabilizer and buffer were kept constant (concentration and volume). 
Table 6.1: Product 1:  Formulations used in the (a) virus volume study and (b) virus pretreatment 
study. 
 
Virus 
pretreatment 
Virus 
medium 
containing 
viruses (µl) 
Medium  
without 
viruses 
(µl) 
Buffer 
(µl) 
Trehalose 
qsp filling 
volume (µl) 
Total 
volume (µl) 
 
 a Normal 30 0 y 9% w/v i + 370 800 
  Normal 100 0 y 9% w/v i + 300 800 
  Normal 400 0 y 9% w/v i + 0 800 
b Normal x 0 y 9% w/v j 800 
 Stressed x 0 y 9% w/v j 800 
 Concentrated x 0 y 9% w/v j 800 
 Medium 0 x y 9% w/v j 800 
 Absent 0 0 y 9% w/v j + x 800 
All symbols (x, y, i and j) represent  absolute values in µl. 
The stabilizer of product 2, containing another live, attenuated virus, is more complex as it 
contains several components. Three formulations containing different doses (125, 50 and 25 
doses) and one placebo formulation were prepared and freeze-dried by Zoetis (Table 6.2).  
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Table 6.2: Product 2: Dose study 
Virus 
pretreatment 
Doses 
Virus 
medium 
volume (ml) 
Stabilizer solution 
qsp filling 
volume, 
medium free 
from viruses 
(ml) 
Total volume 
(ml) 
Normal 125 e 33% (v/v) h-e 5 
Normal 50 f 33% (v/v) h-f 5 
Normal 25 g 33% (v/v) h-g 5 
Absent 0 0 33% (v/v) h 5 
All symbols (e, f, g and h) represent  absolute values in ml. 
 
An overview of all formulations used in this study is presented in Figure 6.1. 
 
Figure 6.1: Overview of the formulations used in the (a) virus pretreatment study (b) virus volume 
study and (c) virus dose study. 
 
 
 
 
(c) Virus dose study
(a) Virus pretreatment study
(b) Virus volume study
Virus medium
Water
20min
4000g
Filter
10.000M
96h @ RT before 
freeze-drying
Stressed
30µl 100µl 400µl
Medium ConcentratedNormalAbsent
Virus medium
Medium
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6.2.2. Freeze-Drying 
Product 1 was freeze-dried using an Amsco FINN-AQUA GT4 freeze-dryer (GEA, Köln, 
Germany). 
A conservative cycle resulting in elegant cakes, without any signs of collapse, was used (The 
process settings can’t be disclosed for confidentiality reasons). All product 1 formulations 
(virus volume study and virus pretreatment study) were freeze-dried together. 
Product 2 was freeze-dried using a Lyostar 3 (SP scientific, Stone Ridge, NY, USA) with a 
conservative cycle providing elegant cakes without signs of collapse (The process settings 
can’t be disclosed for confidentiality reasons). The different dose formulations and the 
placebo formulation were freeze-dried together. 
 
6.2.3. FTIR spectroscopy 
FTIR spectra were recorded using an ATR FTIR spectrometer (Thermo Fisher Scientific, 
Nicolet iS5 ATR FT-IR spectrometer). The sample was grinded in the vial and then pressed 
against a diamond ATR crystal. One spectrum per freeze-dried vial was collected in the 4000 
- 550 cm-1 spectral range with a resolution of 8 cm-1 and averaged over 32 scans. 
 
6.2.4. NIR spectroscopy 
 Besides the traditional applied reference method (titration, see further), NIR spectroscopy 
was also used as additional tool to evaluate the different freeze-dried formulations [17] and 
to compare with the FT-IR observations. NIR spectra of all freeze-dried samples were 
collected off-line using a Fourier-Transform NIR spectrometer (Thermo Fisher Scientific, 
Nicolet Antaris II near-IR analyzer) equipped with an InGaAs detector and a quartz halogen 
lamp. All NIR spectra were recorded in the 10000-4000cm-1 region with a resolution of 8cm-1 
and averaged over 16 scans. One NIR spectrum per freeze-dried sample (in random order) 
was collected through the bottom of the glass vial using the integrating sphere device 
immediately after freeze-drying. 
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6.2.5. Data analysis 
FTIR and NIR spectral data analysis was performed using SIMCA P+ v.13.0.3 (Umetrics, Umeå, 
Sweden).  
Depending on the spectroscopic tool (FTIR or NIR spectroscopy) and analyzed spectral 
region, different pre-processing methods were applied (Table 6.3). The evaluated spectral 
regions were selected in order to reflect information about the coated proteins 
(Haemagglutinin and Neuraminidase) from the freeze-dried live, attenuated viruses (see 
introduction). Therefore, the three amide bands (amide I, II and III) in the FTIR spectra and 
the amide A/II band in the NIR spectra were analyzed.  
Table 6.3: Analyzed spectral ranges and corresponding applied pre-processing  
 
Preprocessing Spectral region Wavenumbers (cm-1) 
 FTIR 
spectroscopy 
SNV Amide I 1700-1600 
SNV Amide II 1600-1500 
SNV 
Amide III 1200-1350 SNV and 2
nd
 derivative 
(17 Savitzky-Golay points) 
NIR spectroscopy 
SNV and 2
nd
 derivative 
(37 Savitzky-Golay points)  
7300-4000 
FTIR spectra were analyzed using principal component analysis (PCA), allowing to examine 
the spectral differences between for instance the different sample types per batch (Table 
6.2). PCA produces an orthogonal bilinear data matrix (D) decomposition, where principal 
components (PCs) are obtained in a sequential way to explain maximum variance:  
D=TPT + E 
= t1p’1 + t2p’2 +…+tQp’Q + E 
Where T is the M x Q score matrix, P is the N x Q loading matrix, E is the M x N model 
residual matrix, i.e., the residual variation of the data set that it is not captured by the 
model. Q is the selected number of PCs, each describing a non-correlated source of variation 
in the data set, and N is the number of collected spectra at M wavelengths [28]. Each 
principal component consists of two vectors, the score vector t and the loading vector p. The 
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score vector contains a score value for each spectrum, and this score value informs how the 
spectrum is related to the other spectra in that particular component. The loading vector 
indicates which spectral features in the original spectra are captured by the component 
studied. These abstract, unique and orthogonal PCs are helpful in deducing the number of 
different sources of variation present in the data. However, these PCs do not necessarily 
correspond to the true underlying factors causing the data variation, but are orthogonal 
linear combinations of them, since each PC is obtained by maximizing the amount of 
variance it can explain [29].  
The number of PC included to describe the model was determined by cross validation. Each 
PC resulting on an increase of the predictive ability (Q2) of the model was kept. 
The collected NIR spectra were also evaluated using principal component analysis (PCA).  
 
6.2.6. Titration 
Titration of product 1 and 2 was done according to Zoetis internal SOPs. Each titer is 
expressed in log10 CCID50 (Cell Culture Infection Dose 50 – Inverse of the highest dilution 
which produces a cytopathogenic effect in 50% of the cells). Titration provides information 
about the number of living viral particles contained in each vial.  For each study (virus 
pretreatment, virus volume and virus dose), statistical analysis was performed to evaluate if 
the titers of different vial populations (e.g. 125-dose, 50 and 25-dose vials or ‘stressed virus’, 
‘normal virus’ and ‘concentrated virus’) were significantly different.  Minitab® 15.1.1.0 
software was used to perform the statistical analysis.  
When the titer distribution was normal (evaluated using a Kolmogorov-Smirnov test) and the 
variance equal (Levene’s test) an Anova I test was performed. When the distribution was 
determined as not normal or when the number of observation in each population was low, a 
non-parametric Kruskal-Wallis analysis of variance was used. In addition to the Kruskal-
Wallis test, in order to determine which population is significantly different from the others, 
Dunn’s test was performed using a Matlab m-file [30] as follow-up test (Matlab 7.12, The 
Mathworks, Natick, MA). 
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6.2.7. Karl Fischer  
The residual moisture content of freeze-dried samples was determined by Karl Fischer 
titration. For product 1, a Mettler Toledo V30 volumetric Karl Fischer titrator 
(Schwerzenbach, Switzerland) with Hydranal® titration solvent from Sigma Chemical 
Company was used. A known volume of dried methanol was added to the sampled vial, and 
left to equilibrate for a few minutes. From the solution, a known volume was then removed 
volumetrically using a syringe and injected into the titration cell. The water content of pure 
methanol was determined in duplicate prior to the measurement and subtracted from the 
result.  
Product 2 was measured with a Metrohm 860 KF Thermoprep (oven) coupled to a Metrohm 
852 Titrando (Herisau, Switzerland). 
 
6.3. RESULTS AND DISCUSSION 
The discussion of the results is divided into three parts: (i) virus volume study (Table 6.1a); 
(ii) virus pretreatment study (Table 6.1b) and (iii) dose study performed using product 2 
(Table 6.2).  
 
6.3.1. Virus volume study 
To evaluate the ability of FTIR spectroscopy to distinguish between applied live, attenuated 
virus medium volume in the freeze-dried samples, three formulations were prepared 
containing 30µl, 100µl and 400µl of virus medium volume, respectively (Table 6.1a). The 
30µl virus medium volume vials had a titer of 6.93±0.2 (n=3) which differed significantly 
from the 400µl virus medium volume vials having a titer of 8.67±0.56 (n=3) (Kruskal-Wallis, 
p<0.05, Figure 6.2). The 100µl virus volume vials had a titer of 7.82±0.21 (n=3) which did not 
significantly differ from the 30µl and 400µl virus volume samples (Kruskal-Wallis, p<0.05, 
Figure 6.2).  Regarding the titration results Figure 6.2(left), a significant difference between 
all groups of sample was expected. This surprising result obtained via Kruskal-Wallis analysis 
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(selected because of the small amount of titrated samples), might be due to the fact that this 
statistical analysis consider the population medians instead of the population means.  
The Karl Fischer analysis revealed an increase in residual moisture with increasing virus 
medium volume. The 30, 100 and 400µl virus medium volume samples had a residual 
moisture of 1.28%±0.05 (n=3), 1.83%±0.13 (n=3) and 3.68%±0.89 (n=3), respectively (Figure 
6.2). 
 
  
Figure 6.2: (left) Titration results of the different virus medium volume samples. Titers are expressed 
as log10 CCID50 (Cell Culture Infection Dose 50). Each titer is the average of three determinations 
(Figure 6.2, right). Residual moisture results of the different virus medium volume samples. Each 
result is the average of three determinations. 
 
After freeze-drying, FTIR spectra of 10 vials per virus medium volume class (i.e., 30 spectra in 
total) were collected.  
As described in the materials and method section, the aim was to evaluate the three amide 
spectral regions (I, II and III) in the FTIR spectra. Figure 6.3 shows an FTIR spectrum of a 
freeze-dried product from this virus volume study and the FTIR spectrum of water. The 
amide I (1700-1600cm-1) and II (1600-1500cm-1) bands clearly overlap with the strong water 
signal. As the residual moisture varies between the three different virus medium volume 
sample types (Figure 6.3), the FTIR spectra of the virus volume study were not analyzed in 
the amide I and II regions. However, since water does not overlap with the amide III region 
(Figure 6.3), the FTIR spectra of the virus volume study were analyzed using the amide III 
(1350-1200cm-1) spectral region using PCA. 
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Figure 6.3: Spectra of water (blue dashed line) and a freeze-dried virus volume study sample (black 
line). 
 
The resulting PCA model (composed of two components) described 99.6% of the spectral 
variability. The first PC explained almost all the spectral variability (99.3%) and distinguished 
the samples according their virus medium content (Figure 6.4a). The distances in the scores 
plot between the virus medium volume groups were in agreement with the differences in 
virus medium content. Analysis of the loadings of the first principal component revealed one 
major peak at 1290cm-1 (Figure 6.4b). This peak is located in a spectral range (1300-1270cm-
1) typical for α-helix [19]. Analysis of the SNV corrected spectra (Figure 6.4c) clearly showed a 
difference in peak intensity between the three virus medium volumes and confirmed the 
observation of the scores and loadings plots.  
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Figure 6.4: Scores (a) and loadings (b) plots obtained after PCA on the FTIR spectra (1200-1350cm-1 
spectral region) from the virus volume samples 30, 100 and 400µl. (c) SNV corrected FTIR spectra of 
the 1200-1350cm-1 spectral region (the arrow indicates the positive direction of PC1). 
 
The scores plot of the FTIR PCA models allowed the distinction of the three different virus 
volumes (30µl, 100µl and 400µl).   
To confirm this FTIR analysis, also NIR spectra of twenty vials per virus medium volume class 
were collected and analyzed using the 7300-4000cm-1 spectral region (after SNV and 2nd 
derivative preprocessing), as demonstrated in our previous study [17]. The PCA model 
(composed of two components) developed from the 60 spectra, described 84.3% of the 
spectral variability. The PC1 versus PC2 scores plot showed that the first PC (explaining 
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63.8% of the spectral variability) distinguished the samples according to their virus medium 
volume (Figure 6.5a). Similarly as previously described in [17], analysis of the PC1 loadings 
plot revealed two major contributions: the water bands (~7000 and ~5200cm-1) and the 
amide A/II band (4850cm-1) (Figure  6.5b).  
 
Figure 6.5: Scores (a) and loadings plots (b) obtained after PCA on the NIR spectra from the samples 
30, 100 and 400µl using the 7300-4000cm-1 spectral region. 
 
To avoid the contribution of the water bands on the principal component analysis of the NIR 
spectra, a new PCA model was built for the 5029-4000cm-1 spectral range. The new two 
component PCA model explained 76.4% of the spectral variance and also distinguished 
between the different virus volumes (data not shown). 
These results described above confirm that FTIR spectroscopy is able to distinguish between 
different virus medium volumes in the freeze-dried formulations. Analysis of the loadings 
plot has shown that this distinction was caused by a difference in α-helix between the 
different virus medium volumes. The variation of this protein secondary structure between 
the different virus medium volumes was not detected with NIR spectroscopy. To avoid the 
impact of the residual moisture variation on the virus volume determination, the amide III 
spectral region should be used, since this spectral band does not overlap with water bands. 
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6.3.2. Virus pretreatment study 
To evaluate the ability of FTIR spectroscopy to distinguish between differently pre-freeze-
drying treated live, attenuated virus samples, five formulations were prepared as 
overviewed in Table 6.1b. The three formulations containing viruses were titrated. The 
‘stressed virus’ samples had a titer of 6.12±0.1 (n=3) which significantly differed from the 
‘concentrated virus’ samples having a titer of 7.72±0.06 (n=3) (Kruskal-Wallis, p<0.05, Figure 
6.6 left). The ‘normal virus’ samples had a titer of 6.93±0.2 (n=3) which did not significantly 
differ from the ‘stressed’ and ‘concentrated’ virus samples. A significant titer difference 
between all groups of sample was expected. The analysis of the population medians 
performed by the Kruskal-Wallis procedure might explain this surprising statistical results. 
Karl Fischer analysis revealed no significant difference in residual moisture between the 
different pre-treated samples. The normal, stressed, concentrated, absent and medium had 
a residual moisture of 1.28±0.05 (n=3), 1.26±0.18 (n=3), 1.42±0.1 (n=3), 1.19±0.11 (n=3) and 
1.30±0.2 (n=3), respectively (Figure 6.6 right). 
 
 
Figure 6.6: Titration results of the different pre-treated samples (left). Titers are expressed as log10 
CCID50 (Cell Culture Infection Dose 50). Each titer is the average of three determinations. Residual 
moisture results of the different pretreated virus samples (right). Each result is the average of three 
determinations. 
 
After freeze-drying, ten FTIR spectra per pretreatment group (i.e., 50 spectra in total) were 
collected. Because the residual moisture was not significantly different between the 
different pretreatment groups, the FTIR spectra were analyzed using PCA for different 
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spectral ranges, i.e., the 1700-1600cm-1 (amide I band), the 1600-1500cm-1 (amide II band) 
and the 1200-1350cm-1 (amide III band). According to the titration results, only two groups 
containing viruses have significantly different titers, being the ‘stressed’ and ‘concentrated’ 
samples. Therefore, PCA models were first built using the spectra of these both groups. 
6.3.2.1. Spectral region 1700-1600cm-1, amide I band 
The PCA model (composed of three principal components) developed from the 20 FTIR 
spectra of the ‘stressed’ and ‘concentrated’ samples described 95% of the overall spectral 
variability. It was not possible to distinguish between concentrated and stressed samples 
using the amide I band (data not shown).   
6.3.2.2. Spectral region 1600-1500cm-1, amide II band 
The PCA model (composed of five principal components) developed using the 20 spectra 
described 99.2% of the spectral variability. Using the amide II band, it was also not possible 
to distinguish between concentrated and stressed samples (data not shown).  
6.3.2.3. Spectral region 1200-1350cm-1, amide III band 
The PCA model (composed of four principal components) developed using the 20 spectra 
(from the ‘stressed’ and ‘concentrated’ samples) described 95.3% of the overall spectral 
variability. The first principal component (capturing 68.7% of the spectral variability) was 
able to distinguish between both groups (stressed and concentrated) (Figure 6.7a). Analysis 
of the loadings plot revealed a broad peak at 1290cm-1 (α-helical structure) responsible for 
the grouping according virus pretreatment (Figure 6.7b).  
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Figure 6.7: Scores (a) and loadings plots (b) obtained after PCA of the FTIR spectra from the 
concentrated and stressed samples using the 1350-1200cm-1 spectral region. 
 
Besides FTIR, NIR spectra of 40 vials (20 stressed and 20 concentrated pretreated samples) 
were also collected and analyzed using the 7300-4000cm-1 spectral region [17] to confirm 
the FTIR findings. The two component PCA model developed from these 40 spectra 
described 75.8% of the overall spectral variability. The PC1 versus PC2 scores plot showed 
that the first PC (explaining 45.9% of the spectral variability) and the second PC (explaining 
29.9% of the spectral variability) allowed distinguishing the samples according their 
pretreatment (Figure  6.8).  
 
Figure 6.8: Scores plot obtained after PCA on the NIR spectra collected from the stressed and 
concentrated pre-treated samples using the 7300-4000cm-1 spectral region. 
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In addition to the evaluation of ‘stressed’ and ‘concentrated’ pretreated samples, 
characterized by a significantly different virus titer, the class ‘medium’ was also studied. This 
class was interesting to analyze since the only difference between these samples and the 
other pretreated samples (i.e., ‘normal’, ‘stressed’ and ‘concentrated’) is the absence of 
virus particle in the vials (Table 6.1b).  
Using the amide III spectral range, different PCA models were built using: (i) the FTIR spectra 
from the 'normal' and 'medium' samples, (ii) the FTIR spectra from the 'concentrated' and 
'medium' samples and  (iii) the FTIR spectra from the 'stressed' and 'medium' samples 
(Figure 6.9). The first model (‘normal’ and ‘medium’ samples) was composed of five PCs 
describing 98.3% of the spectral variability. The PC1 versus PC2 scores plot distinguished 
between both groups of samples (Figure 6.9a). The loadings of the first and second principal 
component are presented in Figure 6.9d. The first principal component distinguished 
between the spectra by a large peak around 1290cm-1. The second principal component 
distinguished between the spectra by a peak at 1315cm-1. Both peaks are located in a 
spectral range typical for α-helical structure [21, 22]. A difference between the ‘normal’ and 
‘medium’ samples in this spectral range was also visible in the SNV and 2nd derived spectra 
(Figure 6.9e).  The second PCA model was built using the 'medium' and 'concentrated' 
spectra and consisted of five PCs describing 97.2% of the spectral variability. The first 
principal component (73.3% of the spectral variability) clearly distinguished between the two 
groups (Figure 6.9b). The PC1 loadings plot revealed one peak at 1290cm-1 (α-helical 
structure) (data not shown). The last PCA model (‘stressed’ and ‘medium’ samples) was 
composed of six PCs explaining 97.7% of the spectral variability. Loadings of the second 
principal component showed different peaks, one located at 1280cm-1 typical for β-turn 
[21,22] and another one located at 1233cm-1 typical for β-sheet [21,22]  (data not shown).  
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Figure 6.9: Scores plots obtained after PCA using the 1350-1200cm-1 (Amide III) spectral region of the 
FTIR spectra of; a) normal and medium samples, b) concentrated and medium samples, c) stressed 
and medium samples. The loadings plot of the PCA using normal and medium samples (d) (PC1 black 
and PC2 blue) and the spectra of the medium (yellow) and normal (red) samples (snv and 2nd derived) 
(e) are also presented.   
 
These PCA models developed from ‘medium’ samples containing no viruses on the one hand 
and the differently pretreated samples on the other hand, allowed distinguishing between 
the presence and absence of viruses. As can be derived from the loadings plots, one peak 
around 1290cm-1 and typical for α-helical protein secondary structure was involved in the 
spectral distinction between normal and medium samples as well as concentrated and 
medium samples. Loadings of the principal component distinguishing between stressed and 
medium samples showed two different peaks, located at 1280cm-1 (β-turn) and at 1233cm-1 
(β-sheet).  
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6.3.3. Virus dose study 
In this part of the study, the ability of FTIR spectroscopy to detect another live, attenuated 
virus as well as to distinguish between vaccines containing different doses was evaluated.  
The three formulations, different in virus dose (Table 6.2), were titrated. The 125 doses 
samples had a titer of 5.09±0.16 (n=8), the 50 doses samples had a titer of 4.73±0.08 (n=8) 
and the 25 doses had a titer of 4.41±0.18 (n=8). These titers were significantly different 
(Anova I, p<0.05, Figure 6.10 left). 
Unlike the virus volume study, Karl Fischer analysis revealed no significant difference in 
residual moisture between the different dose samples. The 125, 50, 25 and placebo samples 
had a residual moisture of 1.44±0.33 (n=3), 1.31±0.16 (n=3), 1.44±0.21 (n=3), and 1.36±0.07 
(n=3), respectively (Figure 6.10, right). 
 
Figure 6.10: Titration results of the different dose samples (left). Titers are expressed as log10 CCID50 
(Cell Culture Infection Dose 50). Each titer is the average of eight determinations. Residual moisture 
results of the different pre-freeze-drying treated virus samples (right) (n = 3).  
 
After freeze-drying, ten FTIR spectra per dose group and five FTIR spectra of the placebo 
group (i.e., 35 spectra in total) were collected. The FTIR spectra, SNV preprocessed, were 
analyzed using PCA applying different spectral ranges, i.e., the 1700-1600cm-1 (amide I 
band), the 1600-1500cm-1 (amide II band) and the 1200-1350cm-1 (amide III band). 
6.3.3.1. Spectral region 1700-1600cm-1, amide I band 
The PCA model (composed of two principal components) developed from the 35 spectra 
described 97.7% of the overall spectral variability. The first PC capturing 78.2% of spectral 
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variability distinguished between the samples according to their doses (Figure 6.11a). The 
distances in the scores plot between the dose groups is in agreement with their actual dose 
difference. Among the different peaks observed in the PC1 loadings plot (1632 cm-1, 1645 
cm-1, 1660 cm-1, 1680 cm-1, 1695cm-1) (Figure 6.11b), the two peaks located at 1632 cm-1 and 
1645 cm-1 also clearly varied in the SNV preprocessed spectra (Figure 6.11c). These two 
peaks might represent turn/β sheet (1638cm-1) [26] and α-helix (1645cm-1) [26], 
respectively.  
6.3.3.2. Spectral region 1600-1500cm-1, amide II band 
The PCA model (composed of three principal components) developed using the 35 spectra 
described 99.3% of the spectral variability. No PCs combination was able to distinguish 
between the different doses using the amide II band (data not shown).  
6.3.3.3. Spectral region 1200-1350cm-1, amide III band 
The PCA model (composed of two components) developed from the 35 spectra using the 
amide III spectral region described 91.4% of the spectral variability. The first PC explained 
63.6% of the spectral variability and distinguished between the samples according to their 
dose (Figure 6.12a). In contrast to the amide I band, the separation between the different 
doses was less clear. Nevertheless, the placebo was better separated from the other 
samples. Analysis of the loadings of the first principal component revealed one major peak 
at 1290cm-1 (Figure 6.12b). This peak is located in a spectral range (1300-1270cm-1) typical 
for α-helix [19]. Analysis of the SNV corrected spectra (Figure 6.12c) clearly showed a 
difference in peak intensity between the different doses and confirmed the observation of 
the scores and loadings plots.  
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Figure 6.11: PC1 versus PC2 scores (a) and PC1 loadings (b) plots obtained after PCA of the FTIR 
spectra from the samples 0 (placebo), 25, 50 and 125 doses using the 1600-1700cm-1 spectral region. 
(c) SNV corrected spectra of the 1600-1700cm-1 spectral region (the arrow indicates the positive 
direction of PC1). 
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Figure 6.12: PC1 versus PC2 scores (a) and PC1 loadings (b) plots obtained after PCA of the FTIR 
spectra from the 0, 25, 50 and 125 dose samples using the 1350-1200cm-1 spectral region. (c) SNV 
corrected spectra of the 1350-1200cm-1 spectral region (the arrow indicates the positive direction of 
PC1). 
 
NIR analysis was also performed using the virus dose samples. Spectra from 18 vials per virus 
dose were collected and analyzed using the 7300-4000 cm-1 spectral regions (after SNV and 
2nd derivative pre-processing), as demonstrated in [17]. The PCA model (composed of four 
components) developed from the 72 spectra described 93.3% of the spectral variability. The 
PC2 (18.2% of the spectral variability) versus PC4 (8.48% of spectral variability) scores plot 
allowed distinguishing the samples according to their virus dose (Figure 6.13).  
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Figure 6.13: Scores plot obtained after PCA on the NIR spectra from the virus dose samples using the 
7300-4000cm-1 spectral region. 
 
6.4. CONCLUSION 
This study is, to our best knowledge, the first one evaluating and demonstrating the ability of 
FTIR spectroscopy to detect live, attenuated viruses in a freeze-dried formulation. FTIR was 
able to distinguish between freeze-dried formulations varying in “virus volume”, “virus 
pretreatment” and “virus dose”.  
In the virus volume study, the amide III spectral region was used hence avoiding the 
influence of the residual moisture which was different for the different virus medium volume 
samples. Using this spectral region, it was possible to distinguish between the different virus 
medium volume samples.  
No residual moisture difference was detected for the samples of the virus pretreatment 
study. Among the three amide (I, II, III) spectral ranges studied, the amide III spectral range 
was the most appropriate one to distinguish the different pretreated samples. 
Finally, in the virus dose study, the three amide spectral ranges were also compared (as no 
difference in residual moisture was seen between the different doses). Both, the amide I and 
III spectral ranges distinguished the samples according to their doses. Using the amide I 
spectral range, the distance between the different groups in the scores plot was in 
agreement with the dose content. Using the amide III spectral range, the placebo samples 
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were better separated from the samples containing doses but the distinction between the 
different dose samples was less clear. 
The presented results demonstrate the ability of FTIR spectroscopy to evaluate live, 
attenuated viruses in freeze-dried formulations.  
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ABSTRACT 
This chapter evaluates a freeze-dried live, attenuated virus vaccine during an accelerated 
stability study using Near Infrared (NIR) and Fourier Transform Infrared (FTIR) spectroscopy 
in addition to the traditional quality tests (i.e., potency assay, residual moisture analysis) and 
Modulated Differential Scanning Calorimetry (MDSC). Therefore, freeze-dried live, 
attenuated virus vaccines were stored during four weeks at 4°C (i.e., recommended storage 
condition) and at 37°C (i.e., accelerated storage condition) and weekly analyzed using these 
techniques. The potency assay showed that the virus titer decreased in two phases when the 
samples were stored at 37°C. The highest titer loss occurred during the first week storage at 
37°C after which the degradation rate decreased. Both the residual moisture content and 
the relaxation enthalpy also increased according to this two-phase pattern during storage at 
37°C. In order to evaluate the virus and its interaction with the amorphous stabilizer in the 
formulation (trehalose), the NIR spectra were analyzed via principal component analysis 
(PCA) using the amide A/II band (5029-4690cm-1). The FTIR spectra were also analyzed via 
PCA using the amide III spectral range (1350-1200cm-1). Analysis of the amide A/II band in 
the NIR spectra revealed that the titer decrease during storage was probably linked to a 
change of the hydrogen bonds (i.e., interaction) between the virus proteins and the 
amorphous trehalose. Analyzing the amide III band (FTIR spectra) showed that the virus 
destabilization was coupled to a decrease of the coated proteins β-turn and an increase of α-
helix. During storage at 4°C, the titer remained constant, no enthalpic relaxation was 
observed and neither the amide A/II band (NIR spectra) nor the amide III band (FTIR spectra) 
varied.  
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CHAPTER 7 
SPECTROSCOPIC EVALUATION OF A FREEZE-
DRIED VACCINE DURING AN ACCELERATED 
STABILITY STUDY 
 
7.1. INTRODUCTION 
Worldwide, the success of immunization programs is partly dependent on the stability of 
vaccines [1]. The stability of a vaccine is its ability to retain its chemical, physical, 
microbiological and biological properties within specified limits throughout its shelf-life [1]. 
The potency of live, attenuated virus vaccines is severely compromised by their low stability 
in aqueous solution. Therefore, freeze-drying is often applied to remove the bulk water and 
improve the vaccine stability during distribution and storage.   
Freeze-drying consists of 3 main consecutive steps: freezing, primary drying and secondary 
drying. During the freezing step, the temperature is decreased to convert most of the water 
into ice. Herewith, the solutes are crystallized or transformed into an amorphous system. 
During primary drying, vacuum is introduced in the freeze-drying chamber and the ice is 
removed by sublimation. The secondary drying step, usually occurring under deep vacuum, 
ends the process by removing the unfrozen water by desorption [2]. 
Most often, the stability of freeze-dried vaccines is evaluated in long-term stability studies 
and under accelerated and stress conditions. Long term stability studies are performed 
under the conditions (temperature and humidity) specified for the product storage and 
serve as a base to attribute an expiration date to the product. Accelerated and stress 
stability testing, under conditions carefully selected on a case-by-case basis, are strongly 
suggested by the regulatory authorities [3]. Studies under accelerated conditions are 
performed at higher temperatures than those recommended for storage [1] and are useful 
to provide product stability information for future development. Furthermore, studies under 
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accelerated conditions assist in the validation of analytical methods for the stability 
program, and provide information that may help to understand the degradation profile of 
the product [3]. Studies under stress conditions, on the other hand, are useful to evaluate 
whether accidental exposures to conditions other than those intended (such as light and 
extreme temperature [1]) are detrimental, which is also useful to develop product stability 
knowledge [3]. 
The stabilization mechanisms of live, attenuated viruses during freeze-drying and in the 
dried state (i.e., during storage) are not clearly described in literature and hence elucidated. 
This lack of information can be attributed to two main reasons: (i) measuring the 
destabilization mechanisms is complex because of the multiple potential destabilization 
pathways (such as oxidation, light-catalyzed reaction, change in ionic strength, pH shift due 
to buffer crystallization and possibly mechanical membrane damage due to ice crystal 
growth) [4,5], and (ii) the analytical tools allowing the evaluation of live, attenuated viruses 
during freeze-drying are lacking.  
A review describing the current knowledge on the freeze-drying process of live attenuated 
virus vaccines, the potential destabilization mechanisms occurring during the freezing and 
the drying steps and the strategies used to protect viruses during freeze-drying has been 
recently published [6]. 
Near Infrared (NIR) and Fourier Transform Infrared (FTIR) spectroscopy have been 
demonstrated to have potential to evaluate freeze-dried live, attenuated viral vaccines [7, 
8]. NIR spectroscopy was able to distinguish between samples prepared using different virus 
medium volumes or using different pre-freeze-drying treatments [7]. This distinction was 
possible by evaluating two NIR spectral regions: (i) the 7300-4000cm-1 region containing the 
amide A/II band which might reflect information on the coated proteins of the live, 
attenuated viruses; and (ii) the C-H vibration overtone regions (10,000-7500 and 6340-
5500cm-1) which might supply information about the lipid layer surrounding the live, 
attenuated viruses.  
FTIR spectroscopy was also able to distinguish between lyophilized samples prepared using 
different virus medium volumes or using different pre-freeze-drying treatments as well as 
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between samples containing different doses of viruses [8]. Among the three amide bands 
(i.e., amide I, amide II, amide III) in FTIR spectra, the amide III band (1350-1200cm-1) showed 
to be the most suitable one for analysis since this band is not influenced by water.  
The aim of this chapter is to evaluate freeze-dried live, attenuated virus vaccines during an 
accelerated stability study using NIR and FTIR spectroscopy.  Both spectroscopic tools were 
used to potentially clarify the observations made using traditional quality tests (i.e., potency 
assay, residual moisture analysis and modulated differential scanning calorimetry (MDSC)), 
and to increase the knowledge about the viability decrease of live, attenuated virus vaccines 
during storage. For this study, freeze-dried samples from a live, attenuated virus vaccine 
formulation were stored at 4°C (i.e., recommended storage condition) and at 37°C (i.e., 
accelerated storage condition) during four weeks and weekly evaluated using all analytical 
techniques described above. 
 
7.2. MATERIALS AND METHODS 
7.2.1. Materials  
The live, attenuated viruses were provided by Zoetis. Trehalose (Cargill, Krefeld, Germany), a 
well-known cryo-/lyoprotectant utilized in many freeze-dried formulations, was used as 
stabilizer at a concentration of 9% (w/v).  
 
7.2.2. Freeze-Drying 
The vaccines were freeze-dried using an Amsco FINN-AQUA GT4 freeze-dryer (GEA, Köln, 
Germany), resulting in elegant cakes, without any signs of collapse (the freeze-drying process 
settings cannot be disclosed for confidentiality reasons). At the end of the process, the vials 
were stoppered under inert gas atmosphere and sealed with aluminum crimps. 
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7.2.3. Study design 
Unless explicitly mentioned, the term ‘stability study’ in this chapter refers to both storage 
conditions used for the study described in this chapter, i.e., storage at 4°C (i.e., 
recommended storage conditions) and storage at 37°C (i.e., accelerated storage conditions). 
The stability study setup is presented in Figure 7.1. After freeze-drying and before starting 
the stability study (i.e., at time 0, T0), the following measurements were done: NIR and FTIR 
spectra collection, titration (i.e., viability evaluation), MDSC and Karl Fischer (i.e., residual 
moisture determination). Afterwards, the stability study started and identical measurements 
as at T0 were performed weekly during 4 weeks. In addition, during the first week of 
storage, NIR spectra were collected every day. 
 
Figure 7.1: Schematic overview of the stability study. 
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The number of freeze-dried samples (vials) used for each analysis at each time point is 
presented in Table 7.1. In total, 207 vials were analyzed in this study. In contrast to all other 
applied analytical techniques, NIR spectroscopy offers the advantage of not requiring sample 
preparation and being non-destructive, hence allowing to evaluate the same vials 
throughout the entire study. Twenty vials stored at 4°C and twenty other vials stored at 37°C 
were hence monitored using NIR spectroscopy during the entire stability study. Every week, 
five vials were analyzed using FTIR spectroscopy, Karl Fischer and titration while three vials 
were analyzed via MDSC for both storage temperatures. 
Table 7.1: Repartition of the freeze-dried samples used during the stability study. 
Storage time 
NIRa FTIR MDSC Karl Fischer Titration 
4°C 37°C 4°C 37°C 4°C 37°C 4°C 37°C 4°C 37°C 
0 20 20 5 3 5
 
10
 
1day - 6days 20 20 NA NA NA NA NA NA NA NA 
1 week 20 20 5 5 3 3 5 5 5 5 
2 weeks 20 20 5 5 3 3 5 5 5 5 
3 weeks 20 20 5 5 3 3 5 5 5 5 
4 weeks 20 20 5 5 3 3 5 5 5 5 
Total vials 20 20 45 27 45 50 
a
 NIR analysis is non-destructive, allowing analysis of the same vials throughout the entire stability study 
 
7.2.4. NIR spectroscopy 
NIR spectra of the freeze-dried samples were collected off-line using a Fourier-Transform 
NIR spectrometer (Thermo Fisher Scientific, Nicolet Antaris II near-IR analyzer) equipped 
with an InGaAs detector and a quartz halogen lamp. All NIR spectra were recorded in the 
10000-4000cm-1 region with a resolution of 8 cm-1 and averaged over 16 scans. One NIR 
spectrum per freeze-dried sample was collected through the bottom of the glass vial using 
the integrating sphere device. All measured vials were systematically kept at room 
temperature for 30 min prior the collection of the spectra.  
Chapter 7 – Spectroscopic evaluation of a freeze-dried vaccine during an accelerated stability 
study 
 
174 
 
7.2.5. FTIR spectroscopy 
FTIR spectra were recorded using an ATR FT-IR spectrometer (Thermo Fisher Scientific, 
Nicolet iS5 ATR FT-IR spectrometer). Prior to analysis, the freeze-dried sample was grinded in 
the vial and then pressed against a diamond ATR crystal. One spectrum per freeze-dried 
sample was collected in the 4000 - 550 cm-1 spectral range with a resolution of 8 cm-1 and 
averaged over 32 scans. 
 
7.2.6. Data analysis 
NIR and FTIR spectral analysis was performed using SIMCA 14 (Umetrics, Umeå, Sweden).  
Depending on the spectroscopic tool (FTIR or NIR spectroscopy) and the analyzed spectral 
range, different spectral pre-processing methods were applied (Table 7.2). The evaluated 
spectral regions (Table 7.2) were selected since they might reflect information on the coated 
proteins (Haemagglutinin and Neuraminidase) of the freeze-dried live, attenuated viruses 
(see introduction).  
Table 7.2: Analyzed spectral ranges and applied spectral pre-processing  
 
Preprocessing Analyzed bands Spectral range (cm-1) 
FTIR spectroscopy SNV Amide III 1200-1350 
NIR spectroscopy 
SNV 
Water band and Amide 
A/II 7300-4000 
SNV and 2
nd
 derivative 
Amide A/II 5029-4690 (37 Savitzky-Golay 
points) 
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Both, FTIR and NIR spectra were separately analyzed using principal component analysis 
(PCA). PCA produces an orthogonal bilinear data matrix (D) decomposition, where principal 
components (PCs) are obtained in a sequential way to explain maximum variance:  
D=TPT + E 
= t1p’1 + t2p’2 +…+tQp’Q + E 
 
Where T is the M x Q score matrix, P is the N x Q loading matrix, E is the M x N model 
residual matrix, i.e., the residual variation of the data set that it is not captured by the 
model. Q is the selected number of PCs, each describing a non-correlated source of variation 
in the data set, and N is the number of collected spectra at M wavelengths [9]. Each principal 
component consists of two vectors, the score vector t and the loading vector p. The score 
vector contains a score value for each spectrum, and this score value informs how the 
spectrum is related to the other spectra in that particular component. The loading vector 
indicates which spectral features in the original spectra are captured by the component 
studied. These abstract, unique and orthogonal PCs are helpful in deducing the number of 
different sources of variation present in the data. However, these PCs do not necessarily 
correspond to the true underlying factors causing the data variation, but are orthogonal 
linear combinations of them, since each PC is obtained by maximizing the amount of 
variance it can explain [10].  
The number of PCs included in the PCA model was determined by cross validation using the 
approach of Krzanowski [11]. The spectral data of the dataset was divided into 7 groups and 
a model was generated for the data devoid of one group. The deleted group was predicted 
by the model and the squared differences between the predicted and observed values were 
summed to form the Predictive Residual Sum of Squares (PRESS). This procedure was then 
repeated 7 times, followed by the summation of all partial PRESS-values in terms of an 
overall PRESS-value. If a new PCi enhanced the predictive power compared with the 
preceding PCi-1, the new PCi was kept in the model [12]. 
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7.2.7. Titration 
Titration was done according to a Zoetis internal SOPs. Each titer is expressed in log10 CCID50 
(Cell Culture Infection Dose 50 – Inverse of the highest dilution which produces a 
cytopathogenic effect in 50% of the cells). Titration provides information about the number 
of living viral particles in a freeze-dried vial.  
 
7.2.8. Karl Fischer  
The residual moisture content of the freeze-dried samples was determined via Karl Fischer 
titration. A Mettler Toledo V30 volumetric Karl Fischer titrator (Schwerzenbach, Switzerland) 
with Hydranal® titration solvent from Sigma Chemical Company was used. A known volume 
of dried methanol was added to the sampled vial, and left to equilibrate for a few minutes. 
From the solution, a known volume was then removed volumetrically using a syringe and 
injected into the titration cell. The water content of pure methanol was determined in 
duplicate prior to the measurement and subtracted from the result.  
 
7.2.9. MDSC 
The thermal behaviour of the freeze-dried samples was evaluated using a differential 
scanning calorimeter Q2000 (TA Instruments, Zellik, Belgium) equipped with a refrigerated 
cooling system. The DSC was calibrated for temperature and enthalpy using an indium 
standard. Tzero calibration was performed in 2 steps; baseline calibration (without samples 
or pans) and sapphire calibration (using large sapphire disks on both the sample and 
reference positions). Small sapphire disks, placed in a Tzero pan, were used for the heat 
capacity calibration. For the MDSC experiments, samples (±3 mg) were run in Tzero pans (TA 
Instruments, Zellik, Belgium) with an underlying heating rate of 5 °C/min (from -20°C to 
120°C). The modulation period and amplitude were set at 40 s and 0.531 °C, respectively. 
Data were analyzed using the Universal Analysis software (TA Instruments). Glass transition 
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temperature was determined in the reverse heat flow signal and the enthalpic recovery 
peaks were integrated in the non reverse heat flow signal.  
 
7.3. RESULTS 
7.3.1. Evaluation of the virus titer 
The titration results are presented in Figure 7.2. At T0, prior to storage, the samples had a 
titer of 6.39±0.21 (n=10). No titer difference was observed between the T0 samples and the 
samples stored during 1, 2 and 3 weeks at 4°C having titers of 6.32±0.05 (n=5), 6.33±0.2 
(n=5) and 6.15±0.22 (n=5), respectively. At a storage temperature of 37°C, the titer was 
found to decrease in two phases. After one week storage, the titer decreased from 
6.39±0.21 (n=10) at T0 to 5.2±0.22 (n=5) at T1 corresponding to a titer loss of 1.17 log. 
Afterwards, the titer loss slowed down and the vials stored 2 and 3 weeks at 37°C had titers 
of 4.82±0.08 (n=5) and 4.47±0.22 (n=5), respectively. This second phase of titer decrease is 
characterized by a titer loss of 0.4 log. Unfortunately, the virus titers obtained for the vials 
stored during four weeks are not valid because a cytopathogenic effect was detected in the 
negative controls of the potency assay.  
This two-phase degradation profile has also been observed during the accelerated stability 
study of the same virus using other stabilizers (data not shown). Similarly, accelerated 
stability studies of pseudorabies virus [13], canine distemper vaccine [14], measles vaccine 
[15] and Rinderpest vaccine [16] showed the same two phase titer loss trend. Their 
degradation curves were analyzed using a two-phase model that separates the degradation 
process into a rapid initial decay followed by a gradual linear decrease [15, 16]. Regression 
modelling of the gradual linear decrease (i.e., the second phase) offered the advantage to 
provide additional information  (degradation constant (i.e., the slope), the y-intercept 
(obtained from linear regression analysis beginning at T1) and the shelf life (calculated from 
the regression analysis, and function of the desired minimum titer)) to characterize the 
product stability and was used to compare the effect of different stabilizers, formulations or 
process settings on the product stability.  
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Figure 7.2: Titration results of the freeze-dried samples stored at 4°C and 37°C. Titers are expressed 
as log10 CCID50 (Cell Culture Infection Dose 50). The initial titer (T0) is the average of 10 
determinations in duplicate and each titer of the stored samples is the average of 5 determinations 
in duplicate. 
 
7.3.2. Evaluation of the residual moisture 
Residual moisture analysis by Karl Fischer (Figure 7.3) was also performed weekly (see Figure 
7.1). Before the stability study (T0), the samples had a residual moisture content of 1.86±0.3 
(n=5). After 1, 2, 3 and 4 weeks storage at 4°C, residual moisture values of 1.82±0.16 (n=5), 
1.95±0.25 (n=5), 1.73±0.39 (n=5) and 1.92±0.12 (n=4) respectively were obtained. The 
residual moisture hence remained similar during storage at 4°C. During storage at 37°C, the 
residual moisture increased gradually (above 2%) with values of 2.09±0.24 (n=5), 2.18±0.15 
(n=5), 2.45±0.25 (n=5) and 2.30±0.15 (n=5) after 1, 2, 3 and 4 weeks storage, respectively. In 
contrast to the observed titer decrease during storage at 37°C, the residual moisture 
increase did not show a two-phase pattern. 
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Figure 7.3: Residual moisture content of the freeze-dried samples stored at 4°C and 37°C. Each result 
is the average of three measurements. 
 
NIR spectra were also collected at each time point during the stability study (Figure 7.1). NIR 
spectroscopy offers the advantage (among others) of providing multivariate information 
related to biological, chemical and physical attributes of the materials being processed [17] 
and has been demonstrated several times to be an effective tool for the determination of 
the residual moisture content in freeze-dried end products [18-21].  
Twenty samples stored at 37°C were monitored with NIR spectroscopy every week. Principal 
component analysis was performed on these spectra (i.e., 100 spectra, 1 spectrum per 
sample, 20 samples per week, 5 time points). All SNV preprocessed NIR spectra were 
decomposed into two principal components (PCs) explaining 95.6% of the spectral variance, 
where PC1 accounted for 90.7% of the spectral variance and PC2 for 4.9% of the spectral 
variance. The PC1 scores versus storage time plot (Figure 7.4a) clearly showed a two-phase 
variation in the first principal component. 
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Figure 7.4: Scores and loadings plots obtained after principal component analysis of the NIR spectra 
collected on the samples stored at 37°C. a) PC1 scores versus storage time plot. The dashed colored 
lines visualize the evolution of three (out of the 20) samples. T1w, T2w, T3w and T4w represent 1 
week, 2 weeks, 3 weeks and 4 weeks storage respectively b) PC1 loadings plot. 
 
The broad peak around 5100-5200cm-1 in the corresponding PC1 loadings plot representing 
water [22] (Figure 7.4b), indicated that PC1 differentiated between the samples according to 
their moisture content. Moreover, the loadings plot indicated that the intensity of the water 
band increased during storage, (positive values of PC1 in the scores plot are characterized by 
an increase of peak intensity) confirming that the residual moisture increased during 
storage. Interestingly, the sample moisture content trend detected by NIR spectroscopy 
T0 T1w T2w T3w T4w
b) water
a)
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followed the same two-phase pattern as the virus titer decrease trend during storage at 37°C 
(Figure 7.2).  
The evaluation of the SNV preprocessed spectra (Figure 7.5) confirmed the intensity increase 
of the water band (5100-5200cm-1) upon storage at 37°C.  
 
Figure 7.5: NIR SNV preprocessed spectra of the freeze-dried samples stored at 37°C, collected 
weekly. Arrow indicates the evolution of the spectral signals during storage time. 
 
During the first week of the stability study, NIR spectra were collected every day (Figure 7.1) 
and PCA was also performed on these spectra (i.e., 120 spectra, 1 spectrum per sample, 20 
samples per storage time point). All SNV preprocessed NIR spectra were decomposed into 
two principal components (PCs) explaining 91.9% of the spectral variance. The PC1 (covering 
81.9% of the spectral variance) scores versus storage time plot (Figure 7.6a) clearly showed a 
two-phase trend. The peak around 5100-5200cm-1 in the corresponding PC1 loadings plot 
representing water [22] (Figure 7.6b), indicated that PC1 differentiated between the samples 
according to their water content.  
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Figure 7.6: a) PC1 scores versus storage time plot obtained after principal component analysis of the 
NIR spectra collected daily during the first week of storage at 37°C. The dashed colored lines help to 
visualize the evolution of three (out of the 20) samples daily analyzed. T1d, T2d, T3d, T4d and T5d 
represent 1day, 2 days, 3 days, 4 days and 5 days storage respectively. b) PC1 loadings plot. 
 
Similarly, twenty samples stored at 4°C were also monitored with NIR spectroscopy every 
week. PCA was performed on the collected spectra (i.e., 100 spectra, 1 spectrum per sample, 
20 samples per storage time point). All SNV preprocessed NIR spectra were decomposed 
into three principal components (PCs) explaining 93.8% of the spectral variance. The PC1 
(explaining 68.7% of the spectral variance) scores versus storage time plot (Figure 7.7a) and 
the PC1 loadings plot (Figure 7.7b) showed a slight increase of the water content upon 
storage at 4°C. This residual moisture increase detected by NIR was not detected by Karl 
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Fischer analysis (Figure 7.3) and did not follow the same two-phase pattern as seen during 
storage at 37°C. 
 
 
Figure 7.7: a) PC1 scores versus storage time plot obtained after principal component analysis of the 
NIR spectra collected weekly during storage at 4°C. The dashed colored lines visualize the evolution 
of three (out of the 20) samples. T1w, T2w, T3w and T4w represent 1 week, 2 weeks, 3 weeks and 4 
weeks storage, respectively. b) PC1 loadings plot. 
 
To conclude, NIR spectroscopy demonstrated that the moisture content of the samples 
stored at 37°C increased in two phases. The moisture increased already sharply after one 
day storage and then increased more linearly during the further four weeks of storage. At 
T0 T1w T2w T3w T4w
waterb)
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4°C storage, NIR spectroscopy demonstrated that the moisture content in the samples 
slightly increased (without following a two-phase pattern). 
The residual moisture increase patterns observed by NIR spectroscopy are similar to 
observations made by Pikal and Shah [23]. In their study, both at 40°C and 25°C storage 
temperature, the moisture content of a freeze-dried lactose formulation first increased 
sharply but then reached a plateau. At 5°C storage, the cake residual moisture also increased 
but gradually and almost approached the same residual moisture values as 40°C and 25°C 
storage after 24 months storage. This residual moisture increase observed upon storage was 
caused by moisture release by the stopper, equilibrating the moisture content between the 
stopper and the freeze-dried cake. The rate of reaching the moisture equilibrium was shown 
to be strongly storage temperature dependent [23]. 
To decrease this moisture release by the stopper, either high temperature vacuum drying of 
the stoppers after steam sterilization or the use of stoppers which are less prone to water 
release is advised [2]. 
Moisture release by the stopper most probably explains the residual moisture increase 
observed by NIR spectroscopy in our study.  
 
7.3.3. Thermal behaviour of the stored samples 
According to the NIR observations, the residual moisture increased upon storage at 4°C and 
37°C. The moisture content increase was higher at 37°C than at 4°C storage. Interestingly, at 
37°C storage, the sample moisture content trend detected by NIR followed the same two-
phase pattern as the virus titer decrease trend observed during storage at 37°C. In contrast, 
at 4°C storage, the titer remained constant and the moisture content only slightly increased 
(only detected by NIR) without following the two-phase pattern observed at 37°C. These 
observations suggested the link between storage temperature, moisture content increase 
and virus stability. To understand these observations in more detail, thermal analysis of the 
stored samples using MDSC was performed (Table 7.1). 
Thermal analysis of the samples stored at 37°C showed two events: both the enthalpic 
recovery (Figure 7.8) and the glass transition temperature (Tg) (Figure 7.9) increased in 
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function of storage time. Interestingly, this increase followed the same two-phase pattern 
(Figure 7.10) as the titer decrease and the residual moisture increase observed by NIR 
spectroscopy.  
 
Figure 7.8: MDSC curves: Non reverse heat flow in function of the temperature of samples stored at 
37°C. A, B, C and D represent 0 week, 1 week, 2 weeks and 3 weeks of storage, respectively. Enthalpic 
recovery peaks are marked with an asterisk. 
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Figure 7.9: MDSC curves: Reverse heat flow in function of the temperature of samples stored at 37°C. 
A, B, C and D represent 0 week, 1 week, 2 weeks and 3 weeks of storage, respectively. 
 
 
Figure 7.10: a) Relaxation enthalpy and b) Glass transition temperature in function of storage time of 
samples stored at 4°C and 37°C. 
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The enthalpic recovery detected with MDSC is a measure of the relaxation enthalpy. When 
an amorphous material is stored at a temperature near below its glass transition 
temperature (Tg), it might undergo “relaxation” and spontaneously lose enthalpy and free 
volume. The rate of this loss is considered to reflect the level of molecular mobility in the 
non equilibrium glassy amorphous sample [24]. Kawai and co-workers suggested that the 
activation energy for enthalpy relaxation decreases with increasing molecular mobility [25].  
The first observation, the two-phase pattern of the relaxation enthalpy increase, can be 
explained by the residual moisture increase detected by NIR spectroscopy which (by 
increasing the molecular mobility – moisture has a plasticizing effect) decreased the 
activation energy of relaxation enthalpy. The second observation, the Tg increase according 
to a two-phase pattern is an effect of the relaxation enthalpy. Similar increases of the Tg and 
enthalpic recovery have already been reported for amorphous trehalose and amorphous 
lactose [26, 27]. The Tg increase was suggested to be caused by the lactose molecules 
becoming closer (i.e., the free volume decreased) and forming a rigid matrix with low 
molecular movement (i.e., relaxation) [27].   
In freeze-dried samples, sorption of water causes plasticization of the amorphous phase 
thereby lowering the Tg [2, 26].  However, in this study, despite the residual moisture 
increase observed by NIR spectroscopy, the Tg of the samples stored at 37°C increased.  This 
can be explained by the fact that the residual moisture increase upon storage was rather low 
(approx. 0.5%), which seems to be not sufficient enough to combat the Tg increasing effect 
caused by the enthalpic recovery. Hence, the effect of relaxation on Tg was superior to the 
plasticization effect of water.  
Upon storage at 4°C, no relaxation enthalpy (Figure 7.10) was observed. The absence of 
relaxation upon storage at 4°C can be explained by the fact that the relaxation rate is 
maximal close to Tg (e.g., at a storage temperature of 37°C) while negligible relaxation 
occurs at temperatures far below Tg (e.g., at a storage temperature of 4°C) [26]. In addition, 
the activation energy of the relaxation enthalpy remained high since only a slight increase of 
residual moisture was observed by NIR spectroscopy (Figure 7.7), which was even not 
detected with Karl Fischer. Finally, the Tg of the samples stored at 4°C remained constant 
during the first week of storage and then increased (Figure 7.10). This Tg increase was not 
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coupled to an increase of the relaxation enthalpy in the MDSC thermogram. Nevertheless, 
the Tg increase might be caused by secondary relaxation undetectable by MDSC. 
Supplemental analysis with other equipment (e.g., by broadband dielectric spectroscopy) 
should be performed to verify this hypothesis. 
According to the glass dynamic hypothesis (a well-known stabilization hypothesis of proteins 
in glassy systems, thoroughly described in [24]), instability requires molecular mobility in the 
amorphous solid. The detection of relaxation enthalpy in the samples stored at 37°C 
indicates that the glass is subjected to molecular mobility [28]. A correlation has already 
been shown between molecular mobility and protein aggregation [29, 30] as well as 
chemical stability [31]. 
Similarly as the relaxation enthalpy, the virus titer was shown to decrease according a two-
phase pattern (Figure 7.2) suggesting that the virus destabilization is linked to the molecular 
mobility increase. Therefore, the virus titer decrease via virus particles aggregation, virus 
coated proteins unfolding or any other destabilization mechanism already described for 
proteins and requiring mobility are likely. 
 
7.3.4. FTIR and NIR spectroscopic evaluation of the live, attenuated 
virus during storage. 
Recently, NIR and FTIR spectroscopy have been demonstrated to be useful to evaluate live, 
attenuated viruses in freeze-dried formulations [7, 8]. In order to further clarify the observed 
titer decrease during storage in this study, both spectroscopic tools were used to provide 
direct information about the viruses and their interaction with the stabilizer (trehalose) in 
function of the storage temperature.  
7.3.4.1. NIR spectroscopy 
To evaluate the impact of the storage temperature on the viruses, two PCA models were 
built. The first model was developed with the NIR spectra collected directly after the freeze-
drying process (i.e., T0 samples) and the NIR spectra collected after one day storage at 37°C. 
The second PCA model was built using the NIR spectra of the T0 samples and the NIR spectra 
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of the samples stored 1 day at 4°C. To avoid the influence of the water bands and moisture 
variability between spectra on the PCA, a small spectral range (5029-4690cm-1) only 
containing the amide A/II band (4850cm-1) (i.e., not influenced by water), was used to build 
the PCA models.  
The first PCA model built from the SNV and 2nd derivative preprocessed NIR spectra of the T0 
samples and the samples stored during one day at 37°C was developed from 40 spectra and 
consisted of two principal components covering 91.8% of the spectral variability. The PC1 
(explaining 76.3% of the spectral variability) versus PC2 (explaining 15.5% of the spectral 
variability) scores plot showed that the model distinguished the T0 samples from the 
samples stored during one day at 37°C (Figure 7.11a). Interestingly, the loadings plot of the 
second principal component revealed two peaks at 4980cm-1 and 4800cm-1 (Figure 7.11c). 
The band at 4800cm-1 can be identified in the spectra (Figure 7.11d) as the amide A/II band 
and its intensity was different between T0 and T1d samples. 
The PCA model built from the SNV and 2nd derivative preprocessed NIR spectra of the T0 
samples and the samples stored during one day at 4°C was also developed from 40 spectra. 
This model consisted of three principal components describing 97.1% of the spectral 
variability and did not allow distinguishing between the T0 samples and the samples stored 
one day at 4°C (PC1 versus PC2 scores plot is presented in Figure 7.11b).  
Protein dehydration and denaturation has been monitored using NIR spectroscopy by 
evaluating the amide A/II frequency which represents the strength of the hydrogen bonds of 
the amide group of proteins [32-34]. At 37°C, a change in the amide A/II band has been 
observed (Figure 7.11) whereas no change was observed upon storage at 4°C (Figure 7.11) 
indicating that hydrogen bonds strength of the virus proteins amide group is affected at 37°C 
storage.  
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Figure 7.11: Principal component analysis of the preprocessed NIR spectra collected of the T0 
samples and the samples stored one day at 37°C or one day at 4°C (5029-4690cm-1 spectral range). a) 
PC1 versus PC2 scores plot of T0 samples and samples stored one day at 37°C.   b) PC1 versus PC2 
scores plot of T0 samples and samples stored one day at 4°C. c) PC1 and PC2 loadings plot of T0 
samples and the samples stored one day at 37°C. d) NIR SNV and 2nd derivative spectra of a T0 
sample and a sample stored 1 day at 37°C. 
 
7.3.4.2. FTIR spectroscopy 
Hydrogen bonding influences the protein secondary structure [28]. Therefore, in order to 
evaluate whether the virus coated protein secondary structure is influenced by storage at 
37°C, FTIR spectroscopy, recognized to be an excellent tool to study protein secondary 
structure, was used. Two PCA models were built using the FTIR spectra collected during the 
stability study (Figure 7.1). All time points were used in these PCA models because only five 
T0 T1
a) b)
T0
T1
PC1
PC2
c) d)
4800cm-1
4800cm-1
Amide A/II
4980cm-1
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FTIR spectra per time point were available. In order to avoid the contribution of the water 
bands on the principal component analysis, the PCA models were built using the SNV 
preprocessed amide III spectral range (1350-1200cm-1) which is not disturbed by water [8]. 
The first PCA model was built using the FTIR spectra of the T0 samples and the samples 
stored during 1, 2, 3 and 4 weeks at 37°C. This PCA model, developed from 24 spectra and 
composed of two principal components, described 93.2% of the spectral variability. The PC1 
(explaining 74.2% of the spectral variability) versus PC2 (explaining 19% of the spectral 
variability) scores plot showed that the model distinguished between the T0 samples and the 
samples stored at 37°C (Figure  7.12a). Analysis of the loadings plot of the first principal 
component (Figure  7.12b) revealed two peaks at 1297cm-1 (α-helix) and 1262cm-1 (β-turn) 
being responsible for the distinction between the T0 samples and the samples stored during 
1, 2, 3 and 4 weeks at 37°C. The second PCA model was built using the FTIR spectra of the T0 
samples and the samples stored during 1, 2, 3 and 4 weeks at 4°C. This PCA model, 
developed from 25 spectra and composed of three principal components, described 94% of 
the spectral variability and did not allow distinguishing the T0 samples from the samples 
stored 1, 2, 3 and 4 weeks at 4°C (Figure 7.12c).  
Evaluation of the spectra (Figure 7.13) showed that upon storage at 37°C (Figure 7.13a), the 
peak intensity of the β-turn decreased while the spectral range typical of α-helix was shifted 
to a higher intensity. Conversely, no spectral difference between both, T0 samples and the 
samples stored at 4°C during 1, 2, 3 and 4 weeks can be seen (Figure 7.13b).  
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Figure 7.12: PC1 versus PC2 scores plots and PC1 loadings plot obtained after principal component 
analysis of the FTIR spectra collected on the T0 samples and the samples stored at 37°C or at 4°C 
(1200-1350cm-1 spectral range, amide III). a) PC1 versus PC2 scores plot of T0 samples and the 
samples stored at 37°C. b) PC1 loadings plot of T0 sample and samples stored at 37°C. c) PC1 versus 
PC2 scores plot of T0 samples and the samples stored at 4°C. 
a)
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Figure 7.13: a) FTIR spectra of a T0 sample and a sample stored 1 week at 37°C.b) FTIR spectra of a T0 
sample and a sample stored 1 week at 4°C. 
 
7.4. CONCLUSION 
This study is, to our best knowledge, the first one combining NIR and FTIR spectroscopy with 
traditional residual moisture, titration and MDSC analysis to better understand the viability 
decrease of a freeze-dried live, attenuated virus vaccine during an accelerated stability 
study. During storage at 37°C, titration of the samples showed that the viability decreased 
according to a two-phase pattern. Moreover, the residual moisture (evaluated with Karl 
Fischer and NIR spectroscopy), the glass transition temperature and the relaxation enthalpy 
also increased according to this two-phase pattern. During storage at 4°C, the virus titer 
remained constant, no relaxation enthalpy was detected and the residual moisture increased 
only very slightly. 
During storage, the moisture content increase was caused by moisture release from the 
stopper, equilibrating the moisture content between the stopper and the freeze-dried cake 
at a temperature-dependent rate. Similarly, the relaxation enthalpy was also found to be 
different between both storage temperatures. No relaxation enthalpy was detected at 4°C 
storage whereas at 37°C storage (a temperature close to the formulation Tg) the relaxation 
a)
α helix
β turn
T0
T1
b)
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enthalpy was found to increase according to a two-phase pattern. This increase reflected the 
increased degree of mobility in the amorphous samples during storage due to the moisture 
release by the stopper.   
The measured virus titer decrease at 37°C storage followed the same two-phase pattern as 
the relaxation enthalpy increase and suggested a link between mobility and virus 
destabilization. This assumption was supported by the stability of the virus stored at 4°C 
where no relaxation enthalpy was detected.  
Evaluation of the amide A/II band (NIR spectra) revealed that the destabilization of the virus 
was probably linked to a change in the hydrogen bonds strength between trehalose and the 
virus proteins. By studying the amide III band (FTIR spectra), it was found that the virus 
destabilization was coupled to a decrease of β-turn and an increase of α-helix. Together, NIR 
and FTIR spectroscopy have shown that the relaxation enthalpy (i.e., the molecular mobility) 
increase upon storage played a role in the stability of the viruses by modifying the strength 
of the hydrogen bonds between the virus coated proteins and the amorphous trehalose 
used as stabilizer.  
Concluding from all these observations, avoiding an increase in mobility during storage 
might result in a decreased degradation rate. To achieve the lowest possible mobility 
increase during storage, an annealing step performed at a temperature of 15 to 20°C below 
Tg for a short time (from 5h to 20h depending on the formulation) during the secondary 
drying step of the freeze-drying process might be effective [35, 36]. 
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ABSTRACT 
This chapter examines the applicability of near-infrared (NIR) spectroscopy to classify freeze-
dried live, attenuated virus vaccines according to their dose. Therefore, three different dose 
presentations (i.e., 125, 50, 25) and a placebo were used. In total, 6 batches were freeze-
dried, corresponding to a total of 844 vials (i.e., 243 125-dose vials, 246 50-dose vials, 244 
25-dose vials and 111 placebo vials). NIR spectra were collected from each freeze-dried vial 
and these spectra were first analyzed with principal component analysis (PCA) using the 
spectral region 7300-4000cm-1, previously demonstrated to allow evaluating freeze-dried 
live, attenuated virus products. In the PCA scores plot, the 125-dose vials and the placebo 
vials were well distinguished whereas the 50-dose vials and the 25-dose vials were not well 
separated.  
In a next step, Soft Independent Modelling of Class Analogy (SIMCA) was applied to classify 
the four dose presentations. Three batches were used to build the model (i.e., the 
calibration set), two batches were used to test the model (i.e., the test set) and finally, one 
batch was used to evaluate the robustness of the model. Global correct classification rates of 
95.49% and 71.77% were obtained with this model (test set Zoe 4 and Zoe 5 respectively). 
Afterwards, Orthogonal Partial Least Squares (OPLS) regression modelling was performed 
allowing the optimization of the spectral range to be used, resulting in an improved SIMCA 
classification model. A global correct classification rate up to 98.5% was obtained (test set 
Zoe 4). Finally, in agreement with the European Medicines Agency (EMA) guidelines, the 
classification model specificity, sensitivity and accuracy was evaluated and a robustness 
study was performed. This study demonstrated that the classification model was very 
sensitive to the residual moisture content of the vials to be classified. To conclude, the 
obtained results suggest that NIR spectroscopy could be used as a fast screening tool to 
evaluate the dose content of a freeze-dried live, attenuated virus vaccine formulation. 
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CHAPTER 8 
SPECTROSCOPIC DOSE CLASSIFICATION OF A 
FREEZE-DRIED LIVE ATTENUATED VIRUS 
VACCINE 
 
8.1. INTRODUCTION 
Vaccines are among the most cost-effective health interventions ever developed. They save 
millions of lives every year and have lead to the eradication of smallpox, the near eradication 
of polio and a 75 percent reduction in childhood deaths from measles over the past decade 
[1].  
The live attenuated vaccine is one of the seven different types of vaccines. It contains 
weakened, attenuated versions of infectious viruses and bacteria and is considered as a 
good “teacher” of the immune system and is very similar to a natural infection [2]. The 
instability of live attenuated vaccines in aqueous media is well known [3, 4]. In water, they 
are susceptible to inactivation by physical (e.g. unfolding) and chemical (e.g. hydrolysis, 
oxidation, deamidation and the breakage or formation of disulfide bonds) processes which 
can lead to the disruption of the conformation and function of the structural proteins and 
glycoproteins [4]. In addition, the lipid bilayer envelope of viruses is extremely susceptible to 
damage because of their osmotic sensitivity as well as the complex composition of their 
lipid, carbohydrate and protein components [4, 5].  
In order to preserve the potency of live, attenuated vaccines during distribution and long 
term storage, lyophilization is often used. This process consists of three consecutive steps: 
sample freezing, primary drying (sublimation) and secondary drying (desorption) [6]. At the 
end of the freeze-drying process, the overall potency of vaccines is generally determined via 
cell-based viral plaque assays. This biological method is considered as the gold standard for 
infective viral particles quantification. In such assays, serial dilutions of the vaccine are used 
to infect confluent monolayer of adherent cells. After several days of incubation, the cells 
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are examined in order to find any cytopathic effect. The number of infectious particles can 
then be calculated from the dilution factor and the number of cytopathic effects detected. 
Potency assays have the advantage of being time-honored and widely accepted, but are also 
known to be relatively imprecise and inaccurate, labor-intensive and time-consuming [7-9].  
Encouraged by the process analytical technology (PAT) initiative, interest has arisen to 
develop new fast and non-destructive analytical methods.  
Near Infrared (NIR) spectroscopy is a PAT tool that has been demonstrated to be able to 
evaluate live, attenuated viruses in a freeze-dried vaccine formulation [10]. NIR spectroscopy 
was able to distinguish between samples prepared using different virus medium volumes or 
using different pre-freeze-drying treatments. This distinction was possible using two NIR 
spectral regions: (i) the 7300-4000cm-1 region containing the amide A/II band which might 
reflect information on the coated proteins of the freeze-dried live, attenuated viruses; and 
(ii) the C-H vibration overtone regions (10,000-7500 and 6340-5500cm-1) which might supply 
information on the lipid layer surrounding the freeze-dried live, attenuated viruses.  
In 2000, approximately 80% of all vaccinations administered globally were produced and 
supplied as multi-dose products (i.e., products containing more than one dose of 
medication) [11]. Single-dose formats are more costly than multi-dose products, for three 
main reasons. The fillings costs of single-dose products are higher and amplified with 
lyophilized vaccines, single-dose formats need more vaccine overfill per dose than multi-
dose products and finally, the packaging costs are higher [12].  
The aim of this chapter is to develop and validate an NIR spectroscopic dose classification 
model able to classify a new freeze-dried live, attenuated virus vaccine vial according to 
dose. For one vaccine, three different dose presentations (i.e., 125-dose vial, 50-dose vial, 
25-dose vial) and a placebo were prepared. Principal Component Analysis (PCA) was first 
used to evaluate the ability of NIR spectroscopy to distinguish between the freeze-dried 
formulations containing different virus doses (i.e., 125-dose, 50-dose, 25-dose and placebo). 
Soft Independent Modelling of Class Analogy (SIMCA) was then applied to classify the four 
dose presentations. Once built, the SIMCA model was optimized using Orthogonal Partial 
Least Squares (OPLS) regression modelling allowing the selection of the optimal spectral 
range (better than the spectral range (7300-4000cm-1) used in [10]). The model was 
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afterwards validated according to the European Medicines Agency (EMA) guidelines by 
evaluating its accuracy, specificity and sensitivity for the classification of new independent 
observations. In addition, a robustness study was performed by evaluating the ability of the 
model to classify vials lyophilized in another freeze-drier than the vials used to build the 
model. 
 
8.2. MATERIALS AND METHODS 
8.2.1. Materials 
The live, attenuated virus used as vaccine in this study as well as its stabilizer solution, were 
obtained from Zoetis. The applied four different dose formulations are presented in Table 
8.1. The virus medium (i.e., the medium containing the viruses) volume was varied in order 
to obtain the correct number of doses. The stabilizer solution was kept constant (volume 
and concentration) in the four formulations. Ultraculture (Lonza, Belgium), a medium free 
from virus, was used to keep the total volume of the four dose formulations identical. For 
clarity, the four different virus medium volumes (i.e., x, y, z and 0ml, Table 8.1) used to 
prepare the different doses were compensated by the addition of an appropriate volume of 
medium free of virus (i.e., v-x, v-y, v-z and v, Table 8.1) in order to have a total volume of 5ml 
(Table 8.1). Therefore, the only difference between the dose formulations is the number of 
virus particles because the volume of “medium” is equal for all dose formulations. Finally, for 
each dose formulation, samples were prepared with either filtered (0.45µm) virus medium 
or non-filtered virus medium to evaluate whether cell fragments, that might still be present 
in the virus medium, interfere with the NIR spectral classification.  
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Table 8.1: Overview of the studied live, attenuated virus formulations 
 
Virus medium (ml) 
Filtration 
(0.45µm) 
Stabilizer 
(ml) 
Ultraculture (ml) Total volume (ml) 
125-dose vial x No s v-x 5 
125-dose vial x Yes s v-x 5 
50-dose vial y No s v-y 5 
50-dose vial y Yes s v-y 5 
25-dose vial z No s v-z 5 
25-dose vial z Yes s v-z 5 
Placebo vial 0 NA s v 5 
 
A total of six batches were freeze-dried and as overviewed in Table 8.2. Five batches were 
produced at Zoetis and one batch was produced at the Ghent university research lab 
(UGent). The three first batches produced at Zoetis (Zoe 1, Zoe 2 and Zoe 3) were used as 
calibration set (i.e., the dataset used to build the model) and the two other batches (Zoe 4 
and Zoe 5) were used as independent test sets (i.e., independent dataset used to test and 
validate the model). The batch produced at the Ghent university research lab (UG) was used 
as independent test set to evaluate the robustness of the classification model to a freeze-
dryer change.  
 
Table 8.2: Overview of the freeze-dried batches  
Batches Batch ID Batch purpose 
Number of samples per dose 
presentation1 
Number of titrated 
samples1,2 
Zoetis 1 Zoe 1 Calibration set 
125 doses NF: 18 
125 doses F: 20 
50 doses NF: 18 
50 doses F: 17 
25 doses NF: 18 
25 doses F: 19 
Placebo: 19 
TOTAL : 129 
125 doses NF: 5/18 
125 doses F: 3/20 
50 doses NF: 5/18 
50 doses F: 3/20 
25 doses NF: 5/18 
25 doses F: 3/19 
Placebo: NA 
TOTAL: 24 
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Table 8.2: Overview of the freeze-dried batches (continued). 
Zoetis 2 Zoe 2 Calibration set 
125 doses NF: 19 
125 doses F: 16 
50 doses NF: 18 
50 doses F: 18 
25 doses NF: 17 
25 doses F: 15 
Placebo: 17 
TOTAL: 120 
125 doses NF: 10/19 
125 doses F: 3/16 
50 doses NF: 10/18 
50 doses F: 3/18 
25 doses NF: 9/17 
25 doses F: 3/15 
Placebo: NA 
TOTAL: 38 
     
Zoetis 3 Zoe 3 Calibration set 
125 doses NF: 19 
125 doses F: 18 
50 doses NF: 19 
50 doses F: 18 
25 doses NF: 19 
25 doses F: 18 
Placebo: 19 
TOTAL: 130 
125 doses NF: 10/19 
125 doses F:  3/18 
50 doses NF: 10/19 
50 doses F: 3/18 
25 doses NF: 10/19 
25 doses F: 3/18 
Placebo: NA 
TOTAL: 39 
Zoetis 4 Zoe 4 Test set 
125 doses NF: 17 
125 doses F: 18 
50 doses NF: 17 
50 doses F: 18 
25 doses NF: 18 
25 doses F: 17 
Placebo: 28 
TOTAL: 133 
125 doses NF: 9/17 
125 doses F: 3/18 
50 doses NF: 9/17 
50 doses F: 3/18 
25 doses NF: 9/18 
25 doses F: 3/17 
Placebo: NA 
TOTAL: 36 
     
Zoetis 5 Zoe 5 Test set 
125 doses NF: 49 
125 doses F: 15 
50 doses NF: 41 
50 doses F: 22 
25 doses NF: 34 
25 doses F: 30 
Placebo: 18 
TOTAL: 209 
125 doses NF: 10/49 
125 doses F: 3/15 
50 doses NF: 10/41 
50 doses F: 3/22 
25 doses NF: 10/34 
25 doses F: 3/30 
Placebo: NA 
TOTAL: 39 
      
 
Chapter 8 – Spectroscopic dose classification of a freeze-dried live attenuated virus vaccine 
 
206 
 
Table 8.2: Overview of the freeze-dried batches (continued). 
UGent UG 
Test set 
(Robustness) 
125 doses NF: 20 
125 doses F: 18  
50 doses NF: 20  
50 doses F: 20 
25 doses NF: 20 
25 doses F: 19 
Placebo: 10 
TOTAL: 127 
125 doses NF: 8/20 
125 doses F: 5/18 
50 doses NF: 6/20 
50 doses F: 5/20 
25 doses NF: 8/20 
25 doses F: 5/19 
Placebo: NA 
TOTAL: 37 
1
Filtered (F) and non-filtered (NF) 
2
Each vial has been titrated two times. 
 
8.2.2. Freeze-drying 
Five batches were produced at Zoetis (Zoetis 1-5) using a Lyostar 3 (SP scientific, Stone 
Ridge, NY, USA) and 1 batch was produced at Ghent University (UGent) using a LyoBeta 25 
(Telstar, Terrassa, Spain). 
All batches were freeze-dried using the same freeze-drying settings, optimized by Zoetis, 
which cannot be disclosed for confidentiality reasons. All the freeze-dried vials had a visually 
acceptable cake aspect. 
 
8.2.3. Titration 
Titration (potency assay) was done according to Zoetis’ internal SOPs. Each titer is expressed 
in log10 CCID50 (Cell Culture Infection Dose 50). Titration provides information about the 
number of living viral particles contained in each freeze-dried vial. Each analyzed sample was 
titrated twice.   
 
8.2.4. Residual moisture analysis 
The residual moisture content of freeze-dried samples was determined using Karl Fischer 
titration. After each freeze-drying cycle, the samples were analyzed with a Metrohm 860 KF 
Thermoprep (oven) coupled to a Metrohm 852 Titrando (Herisau, Switzerland). Three 
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filtered and three non-filtered vials of each dose formulation and three placebo vials were 
measured. 
 
8.2.5. NIR spectroscopy 
NIR spectra of all freeze-dried samples were collected off-line using a Fourier-Transform NIR 
spectrometer (Thermo Fisher Scientific, Nicolet Antaris II near-IR analyzer) equipped with an 
InGaAs detector and a quartz halogen lamp. All NIR spectra were recorded in the 10000-
4000 cm-1 region with a resolution of 8 cm-1 and averaged over 16 scans. One NIR spectrum 
per freeze-dried sample (in random order) was collected through the bottom of the glass vial 
using the integrating sphere device immediately after freeze-drying. 
 
8.2.6. Data analysis 
NIR spectral data analysis was done using SIMCA 14.0 (Umetrics, Umea, Sweden). Based on a 
previous study [10], the spectral region 7300-4000cm-1, containing the amide A/II band was 
evaluated. All collected NIR spectra were mean centered and preprocessed using standard 
normal variate (SNV) in order to eliminate additive baseline offset variations and 
multiplicative scaling effects in the spectra which may be caused by possible differences in 
sample density and sample-to-sample measurement variations.  
8.2.6.1. Principal Component Analysis 
All collected NIR spectra per batch were first analyzed as one data matrix (D) using  principal 
component analysis (PCA), which is an unsupervised multivariate data analysis method 
allowing to examine whether NIR spectroscopy can distinguish between the different doses. 
In addition, PCA was also used to understand and explain misclassifications. 
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PCA produces an orthogonal bilinear data matrix (D) decomposition, where principal 
components (PCs) are obtained in a sequential way to explain maximum variance:  
D=TPT + E 
= t1p’1 + t2p’2 +…+tQp’Q + E 
 
Where T is the M x Q score matrix, P is the N x Q loading matrix, E is the M x N model 
residual matrix, i.e., the residual variation of the data set that it is not captured by the 
model. Q is the selected number of PCs, each describing a non-correlated source of variation 
in the data set, and N is the number of collected spectra at M wavelengths [13]. Each 
principal component consists of two vectors, the score vector t and the loading vector p. The 
score vector contains a score value for each spectrum, and this score value informs how the 
spectrum is related to the other spectra in that particular component. The loading vector 
indicates which spectral features in the original spectra are captured by the component 
studied. These abstract, unique, and orthogonal PCs are helpful in deducing the number of 
different sources of variation present in the data. However, these PCs do not necessarily 
correspond to the true underlying factors causing the data variation, but are orthogonal 
linear combinations of them, since each PC is obtained by maximizing the amount of 
variance it can explain [14].  
The number of PCs included in the PCA model was determined by cross validation using the 
approach of Krzanowski [15]. The data are divided into 7 groups and a model was generated 
for the data devoid of one group. The deleted group was predicted by the model and the 
squared differences between the predicted and observed values were summed to form the 
Predictive Residual Sum of Squares (PRESS). This procedure was repeated 7 times, followed 
by the summation of all partial PRESS-values in terms of an overall PRESS-value. If a new PCi 
enhanced the predictive power compared with the preceding PCi-1, the new PCi was kept in 
the model [16]. 
8.2.6.2. Soft Independent Modelling of Class Analogy  
Soft Independent Modelling of Class Analogy (SIMCA) was chosen for the development of 
the classification model based on the NIR spectra from the different dose-vials (125-dose, 
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50-dose, 25-dose and placebo). As already mentioned (Table 8.2), the batches Zoe 1, Zoe 2 
and Zoe 3 were used for calibration of the model. SIMCA [17] is a widely used classification 
technique which puts more emphasis on similarity within a class than on discrimination 
between classes [18].  In SIMCA, each class of a training set of observations of known classes 
is modeled separately by disjoint PCA models. After the separate modelling of each class, a 
likely class membership of each new observation is predicted.  
8.2.6.3. Orthogonal PLS  
Orthogonal Partial Least Squares to latent structures (OPLS) is a modification of PLS designed 
to handle variation in X (i.e., in this study the spectroscopic data matrix) that is orthogonal to 
Y (i.e., in this study the class membership). OPLS separates the systematic variation in X into 
two parts, one that is linearly related (and therefore predictive) to Y and one that is 
uncorrelated (orthogonal) to Y. The predictive variation of Y in X is modeled by the predictive 
component whereas the variation in X, which is orthogonal to Y, is modeled by the 
orthogonal components. This partitioning of the X-data provides improved model 
transparency and interpretability. In this study, the analysis of the loadings plot of the 
predictive component allowed identifying the spectral contribution responsible for the 
distinction between the different dose vials. Based on this, the spectral range of the SIMCA 
classification model was optimized. 
8.2.6.4. Evaluation of model performance 
The ability of each developed SIMCA model to classify new observations correctly was 
evaluated using a misclassification table. Such a table shows the proportion of correct 
classifications of the test set vials (e.g., Zoe 4 and Zoe 5).  
From the misclassification table, the number of true positives (TP), true negatives (TN), false 
positives (FP) and false negatives (FN) can be determined. Afterwards, in order to validate 
the classification model according to the EMA guidelines [19], the percent classification 
accuracy, sensitivity and specificity are calculated using the following equations: 
% Accuracy: ((TN + TP)/(TN+TP+FN+FP))*100 
% Sensitivity: ((TP)/(TP+FN))*100 
% Specificity: (TN/(TN+FP))*100 
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The sensitivity reflects the model ability to correctly classify the doses whereas the 
specificity reflects the ability of the model to correctly reject doses when they do not belong 
to a class. Both are combined to determine the accuracy of the model. 
 
8.3. RESULTS AND DISCUSSION 
The results are discussed in three parts: (i) the titer and residual moisture determination of 
vials from the different batches, (ii) the Principal Component Analysis (PCA) of the NIR 
spectra and, (iii) the development and validation of the NIR classification model.    
 
8.3.1. Titration and residual moisture analysis 
The potency assay performed to analyze the titer of the different dose vials is the only 
reference method that is currently used to evaluate the viability of the viruses after freeze-
drying and during storage. The titration results obtained immediately after freeze-drying are 
presented in Figure 8.1. The titration results showed that there was no difference between 
the filtered and non-filtered vials. Secondly, the titers of the UGent batch were lower than 
the titers of the Zoetis batches. Finally, the titers of the 125-dose vials, the 50-dose vials and 
25-dose vials were different within each batch. 
 
Figure 8.1: Titration results of the different dose vials - filtered (F) and non-filtered (NF) - of Zoetis 
and UGent batches. Titers are expressed as log10 CCID50 (Cell Culture Infection Dose 50). Each vial has 
been titrated twice and each titer is the mean of several vials (number of titrated vials varies with 
batch) +/- standard deviation.  
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The residual moisture content results are presented in Figure 8.2. All evaluated vials had a 
residual moisture below 2%. Furthermore, for each dose no difference in residual moisture 
content was detected between filtered and non-filtered vials. Thirdly, the measured 125-
dose vials, 50-dose vials and 25-dose vials had similar residual moisture content within each 
batch. Finally, the residual moisture of batch UGent was higher than the residual moisture of 
the other batches. This difference might be caused by several reasons; (i) a different degree 
of supercooling caused by different environmental conditions (i.e., less particles in GMP 
conditions) leading to differences in cake pore size, (ii) cake rehydration between transport 
from Ghent to Zoetis were the residual moisture analysis were performed. 
 
Figure 8.2: Residual moisture content results of the different dose vials - filtered (F) and non-filtered 
(NF) - of the Zoetis and UGent batches. Residual moisture is expressed in %. Each moisture value is 
the mean of 3 determinations +/- standard deviation. 
 
8.3.2. Principal Component Analysis of the spectra 
The NIR spectra of each batch were first analyzed using principal component analysis (PCA). 
As mentioned in the material and method section, the 7300-4000 cm-1 NIR spectral range 
was evaluated. This first PCA had multiple aims: (i) to evaluate whether NIR spectroscopy 
allows distinguishing between the different doses, (ii) to evaluate whether filtration of the 
virus medium (see materials and methods section) impacts the NIR spectra and (iii) to 
provide an overview of the data (i.e., indicate groups of observations, trends, outliers and 
other anomalies). Figure 8.3 shows the scores and loadings plots of three different PCA 
models developed using the NIR spectra from batch Zoe 1.   
0.5
0.7
0.9
1.1
1.3
1.5
1.7
1.9
2.1
125 NF 125 F 50 NF 50 F 25 NF 25 F Placebo
R
e
si
d
u
al
 m
o
is
tu
re
 (
%
) 
Zoe 1
Zoe 2
Zoe 3
Zoe 4
Zoe 5
UG
Chapter 8 – Spectroscopic dose classification of a freeze-dried live attenuated virus vaccine 
 
212 
 
The first PCA model developed from the SNV preprocessed spectra of the filtered and non-
filtered vials together (i.e., 125 spectra, 1 spectrum per vial) existed of two principal 
components and described 90.6% of the spectral variability. The PC1 versus PC2 scores plot 
(Figure 8.3a) did not show differences between the vials in the first PC (explaining 80.4% of 
the spectral variability). The PC1 loadings plot (data not shown) revealed as main 
contribution the water band at 5140 cm-1 and hence confirmed that there was no difference 
in residual moisture content between the different dose vials. The second PC (explaining 
10.2% of the spectral variability) distinguished the vials according to their dose content 
(Figure 8.3a). The 125-dose vials and the placebo vials were located at each side of PC2 in 
the scores plot. However, no clear distinction between the 50-dose vials and the 25-dose 
vials can be made. The titers of these vials were very close to each others and might explain 
why NIR spectroscopy did not distinguish between the 50- and 25-dose vials. Finally, no 
difference between filtered and non-filtered vials was detected with NIR for each dose 
content. 
 
Figure 8.3: PC1 versus PC2 scores and PC2 loadings plot obtained after PCA of the NIR spectra 
collected from batch Zoe 1. (a, d) scores and loadings plots of the filtered and non-filtered vials 
together, (b, e) scores and loadings plots of the filtered vials, (c, f) scores and loadings plots of the 
non-filtered vials. 
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The second PCA model was developed using the SNV preprocessed spectra of the filtered 
vials only (i.e., 73 spectra, 1 spectrum per vial) and contained two principal components 
describing 91.7% of the spectral variability. Interpretation of the PC1 versus PC2 scores plot 
(Figure 8.3b) led to similar conclusions as for the first PCA model developed for the filtered 
and non-filtered observations together. The first PC (80.6% of the spectral variability) 
described the moisture differences between the vials while the second PC (11.1% of the 
spectral variability) distinguished the vials according to their dose content (except the 50- 
and 25-dose vials).  
A third PCA model was built using the SNV preprocessed spectra of the non-filtered vials 
(i.e., 72 spectra, 1 spectrum per vial) and described 91% of the spectral variability (two 
principal components). The first PC (81.9% of the spectral variability) described the moisture 
differences between the vials. The second PC (covering 9.1% of the spectral variability) 
distinguished the 125-dose vials but not the 50-dose vials, 25-dose vials and the placebos 
(Figure 8.3c). The loadings plots of the second PCs of the 3 PCA models (Figure 8.3d, e, f) 
were similar. Among the different bands involved in the distinction between the dose vials, 
the clear band at 4830cm-1 was identified as the amide A/II band. This band was already 
involved in the distinction between vials composed of different virus volumes (i.e., varying 
virus medium volume compensated by water instead of Ultraculture) in a previous study [10] 
and might reflect information on the viral coated proteins. The same PCA was also 
performed on SNV and 2nd derivative spectra. Nevertheless, the distinction of the different 
dose vials was not possible using this preprocessing (data not shown). 
 
PCA of the SNV preprocessed spectra of Zoe 1 using the 7300-4000cm-1 spectral range has 
shown that the distinction between the different dose vials was possible for 125-dose vials 
and the placebo vials. The distinction between the 50-dose vials and 25-dose vials was 
however not possible. Identical conclusions could be made after PCA of the other batches 
produced at Zoetis. Furthermore, the PCA demonstrated that filtration had no negative 
effect on the NIR spectra because: (i) the PCA performed by combining the filtered and non-
filtered vials did not distinguish them (Figure 8.3a) and (ii) the filtered vials were better 
separated than the non-filtered vials. Nevertheless, an exception was found in the PCA of 
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the filtered vials of batch Zoe 5. The distinction of the different dose formulations was not 
possible with this batch, which might indicate an issue with the filtration step.  
 
8.3.3. Development and validation of a classification model 
The overall aim of this study is to develop a model able to classify new freeze-dried products 
according to their dose content. Soft Independent Modelling of Class Analogy (SIMCA) and 
Partial Least Squares Discriminant Analysis (PLSDA) are two frequently used classification 
methods. One of the required conditions for PLSDA to work reliably is that each class 
occupies a separate volume in the X-space (i.e., the different classes do not overlap) [16]. 
The PCA performed in the previous section has shown that the 50-dose vials and the 25-dose 
vials cannot be easily separated hence making the use of a PLSDA model less appropriate. 
Based on similarity within a class rather than on discrimination between classes, SIMCA 
better deals with slightly overlapping classes and hence constitutes a better choice. 
Therefore, SIMCA was selected as classification model for this study. 
In total, five batches produced at Zoetis were available to build and validate (i.e., test) the 
SIMCA classification model. As mentioned in the material and methods section, the batches 
Zoe 1, Zoe 2 and Zoe 3 were used to build the model, while Zoe 4 and Zoe 5 were used to 
validate the model. Filtered and non-filtered vials were combined in the dataset in order to 
have more observations. This should not negatively influence the classification according to 
dose since the filtration step had no effect on the virus titer and no negative effect on the 
spectra, as demonstrated higher. 
8.3.3.1. Development of the SIMCA classification model 
Based on a previous study [10], the SNV preprocessed spectral range 7300-4000cm-1 was 
selected. Afterwards, the developed SIMCA model was evaluated with an independent test 
set, i.e., batches Zoe 4 and Zoe 5. 
The misclassification table of Zoe 4 is presented in Table 8.3. The 125-dose vials, 50-dose 
vials, 25-dose vials and placebo vials had a correct classification rates (CCR) of 97.14%, 
91.43%, 100% and 92.86% respectively. Globally, this correct classification rate (95.49%) was 
satisfactory. 
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Table 8.3: Misclassification table obtained using Zoe 1-2-3 as calibration set and Zoe 4 as 
independent test set. 7300-4000cm-1 spectral range, SNV preprocessed. 
  
Members 
Correct 
Classification rate 
(CCR, %) 
125-dose 
vial 
50-dose 
vial 
25-dose 
vial 
Placebo No class 
125-dose vial 35 97.14% 34 0 0 0 1 
50-dose vial 35 91.43% 0 32 3 0  
25-dose vial 35 100% 0 0 35 0  
Placebo 28 92.86% 0 0 2 26  
Total 133 95.49% 34 32 40 26 1 
 
Similarly, the misclassification table of batch Zoe 5 is presented in Table 8.4. Its 125-dose 
vials, 50-dose vials, 25-dose vials and placebo vials had correct classification rates (CCR) of 
51.56%, 57.14%, 100% and 94.44% respectively. Surprisingly, the CCR obtained for the 125-
dose vial and the 50-dose vial were far under the scores obtained for batch Zoe 4 (Table 8.3).  
 
Table 8.4: Misclassification table obtained using Zoe 1-2-3 as calibration set and Zoe 5 as 
independent test set. 7300-4000cm-1 spectral range, SNV preprocessed. 
  
Members 
Correct 
Classification rate 
(CCR, %) 
125-dose 
vial 
50-dose 
vial 
25-dose 
vial 
Placebo No class 
125-dose vial 64 51.56% 33 6 8 0 17 
50-dose vial 63 57.14% 0 36 27 0  
25-dose vial 64 100% 0 0 64 0  
Placebo 18 94.44% 0 0 1 17  
Total 209 71.77% 33 42 100 17 17 
 
The PCA previously performed on the filtered vials of batch Zoe 5, already showed that the 
distinction of the different dose formulations, 125-dose vial and placebo included, was not 
possible.  
Before refining the SIMCA model, some more investigations of batch Zoe 5 were performed 
to understand the low correct classification rate of the 125 and 50-dose vials of this batch. A 
PCA performed on each group of dose vial (i.e., 125-dose vial, 50-dose vial and 25-dose vial, 
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separately, hence resulting in three PCA models) and their respective scores plots confirmed 
that the filtered vials of the 125 and 50-dose vial were different from the non-filtered vials 
(Figure 8.4). This explains the low CCR of the 125 and 50-dose vial obtained with the SIMCA 
model.  
In the first PCA model (125-dose vial, 64 spectra, 1 spectrum per vial) composed of three 
principal components explaining 96.8% of spectral variability, an obvious difference between 
the filtered and non-filtered vials (Figure 8.4a) can be observed along PC2 (17.2% of spectral 
variability). In the second PCA model (50-dose vial, 63 spectra, 1 spectrum per vial) 
composed of three principal components and explaining 96.8% of spectral variability, a 
difference between the filtered and non-filtered vials can also be observed (Figure 8.4b) 
along PC3 (3.56% of spectral variability). In the last PCA model (25-dose vial, 64 spectra, 1 
spectrum per vial) composed by three principal components explaining 97.2% of spectral 
variability, no difference between the filtered and the non-filtered vials can be observed in 
the PC scores plot (Figure 8.4c). Analysis of the PC2 loadings plot of 125-dose PCA model 
(Figure 8.4d) identified a peak (4740cm-1) responsible for the difference between the filtered 
and non-filtered vials. This peak, located in a spectral range related to a fundamental N-H 
stretch with amide III [20] can be linked to a protein component of the formulation (i.e., 
virus coated proteins or proteins from the stabilizer solution). 
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Figure 8.4: PCA of each group of dose vials performed on the NIR spectra collected from batch Zoe 5. 
(a, b, c) scores plots of the filtered and non-filtered 125-dose, 50-dose and 25-dose vials 
respectively.(d) PC2 loadings plots of the 125-dose vial.  
 
Although the SIMCA model misclassified the filtered 125 and 50-dose vials of batch Zoe 5 the 
titration results of these vials did not show any differences between the filtered and non-
filtered vials.  
8.3.3.2. Model optimization 
Model optimization was performed to improve the correct classification rates of the model. 
Several optimization strategies such as: (i) evaluation of different spectral preprocessing, (ii) 
evaluation of different spectral range and (iii) decomposition of the model into sub-models 
were tried. Among these, only the spectral range optimization using OPLS significantly 
improved the model predictive power and will therefore be discussed further.  
Filtered Non-Filtered
125-dose vial 25-dose vial50-dose vial
4740cm-1
a) b) c)
d)
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Orthogonal Partial Least Squares regression (OPLS) offers the advantage to separate the 
variation correlated to Y (i.e., the predictive component) and the variation not correlated to 
Y (i.e., the orthogonal component). By applying OPLS on the SNV preprocessed spectra 
(7300-4000cm-1 spectral range) of all batches produced at Zoetis (5 batches, filtered and 
non-filtered vials, 654 spectra), the variation correlated to the dose was captured by the 
predictive component. The developed OPLS model covered 99.2% of the spectral variability 
and was composed by one predictive component (10.2% of the spectral variability) and six 
orthogonal components (89% of spectral variability). The scores plot showing the predictive 
component versus the first orthogonal component allowed clearly distinguishing between 
the doses (Figure 8.5). The 125-dose vials were well separated from the other dose vials and 
the distance in the scores plot between the 125-dose vials and the other classes of vials was 
in agreement with the dose content. Even although slightly overlapping, the 50- and 25-dose 
vials were better separated than with the PCA model.  
Figure 8.5: Predictive  versus  first orthogonal component scores plot obtained after OPLS modelling 
of the SNV pretreated spectra collected from all batches produced at Zoetis.  
 
In order to identify the spectral contribution responsible for the distinction between the 
different dose vials by the predictive component, the loadings plot of the predictive 
component was examined (Figure 8.6). As already observed in the loadings plot of the 
second principal component of the PCA model allowing to distinguish between the different 
doses (Figure 8.3d), a band at 4830cm-1 was clearly co-responsible for distinguishing 
between the different doses (Figure  8.6). This band corresponds to the amide A/II. The 
loadings plot of the predictive component also showed two rather noisy regions (7300-
7054cm-1 and 5700-5200cm-1) having a predictive component value of approximately 0 while 
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this was not the case in the PCA loadings plot (Figure 8.3d). The loadings plot of the 
predictive component also showed a region that did not contain any information (4220-
4000cm-1).  
Figure 8.6: Loadings plot of the predictive component obtained after OPLS of the SNV preprocessed 
spectra and collected from all batches produced at Zoetis. 
 
Based on these findings, a new spectral range more appropriate to separate the dose 
formulations was concluded: 7050-5700 & 5200-4220cm-1.  
To evaluate the effect of this new spectral range on the correct classification rates, a new 
SIMCA model using Zoe 1, Zoe 2 and Zoe 3 (i.e., 379 spectra, 1 spectrum per vial) was 
developed.  
The misclassification table of Zoe 4, used as independent test set, is presented in Table 8.5. 
The 125-dose vial, 50-dose vial, 25-dose vial and placebo had a correct classification rate 
(CCR) of 97.14%, 100%, 97.14% and 100% respectively. Globally, the correct classification 
rate (98.5%) was almost perfect. 
 
 
 
 
 
 
 
 
 
 
7050 5700 5200 4220
4830cm-1
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Table 8.5: Misclassification table obtained using Zoe 1-2-3 as calibration set and Zoe 4 as 
independent test set. 7050-5700 & 5200-4220cm-1 spectral range, SNV preprocessed. 
  
Members 
Correct classification 
rate (CCR, %) 
125-dose 
vial 
50-dose 
vial 
25-dose 
vial 
Placebo 
125-dose vial 35 97.14% 34 1 0 0 
50-dose vial 35 100% 0 35 0 0 
25-dose vial 35 97.14% 0 1 34 0 
Placebo 28 100% 0 0 0 28 
Total 133 98.5% 34 37 34 28 
 
The second independent test set, batch Zoe 5, was also evaluated with the optimized 
spectral range. To avoid introducing misclassification caused by the filtration step (see 
higher), only the non-filtered vials were used. Therefore a SIMCA model using the non-
filtered vials of batches Zoe 1, Zoe 2 and Zoe 3 was built using the spectral range 7050-5700 
& 5200-4220cm-1, SNV preprocessed.  Because a new model was built (with the non-filtered 
vials exclusively), the non-filtered vials from Zoe 4 were also evaluated. The misclassification 
table of both independent test sets (Zoe 4 and Zoe 5) is presented in Table 8.6. 
 
Table 8.6: Misclassification table obtained using Zoe 1-2-3 as calibration set and Zoe 4 and Zoe 5 as 
independent test sets. 7050-5700 & 5200-4220cm-1 spectral range, SNV preprocessed. 
  
Zoe 4 non-filtered Zoe 5 non-filtered 
  
Members 
 CCR, 
% 
125 
dose-
vial 
50 
dose-
vial 
25 
dose-
vial 
Placebo Members CCR, % 
125 
dose-
vial 
50 
dose-
vial 
25 
dose-
vial 
Placebo 
125-
dose 
vial 
17 94.12% 16 1 0 0 49 100% 49 0 0 0 
50-
dose 
vial 
17 100% 0 17 0 0 41 100% 0 41 0 0 
25-
dose 
vial 
18 94.44% 0 1 17 0 34 88.24% 0 4 30 0 
Placebo 28 100% 0 0 0 28 18 94.44% 0 0 1 17 
Total 80 97.50% 16 19 17 28 142 96.48% 49 45 31 17 
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Globally, both test sets were well classified except four 25-dose vials of Zoe 5 which were 
classified as 50-dose vial. This observation is not surprising considering that both classes still 
slightly overlap in the OPLS scores plot (Figure 8.5). 
8.3.3.3. Classification validation 
The above evaluated classification of two independent test sets (i.e., Zoe 4 and Zoe 5) 
already constitutes an important part of the validation. Nevertheless, referring to the EMA 
guidelines, qualitative NIR procedures should be validated for a minimum of specificity and 
robustness [19]. Therefore, the developed classification model in this study (using batches 
Zoe 1-2-3, 7050-5700 & 5200-4220cm-1 SNV preprocessed spectra) was further validated by 
determining its sensitivity, specificity and accuracy. These parameters were determined 
using the two independent test sets available for this study (i.e., Zoe 4 and Zoe 5) and are 
presented in Table 8.7. 
Table 8.7: Validation parameters (sensitivity, specificity, and accuracy) obtained using the optimized 
spectral range (7050-5700 & 5200-4220cm-1) SNV preprocessed: (a) Zoe 1-2-3 filtered and non-
filtered combined in calibration set, Zoe 4 filtered and non-filtered combined as independent test set 
and (b) Zoe 1-2-3 non-filtered as calibration set, Zoe 5 non-filtered as independent test set. 
 
Sensitivity Specificity Accuracy 
a) 
125-dose vial 97.14% 100% 99.25% 
50-dose vial 100% 97.96% 98.50% 
25-dose vial 97.14% 100% 99.25 
Placebo 100% 100% 100% 
b) 
   125-dose vial 100% 100% 100% 
50-dose vial 100% 96.04% 97.18% 
25-dose vial 88.24% 99.07% 96.48% 
Placebo 94.44% 100% 98.59% 
 
All obtained validation values were above 95% except in two cases. The sensitivity reflects 
the ability of the model to correctly classify new doses. The model built using the non-
filtered vials had a lower sensitivity to detect the 25-dose vials. With all values above 96%, 
the specificity of the model was excellent. This means that the risk to attribute a dose vial to 
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a wrong class is very low. Remarkably, both the 125-dose vial and the placebo had a 
specificity of 100%. Finally, the accuracy values of the models were all above 96%.  
The robustness of the model is a measure of its capacity to remain unaffected by small but 
deliberate variations in method parameters and provides an indication of its reliability during 
normal usage [21]. The dose classification of the vials from the batch freeze-dried in another 
freeze-dryer (UGent batch) and having higher residual moisture content was considered as 
being an interesting case for model robustness evaluation.   
Using the model built with batches Zoe 1-2-3 (filtered and non-filtered vials), 7050-5700 & 
5200-4220cm-1 SNV preprocessed spectra, the correct classification rates obtained using UG 
as test sets were 0% for all doses and placebos (data not shown). In addition of being 
lyophilized in another freeze-dryer the vials of UG batch had higher residual moisture 
content than the vials used in the calibration set (Figure 8.2). Considering that the used 
spectral range 7050-5700 & 5200-4220cm-1 contains a water band at 5100-5200cm-1 [22], 
logically, the classification model is sensitive to the residual moisture content of new vials.  
In order to be classified, new vials must have a residual moisture included in the residual 
moisture range of the vials used to build the model.  The classification rates of UG could 
probably be improved by the addition of supplemental batches in the model varying in 
moisture content and produced using different freeze-dryers. The robustness study has 
shown that the model was very sensitive to the residual moisture content of the vials to be 
classified.  
 
8.4. CONCLUSION 
This study demonstrates the possibility of NIR spectroscopy to classify freeze-dried live, 
attenuated virus vaccines according to their dose. A PCA was performed in order to detect 
trends and possible outliers. Two doses (i.e., 50-dose vial and 25-dose vial) could not clearly 
be distinguished in the PCA model. Therefore, the SIMCA modelling approach was selected 
since its ability to better deal with classes that do not occupy a separate volume in the X-
space. The optimization of the calibration model was performed by optimizing the spectral 
range via Orthogonal Partial Least Squares regression. The optimized spectral range 7050-
5700 & 5200-4220cm-1 contained the amide A/II region which was involved in the separation 
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of the different dose vials in the PCA but also identified in the predictive component of the 
OPLS model. The optimized calibration model was able to classify vials of an independent 
test set with a global correct classification rate of 98.5% (test set Zoe 4). The optimized 
model was also characterized for its specificity, sensitivity and accuracy following the EMA 
guidelines. With all values above 96%, the specificity of the model was excellent meaning 
that the risk to attribute a dose vial to a wrong class was very low. In addition, both the 125-
dose vial and the placebo had a specificity of 100%. Finally, the robustness study 
demonstrated that the classification of new vials was sensitive to their residual moisture 
content. In order to be classified, new vials must have a residual moisture included in the 
residual moisture range of the vials used to build the model. 
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ABSTRACT 
This chapter evaluates the possibility to predict the titer of a freeze-dried live, attenuated 
virus vaccine formulation using near-infrared (NIR) spectroscopy. Firstly, the critical dose 
content allowing to detect titer variations of a live, attenuated virus by NIR spectroscopy was 
determined. Therefore, three dose presentations (i.e., 125-dose vials, 50-dose vials and 25-
dose vials) pre-freeze-drying treated by exposure during 0, 3 or 7 days to room temperature 
and resulting in different virus titers, were freeze-dried. After freeze-drying, the off-line 
collected NIR spectra were evaluated using Principal Component Analysis (PCA) and 
demonstrated that the only suitable dose presentation (allowing the detection of titer 
variations) was the 125-dose, being the highest dose content. Secondly, a calibration data 
set existing of NIR spectra of freeze-dried 125-dose vials, exposed 0, 9, 16, 23 or 30 days to 
room temperature prior to freeze-drying and resulting in different virus titers, was modeled 
using orthogonal partial least squares (OPLS) and partial least squares (PLS) regression in 
order to predict the titer of new independent freeze-dried vials. After spectral range and 
spectral preprocessing optimization, a model with a root mean square error of prediction 
(RMSEP) of 0.19 log10 CCID50 was obtained, indicating good predictive performance of the 
model. 
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CHAPTER 9 
FAST AND NON-DESTRUCTIVE TITER 
PREDICTION OF A FREEZE-DRIED VIRUS 
VACCINE FORMULATION USING NIR 
SPECTROSCOPY: A PRELIMINARY STUDY 
 
9.1. INTRODUCTION 
In order to overcome the limited stability of biopharmaceutical products in aqueous 
solution, freeze-drying (also called lyophilization) of the formulation has become a well-
established technique, often used in the biopharmaceutical industry despite its 
disadvantages of cost and process time. Briefly, the freeze-drying process consists of three 
main consecutive steps: freezing, primary drying and secondary drying. During the freezing 
step, the product temperature is decreased (approx. -40 to -50°C) in order to convert most 
of the water into ice. Herewith, the solutes are crystallized or transformed into an 
amorphous system. During primary drying, vacuum is introduced in the freeze-drying 
chamber hence removing the ice by sublimation. The secondary drying step ends the process 
by removing the unfrozen water from the amorphous phase by desorption [1]. 
More and more, the pharmaceutical industry, encouraged by the FDA's process analytical 
technology (PAT) initiative [2], is investing in analytical methods providing ultra-fast (i.e. real-
time) and information-rich data. NIR spectroscopy is a molecular vibrational spectroscopic 
technique allowing fast and non-destructive measurements without any sample preparation 
[3]. Implemented in the freeze-dryer using fiber optic probes, NIR spectroscopy has already 
demonstrated its possibility to in-line monitor critical process [4-6] and product information 
(e.g. protein unfolding [7]). In addition to the well-known possibility to measure off-line the 
residual moisture of a freeze-dried product [8-11], the possibility to use NIR spectroscopy to 
evaluate live, attenuated viruses in freeze-dried samples varying in term of virus medium 
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volume or pre-freeze-drying treatment has also been demonstrated [12]. This was possible 
by evaluating two NIR spectral regions: (i) the 7300-4000cm-1 region containing the amide 
A/II band which might reflect information on the coated proteins of the freeze-dried live, 
attenuated viruses; and (ii) the C-H vibration overtone regions (10,000-7500 and 6340-
5500cm-1) which might supply information on the lipid layer surrounding the freeze-dried 
live, attenuated viruses.  
The possibility to evaluate different pre-freeze-drying treated live, attenuated viruses (and 
hence having different titers) [12] offers several opportunities to develop new applications 
for the pharmaceutical industry. Among these applications, the prediction of the virus titer 
based on NIR spectra collected off-line, after freeze-drying and during storage, is of great 
interest. Indeed, at the end of the freeze-drying process, the overall potency of the vaccine is 
generally measured by cell-based viral plaque assay. Having the advantage of being time-
honored and widely accepted, these assays are also known to be relatively imprecise, labor-
intensive and time-consuming [13-15]. In addition, they do not provide any useful 
information regarding the degradation mechanism that the viruses undergo during the 
process and during storage.  
The aim of this chapter is to evaluate the possibility to predict the titer of new freeze-dried 
samples based on their NIR spectra. The first phase is dedicated to the determination of the 
critical dose content of the studied live, attenuated virus vaccine needed to be able to 
distinguish between different pre-freeze-drying treated live, attenuated viruses (hence 
resulting in different titers). Three dose presentations (i.e., 125-dose vials, 50-dose vials and 
25-dose vials) were pre-freeze-drying treated by exposure during 0, 3 or 7 days to room 
temperature. After freeze-drying, NIR spectra were collected from these samples and were 
evaluated by Principal Component Analysis (PCA) using the 7300-4000cm-1 spectral region 
containing the amide A/II band. The objective of the second phase of the study is to develop 
a calibration model able to predict the virus titer of new freeze-dried vials. Therefore, a 
calibration model was built using NIR spectra of vials (having the critical dose content as 
determined in the first phase of the study) prepared by pre-freeze-drying treatment (i.e., 
exposure during 0, 9, 16, 23 and 30 days to room temperature prior to freeze-drying). Using 
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the developed model, the possibility to predict the titer of vials coming from an independent 
test set (i.e., one independent batch) was then evaluated. 
 
9.2. MATERIALS AND METHODS 
9.2.1. Materials 
The live, attenuated virus used as vaccine in this study as well as its stabilizer solution were 
obtained from Zoetis. The stabilizer solution was kept constant (volume and concentration) 
in all formulations.  
The chapter is divided into two phases. In phase 1 (i.e., the determination of the critical dose 
content), the virus dose as well as the virus pre-freeze-drying treatment were varied. In 
phase 2 (i.e., the evaluation of the possibility to predict the virus titer), the virus dose was 
kept constant (at the dose at which titer variations could be detected) and only the virus 
pre-freeze-drying treatment was varied.  
The formulations used for phase 1 are presented in Table 9.1. Three different virus dose 
presentations (i.e., 125-dose vials, 50-dose vials and 25-dose vials) combined with three 
different pre-freeze-drying treatments were used (i.e., exposure during 0, 3 or 7 days to 
room temperature).  
The virus medium volume was varied in order to obtain the correct number of doses and 
compensated by Ultraculture (Lonza, Belgium), a medium free from virus, in order to keep 
the total volume identical among all samples. For clarity, the three different virus medium 
volumes (i.e., e, f, g ml in Table 9.1) used to prepare the different doses were compensated 
by the addition of an appropriate volume of medium free of virus (i.e. h-e, h-f and h-g, Table 
9.1) in order to have a total volume of 5ml).  
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Table 9.1: Formulations used in phase 1 of the study. 
Stress time (days) Doses 
Virus 
medium 
volume (ml) 
Stabilizer 
solution 
qsp filling volume, 
Ultraculture - medium 
free from viruses (ml) 
Total volume (ml) 
0 25 e 33% (v/v) h-e 5 
3 25 e 33% (v/v) h-e 5 
7 25 e 33% (v/v) h-e 5 
0 50 f 33% (v/v) h-f 5 
3 50 f 33% (v/v) h-f 5 
7 50 f 33% (v/v) h-f 5 
0 125 g 33% (v/v) h-g 5 
3 125 g 33% (v/v) h-g 5 
7 125 g 33% (v/v) h-g 5 
All symbols (e, f, g and h) represent absolute values in µl. 
 
The formulations used for phase 2 are presented in Table 9.2. A fixed dose (i.e., the dose at 
which titer variations could be detected) was used during this study. In order to obtain 
formulations having different titers, the formulations were stressed at room temperature 
during different periods of time (i.e. 0, 9, 16, 23 or 30 days) prior to freeze-drying. An 
independent test set was also prepared according to the same procedure (i.e. exposure of 
the formulation to room temperature before freeze-drying, see also Table 9.2).  
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Table 9.2: Formulations used in phase 2. 
 
Stress time 
(days) 
Doses* 
Virus medium 
volume (ml) 
Stabilizer 
solution 
qsp filling 
volume, medium 
free from viruses 
(ml) 
Total volume 
(ml) 
Calibration 
set 
0 125 g 33% (v/v) h-g 5 
9 125 g 33% (v/v) h-g 5 
16 125 g 33% (v/v) h-g 5 
23 125 g 33% (v/v) h-g 5 
30 125 g 33% (v/v) h-g 5 
Test set 
0 125 g 33% (v/v) h-g 5 
7 125 g 33% (v/v) h-g 5 
11 125 g 33% (v/v) h-g 5 
All symbols (g and h) represent absolute values in µl 
* the dose at which titer variations could be detected (see results). 
 
9.2.2. Freeze drying 
All samples used in this study were produced at Zoetis and freeze-dried using a Lyostar 3 
freeze-dryer (SP scientific, Stone Ridge, NY, USA). The freeze-drying settings were optimized 
by Zoetis and cannot be disclosed for confidentiality reasons. All freeze-dried vials had a 
visually acceptable cake aspect. 
 
9.2.3. Titration 
Titration (potency assay) was done according to Zoetis’ internal SOP. Each titer is expressed 
in log10 CCID50 (Cell Culture Infection Dose 50). Titration provides information about the 
number of living viral particles contained in each sample. Each titrated sample was evaluated 
twice. Three samples per dose and per pretreatment were titrated except for the calibration 
set (phase 2) where 13 samples per pretreatment were titrated.  
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9.2.4. Residual moisture analysis 
The residual moisture content of the freeze-dried samples was determined via Karl Fischer 
titration. After each freeze-drying cycle, three samples per dose and per pretreatment were 
analyzed with a Metrohm 860 KF Thermoprep (oven) coupled to a Metrohm 852 Titrando 
(Herisau, Switzerland).  
 
9.2.5. NIR spectroscopy 
NIR spectra of all freeze-dried samples were collected off-line using a Fourier-Transform NIR 
spectrometer (Thermo Fisher Scientific, Nicolet Antaris II near-IR analyzer) equipped with an 
InGaAs detector and a quartz halogen lamp. All NIR spectra were recorded in the 10000-
4000cm-1 region with a resolution of 8 cm-1 and averaged over 16 scans. One NIR spectrum 
per freeze-dried sample (in random order) was collected through the bottom of the glass vial 
using the integrating sphere device immediately after freeze-drying. 
 
9.2.6. Data analysis 
NIR spectral data analysis was done using SIMCA 14.0 (Umetrics, Umea, Sweden). All 
collected NIR spectra were mean centered and preprocessed using standard normal variate 
(SNV) in order to eliminate the additive baseline offset variations and multiplicative scaling 
effects in the spectra which may be caused by possible differences in sample density and 
different-sample-to-sample measurement variations. Second derivative with 37 Savitzky-
Golay smoothing points was also applied in phases 1 and 2. Second derivative was used for 
(a) spectral discrimination improvement, as a qualitative fingerprinting technique to 
accentuate small structural differences between similar spectra and for (b) spectral 
resolution enhancement.  
9.2.6.1. Principal Component Analysis 
The collected NIR spectra were firstly analyzed as one data matrix (D) using principal 
component analysis (PCA), an unsupervised multivariate data analysis method allowing to 
examine whether NIR spectroscopy can distinguish between the different pre-freeze-drying 
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treatment. PCA produces an orthogonal bilinear data matrix (D) decomposition, where 
principal components (PCs) are obtained in a sequential way to explain maximum variance:  
D=TPT + E 
= t1p’1 + t2p’2 +…+tQp’Q + E 
 
Where T is the M x Q score matrix, P is the N x Q loading matrix, E is the M x N model 
residual matrix, i.e., the residual variation of the data set that it is not captured by the 
model. Q is the selected number of PCs, each describing a non-correlated source of variation 
in the data set, and N is the number of collected spectra at M wavelengths [16]. Each 
principal component consists of two vectors, the score vector t and the loading vector p. The 
score vector contains a score value for each spectrum, and this score value informs how the 
spectrum is related to the other spectra in that particular component. The loading vector 
indicates which spectral features in the original spectra are captured by the component 
studied. These abstract, unique, and orthogonal PCs are helpful in deducing the number of 
different sources of variation present in the data. However, these PCs do not necessarily 
correspond to the true underlying factors causing the data variation, but are orthogonal 
linear combinations of them, since each PC is obtained by maximizing the amount of 
variance it can explain [17].  
The number of PCs included in the PCA model was determined by cross validation using the 
approach of Krzanowski [18]. The data are divided into 7 groups and a model was generated 
for the data devoid of one group. The deleted group was predicted by the model and the 
squared differences between the predicted and observed values were summed to form the 
Predictive Residual Sum of Squares (PRESS). This procedure was repeated 7 times, followed 
by the summation of all partial PRESS-values in terms of an overall PRESS-value. If a new PCi 
enhanced the predictive power compared with the preceding PCi-1, the new PCi was kept in 
the model [19]. 
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9.2.6.2. Partial least squares (PLS) regression 
Partial least squares (PLS) regression is a commonly applied multivariate calibration 
technique. In PLS, a (in our case, spectroscopic) data matrix (X) is decomposed taking into 
account the underlying relationship between X and the y-vector. In PCA, the decomposition 
of the data matrix is performed regardless the y-vector [20].  
9.2.6.3. Orthogonal PLS  
Orthogonal Partial Least Squares to latent structures (OPLS) is a modification of the PLS 
method designed to handle variation in X (i.e., in this study the spectroscopic data matrix) 
that is orthogonal to Y (i.e., in this study the titer). OPLS separates the systematic variation in 
X into two parts, one that is linearly related (and therefore predictive) to Y and one that is 
uncorrelated (orthogonal) to Y. The predictive variation of Y in X is modeled by the predictive 
component whereas the variation in X, which is orthogonal to Y, is modeled by the 
orthogonal components. This partitioning of the X-data provides improved model 
transparency and interpretability.  
9.2.6.4. Permutation test 
In order to check that the built PLS and OPLS model do not only fit the training set well but 
poorly predict the new observations, a permutation test was used. The idea of this validation 
is to compare the goodness of fit (R2) and the goodness of prediction (Q2) of the original 
model with the goodness of fit and the goodness of prediction of several models based on 
data where the Y values have been randomly permuted, while the X-matrix has been kept 
intact. 
9.2.6.5. Evaluation of model performance 
The different models were compared by analyzing their root mean square error of prediction 
(RMSEP) which can be calculated by: 
(Σ(y obs – y pred)2 / n) 1/2. 
 Low values of this chemometric validation parameter indicate good quantitative model 
performances.   
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9.3. RESULTS 
The results are divided according to the two phases; (phase 1) the evaluation of the critical 
dose content allowing to distinguish between the NIR spectra of live, attenuated virus 
samples differently pre-freeze-drying treated (hence resulting in different titers, see further) 
and (phase 2) the evaluation of the possibility to predict the virus titer of new freeze-dried 
vials based on their NIR spectra. 
 
9.3.1. Phase 1: Evaluation of the critical dose content 
9.3.1.1. Titration and residual moisture results 
Three different virus dose presentations (i.e., 125-dose vials, 50-dose vials and 25-dose vials) 
combined with three different pre-freeze-drying treatments (i.e.,  exposure during 0, 3 or 7 
days to room temperature prior to freeze-drying), were used in this study. The virus titer and 
residual moisture results are presented in Figure 9.1. As expected, the titers increased with 
the dose content and decreased with the number of exposition days to room temperature 
(Figure 9.1a). For all dose contents (i.e., 125-dose, 50-dose and 25-dose), the formulations 
exposed 0 and 7 days to room temperature as well as the formulations exposed 0 and 3 days 
to room temperature resulted in different titers. The formulations exposed 3 and 7 days to 
room temperature resulted in different titers only for the 25-dose vials.  
Similarly, samples of each dose presentation and of each stressing time were also analyzed 
using Karl Fischer and all residual moisture values were found to be below 1.6% and not to 
be different from each other (Figure 9.1b).  
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Figure 9.1: Titration (a) and residual moisture (b) results of the different formulations used in phase 
1. Titers are expressed as log10 CCID50 (Cell Culture Infection Dose 50) and presented in a table below 
the titer bar chart. Each titer and residual moisture result is the average of three determinations. 
 
9.3.1.2. Principal Component Analysis 
In order to determine the critical dose content allowing to distinguish between the NIR 
spectra of live, attenuated virus samples differently pre-freeze-drying treated (hence 
resulting in different titers), each dose content (i.e., 125-dose, 50-dose and 25-dose) was 
separately analyzed with PCA using the 7300-4000cm-1 spectral range, SNV and 2nd 
derivative preprocessed. 
The PCA model developed from the NIR spectra of the 125-dose vials exposed during 0, 3 
and 7 days to room temperature (i.e., 35 spectra, 1 spectrum per vial, 12 vials per exposure 
time, 1 outlier left out) was composed by 3 principal components and explained 88.2% of the 
spectral variability. The PC2 (capturing 14.1% of the overall spectral variability) versus PC3 
(capturing 7.96% of spectral variability) scores plot (Figure 9.2a) distinguished between the 
125-dose vials exposed 0, 3 or 7 days to room temperature. The separation was caused by a 
combination of both components.  Analysis of the PC2 loadings plot (Figure 9.2a) showed 
that PC2 correlates mainly with the residual moisture content and was in agreement with 
the Karl Fischer results (i.e., 0 day stressed samples have a bit lower residual moisture 
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content than 3 and 7 days stress). Analysis of PC3 loadings plot (Figure 9.2b) showed that 
several peaks were involved in the separation between vials exposed different days to room 
temperature. Interestingly a peak located in the region of the amide A/II band (4850cm-1) 
can be observed in the PC3 loadings plot.  
  
Figure 9.2: Scores and loadings plot of the PCA model built with SNV and 2nd derivative preprocessed 
NIR spectra of the 125-dose vials exposed during 0, 3 and 7 days to room temperature. (a) PC2 versus 
PC3 scores plot of the PCA built with the spectral range 7300-4000cm-1. (b) PC2 and PC3 loadings plot 
of the PCA built with the spectral range 7300-4000cm-1. 
 
Similarly, a PCA was performed on the 50-dose and 25-dose vials exposed during 0, 3 and 7 
days to room temperature. The PCA model built with the NIR spectra of the 50-dose vials 
exposed during 0, 3 and 7 days to room temperature (i.e., 36 spectra, 1 spectrum per vial, 12 
vials per exposure time) was composed of 4 principal components and explained 95.8% of 
the spectral variability. The PC1 versus PC4 scores plot (Figure 9.3) showed that only the 50-
dose samples exposed during 7 days to room temperature were separated from the other 
exposed samples (i.e., 0 and 3 days) according to PC4 (accounting for 2.44% of spectral 
a
b
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variability). Analysis of the PC4 loadings plot showed that the amide A/II band (4850cm-1) 
was involved in the separation according PC4 (data not shown). 
Figure 9.3: PC1 versus PC4 scores plot of the PCA model built with the spectral range 7300-4000cm-1 
SNV and 2nd derivative preprocessed NIR spectra of the 50-dose vials exposed during 0, 3 and 7 days 
to room temperature.  
 
The last PCA model, built with the NIR spectra of the 25-dose vials exposed during 0, 3 and 7 
days to room temperature (i.e., 36 spectra, 1 spectrum per vial, 12 vials per exposure time), 
was composed of 4 principal components and explained 95.8% of the spectral variability. No 
PC combination was able to distinguish between the differently pre-freeze-drying treated 
vials. 
Using the 7300-4000cm-1 spectral range, containing the amide A/II band which might 
provide information on the virus coated proteins [12], it was possible to distinguish all the 
125-dose vials according to their pre-freeze-drying treatment. Using the 50-dose vials, it was 
only possible to distinguish the vials exposed 7 days to room temperature and finally, no 
distinction between the differently pre-freeze-drying treated 25-dose vials was detected. 
Therefore, 125-dose vial is the critical dose content allowing to distinguish between the NIR 
spectra of live, attenuated virus samples differently pre-freeze-drying treated (hence 
resulting in different titers). 
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9.3.2. Phase 2: Evaluation of the possibility to predict the virus titer 
The aim of phase 2 was to evaluate the possibility of NIR spectroscopy to predict the titer of 
live, attenuated virus vaccine vials after freeze-drying. Therefore, OPLS and PLS models were 
developed. Nevertheless, prior the model development, the selection of an adequate 
calibration set was critical. According to the results presented above (phase 1), the 125-dose 
vials were selected. Indeed, the 125-dose vials were the only ones in which differently pre-
freeze-drying treated live, attenuated viruses (and hence having different titers) could be 
detected by NIR spectroscopy. In order to have the largest possible titer range, 125-dose 
formulations were pre-freeze-drying treated by exposure to room temperature during 
different periods of time  (i.e., 0, 9, 16, 23 and 30 days). After freeze-drying, NIR spectra of 
all vials were collected, the samples of the calibration set (i.e., the dataset used to build the 
model) were titrated, and their residual moisture was measured. In addition, prior to the 
development of the prediction model, a PCA was performed in order to verify whether the 
samples of the calibration set with different titers could be distinguished by NIR 
spectroscopy. 
9.3.2.1. Titration and residual moisture results 
The titration and residual moisture results are presented in Figure 9.4. Regarding the 
obtained titers, the 125-dose vials can be subdivided into 3 groups. The 125-dose vials 
exposed during 0 days to room temperature (5.09±0.20 (n=13)) constitute the first group. 
The 125-dose vials exposed during 9 and 16 days to room temperature, with titers of 
(3.82±0.11 (n=13)) and (3.65±0.18 (n=13)) respectively, form the second group. The third 
group is composed by the 125-dose vials exposed during 23 and 30 days to room 
temperature having titers of 2.98 ±0.15 (n=13) and 3.17 ±0.17 (n=13) respectively.  
The vials were also analyzed with Karl Fischer and all residual moisture values were found to 
be below 1.7% and not to be different from each other although a slight residual moisture 
increase with the number of exposition days to room temperature can be observed. The 
125-dose vials exposed 0, 9, 16, 23 and 30 days had a residual moisture of 1.35%±0.11 (n=3), 
1.37%±0.07 (n=3), 1.49%±0.12 (n=3), 1.54%±0.07 (n=3) and 1.59%±0.09 (n=3), respectively. 
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Figure 9.4: Titration (a) and residual moisture (b) results of the different formulations used as 
calibration set in study 2 (d = exposure day(s) to room temperature). Titers are expressed as log10 
CCID50 (Cell Culture Infection Dose 50). Each titer is the average of 13 determinations and each 
residual moisture result is the average of 3 determinations. 
 
9.3.2.2. Principal Component Analysis 
Before building the calibration model, two PCA were performed. The objective of the first 
PCA model was to determine if the slight residual moisture increase detected by the Karl 
Fischer analysis influenced the NIR spectra. The second PCA model was built in order to 
verify whether NIR spectroscopy was able to distinguish the vials of the calibration set 
having different titers (i.e., exposed 30 days, 9 days and 0 day to room temperature).  
The fist PCA model was developed using a short spectral region containing the water band 
(5450-5021cm-1) and SNV preprocessed spectra. The built model combining the 125-dose 
vials exposed 0, 9 and 30 days to room temperature (i.e., 66 spectra, 1 spectrum per vial, 22 
vials per exposure time) was composed by 2 principal components explaining 99.3% of the 
spectral variability. The PC1 (capturing 94.4% of the spectral variability) scores line plot is 
presented in Figure 9.5. As can be observed, no variation of PC1 accounting for water is 
observed, confirming that the NIR spectra are not influenced by the slight residual moisture 
increase observed by Karl Fischer.  
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Figure 9.5: PC1 scores line plot of the PCA model built with the SNV preprocessed NIR spectra (5450-
5021cm-1 spectral range) of the 125-dose vials exposed during 0, 9 and 30 days to room temperature.  
 
The second PCA model was developed using the same spectral range as used in phase 1 
(7300-4000cm-1) and SNV combined with 2nd derivative preprocessed spectra. The PCA 
model combining the 125-dose vials exposed 0, 9 and 30 days to room temperature (i.e., 66 
spectra, 1 spectrum per vial, 22 vials per exposure time) was composed by 3 principal 
components explaining 96% of the spectral variability. The PC2 (capturing 29.7% of the 
spectral variability) versus PC3 (capturing 8.63% of the spectral variability) scores plot (Figure 
9.6) nearly distinguished the differently pretreated formulations. The formulation exposed 
during 9 days to room temperature was located between the 125-dose vials exposed during 
0 and 30 days in the scores plots but slightly overlapped with the two groups. The analysis of 
the loadings plot was then performed in order to identify the spectral contribution to this 
separation. The amide A/II band (4850cm-1) was identified and no water band was observed 
in both PC loadings plots indicating that the residual moisture did not influence the 
separation of the differently pre-freeze-drying treated viruses.  
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Figure 9.6: Scores plot of the PCA model built with the SNV and 2nd derivative preprocessed NIR 
spectra (7300-4000cm-1 spectral range) of the 125-dose vials exposed during 0, 9 and 30 days to 
room temperature.  
 
9.3.2.3. Development of the prediction model 
An orthogonal partial least squares (OPLS) regression model was first developed and offered 
the advantage to separate the variation correlated to the titer from the variation 
uncorrelated to the titer (for further spectral range optimization). Firstly, SNV preprocessed 
spectra were used but the effect of an additional 2nd derivative preprocessing was also 
evaluated (see further). Using the spectral range containing the amide A/II band (7300-
4000cm-1) demonstrated to be able to separate the different pre-freeze-drying treated 
samples, the developed OPLS model (62 spectra, 1 spectrum per titrated vial) explained 
98.6% of the spectral variability and was composed by 1 predictive component (12.3% of 
spectral variability) and 4 orthogonal components. The predictive component (12.3% of 
spectral variability) versus orthogonal component 1 (71% of spectral variability) scores plot 
distinguished the vials according to the pre-freeze-drying treatment (Figure 9.7).  
Chapter 9 – Fast and non-destructive titer prediction of a freeze-dried virus vaccine 
formulation using NIR spectroscopy: a preliminary study 
 
245 
 
 
Figure 9.7: Scores plot of the OPLS model built with the SNV preprocessed NIR spectra (7300-
4000cm-1 spectral range) of the calibration set. 
 
At first, a permutation test was performed in order to verify that the model did not only fit 
the training set well, while poorly predicting new observations (see materials and methods 
section). The permutation plot is presented in Figure 9.8 and shows that the OPLS model was 
valid for several reasons: (i) the Q2 values of the twenty permutations were lower than the 
Q2 value of the original model, (ii) the Q2 regression line intersected the y axis below 0 and 
finally, (iii) the R2 values of the twenty permutations were lower than the R2 value of the 
original model.   
 
Figure 9.8: Permutation plot of the OPLS model built with the SNV preprocessed NIR spectra (7300-
4000cm-1 spectral range). 
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The prediction of an independent test set (i.e., observations that were not used to build the 
model and coming from another batch) constitutes the best evaluation of the model 
performance.  
The predicted titers and the observed (titrated) titers of the test set are presented in Figure 
9.9. With a root mean square error of prediction (RMSEP) of 0.22 log10 CCID50, the predicted 
titers of the test set were close to the titrated values. 
 
Figure 9.9: Observed and predicted virus titers by the OPLS model built with the SNV preprocessed 
NIR spectra (7300-4000cm-1 spectral range) of the vials coming from the test set. Titers are expressed 
as log10 CCID50 (Cell Culture Infection Dose 50). 
 
Model optimization was performed in order to improve the RMSEP of the model. Several 
optimization strategies such as: (i) PLS modelling, (ii) use of an additional preprocessing step 
(i.e. 2nd derivative) or (iii) selection of different spectral ranges were performed. Two 
supplemental spectral ranges were evaluated based on the loadings plot of the OPLS 
predictive component; (1) the 5029-4000cm-1 spectral range was used in order to avoid the 
contribution of the water bands, (2) the 5029-4690cm-1 spectral range was used in order to 
only consider the contribution of the amide A/II band. The different spectral ranges are 
presented in the loadings plot (Figure 9.10) of the predictive component of the OPLS model.  
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Figure 9.10: Loadings plot of the predictive component of the OPLS model built with the SNV 
preprocessed NIR spectra (7300-4000cm-1 spectral range) of the calibration set. The different spectral 
ranges evaluated in order to optimize the model are also presented. 
 
The performances of the different resulting optimized models (by PLS modelling, 2nd 
derivative preprocessing and spectral range selection) are expressed in RMSEP and are 
presented in Table 9.3. A small RMSEP value indicates good quantitative performance of the 
model. 
As can be seen from Table 9.3, the model type (i.e., PLS or OPLS) had no impact on the 
performance of the models based on the SNV preprocessed spectra. The additional 2nd 
derivative did not improve the prediction of an independent test set since the lowest RMSEP 
values were obtained for the models based on the SNV preprocessed spectra. Moreover, the 
permutation plots obtained for the models based on the spectra preprocessed with SNV and 
2nd derivative showed a low validity of the models (data not shown). Therefore, the SNV 
preprocessed spectra should be used. Concerning the spectral range, the best RMSEP (0.19 
log10 CCID50) was obtained when using the 5029-4000cm
-1 spectral range. 
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Table 9.3: RMSEP values obtained for the different models in order to determine the best predictive 
model. 
Spectral range Model type Preprocessing RMSEP 
7300-4000cm
-1
 
OPLS 
SNV 0.22 
SNV and 2nd derivative 0.24 
PLS 
SNV 0.22 
SNV and 2nd derivative 0.31 
5029-4000cm
-1
 
OPLS 
SNV 0.19 
SNV and 2nd derivative 0.50 
PLS 
SNV 0.19 
SNV and 2nd derivative 0.22 
5029-4690cm
-1
 
OPLS 
SNV 0.26 
SNV and 2nd derivative 0.47 
PLS 
SNV 0.27 
SNV and 2nd derivative 0.50 
 
These results show that NIR spectroscopy is able to predict the titer of a new independent 
test set with a low RMSEP of 0.19 log10 CCID50 using a PLS or an OPLS model, on the condition 
that the dose content is high enough. In order to further evaluate the suitability of the 
model for its intended use, the calibration set should be completed with supplemental 
datasets incorporating batch-to-batch variability.  
 
Nevertheless, the determination of the RMSEP does not suffice to evaluate the risk that 
every future measurement will be close enough to the unknown true value of the sample. 
Appropriate validation (e.g., via accuracy profiles [21]) allowing to make a decision related to 
the validity of a method for future analyses is necessary.  
The Société Française des Sciences et Techniques Pharmaceutiques (SFSTP) has developed a 
validation strategy based on the total error of the procedure (bias + standard deviation) [21]. 
This approach minimizes the risk to accept an inaccurate calibration method or to reject a 
capable method. Validation of the calibration model via accuracy profile should also be 
performed.  
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9.4. CONCLUSION 
The aim of this study was to evaluate the possibility of NIR spectroscopy to predict the titer 
of new freeze-dried live, attenuated virus vaccine samples. The first phase of this study 
demonstrated that the 125-dose vials contained the only suitable dose content allowing to 
distinguish the differently pre-freeze-drying treated formulations (resulting in different 
titers). The second phase of the study demonstrated that NIR spectroscopy was able to 
predict the titer of independent vials with an RMSEP of 0.19 log10 CCID50. PLS and OPLS 
models had the same predictive performance when using SNV preprocessed spectra which 
was the most successful spectral preprocessing method.  
This demonstration of the possibility to predict the virus titer of new freeze-dried vials by 
NIR spectroscopy is promising for the future. Nevertheless, the detection sensitivity of NIR is 
a drawback for this application and the development of new analytical techniques having 
better detection sensitivity is needed. Moreover, before its implementation, the current 
model still needs to be improved by increasing the number of batches in the calibration set 
(including batch-to-batch variability in the model) and by evaluating more test sets. In 
addition, a thorough validation of the model via accuracy profiles is required. 
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SUMMARY AND GENERAL CONCLUSIONS 
 
Freeze-drying is today the preferred method for stabilizing live, attenuated virus vaccines. 
Despite its wide use in the pharmaceutical industry, freeze-drying formulation and process 
development of live, attenuated virus vaccines are still performed by trial-and-error 
experimental work resulting in sub-optimal processes. The stabilization and destabilization 
mechanisms of the live, attenuated viruses during freeze-drying, are still not fully 
understood. The molecular complexity of live, attenuated viruses, the multiple 
destabilization pathways and the lack of analytical techniques allowing the measurement of 
physicochemical changes in the antigen’s structure during and after lyophilization partly 
explain this lack of knowledge. Therefore, the possibility to apply spectroscopic process 
analytical tools, in particular NIR and FTIR spectroscopy, to (i) evaluate live, attenuated 
viruses and their interactions with the stabilizer(s) in freeze-dried samples, (ii) understand 
virus destabilization mechanisms during storage and (iii) develop practical applications using 
chemometric models to predict critical end product quality parameters, has been evaluated 
in this thesis.  
In chapter 2 of this thesis, the freeze-drying process and its used processing equipment is 
outlined. The freeze-drying process consists of 3 main consecutive steps: freezing, primary 
drying and secondary drying. During freezing, most of the water is converted into ice. 
Afterwards, the ice is removed by sublimation (primary drying) and finally, the unfrozen 
water is removed by desorption (secondary drying). 
Although being costly, energy intensive and time consuming, freeze-drying is the preferred 
stabilization method for biopharmaceuticals. However, despite its wide use and decades of 
research, the stabilization and destabilization mechanisms of the live, attenuated viruses, 
the optimal formulation components and process settings are still matter of research. 
Chapter 3 reviews the existing knowledge on the freeze-drying process of live, attenuated 
virus vaccines. The different stresses that viruses may encounter during the different freeze-
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drying process steps as well as the mechanisms and strategies (formulation and process) 
that are used to stabilize them during freeze-drying are overviewed. During freezing, several 
stresses (intra-virus ice formation, osmolarity change, pH shift, coated protein and lipid layer 
destabilization) may decrease the live, attenuated virus stability. The selection of an 
appropriate cryoprotectant and cooling rate are the two main strategies used to avoid these 
stresses. Information related to the destabilization mechanisms during the drying steps is 
rather limited. The lipid membrane and the coated viral proteins are the main attributes 
susceptible to degradation. Both can be protected by the use of stabilizers which stabilize 
the viruses via the vitrification hypothesis and/or the water replacement hypothesis. 
In order to improve product quality and process performance, the pharmaceutical industry is 
encouraged by the regulatory authorities to implement QbD and PAT principles into their 
manufacturing processes.  Chapter 4 summarizes the concept of QbD/PAT and addresses 
some unique considerations coming into play with biotechnological processes and products. 
The different PAT tools such as Tunable Diode Laser Absorption Spectroscopy (TDLAS), 
Manometric Temperature Measurement (MTM), Temperature Remote Interrogation System 
(TEMPRIS), Thermocouples and spectroscopic tools, available to monitor the critical process 
and product parameters during freeze-drying are overviewed. Their main advantages and 
disadvantages are also presented. Finally, the measurement principles of the spectroscopic 
process analytical tools used in this thesis (NIR and FTIR spectroscopy) are described. Several 
studies related to the product monitoring during freeze-drying have been conducted using 
both tools and are also presented. The monitoring of residual moisture content as well as 
the protein behaviour, off-line and in-line, are the most frequent applications of NIR 
spectroscopic monitoring of freeze-drying. FTIR spectroscopy is recognized to be the tool of 
choice for analyzing (off-line) the protein secondary structure. 
In chapter 5, the possibility to use NIR spectroscopy for the distinction between different 
freeze-dried live, attenuated virus formulations is evaluated. NIR spectra of freeze-dried 
samples prepared using different virus medium volumes or using different pre-freeze-drying 
virus treatments (resulting in different virus states) were collected and analyzed using 
principal component analysis (PCA). Distinction between the formulations varying in terms 
of 'virus pretreatment' as well as 'virus volume' was possible. Two specific spectral ranges; 
(1) 7300-4000cm-1 containing the amide A/II region (2) 10,000-7500 and 6340-5500cm-1 
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containing the first and second overtones of CH vibrations allowed this distinction. The 
possibility to classify new samples according to their pre-freeze-drying virus treatment using 
a partial least squares discriminant analysis (PLSDA) model was also assessed. Model cross-
validation was successful (i.e., correct classification rate of 100%) whereas the prediction of 
an external independent data test set was not optimal (i.e., correct classification rates of 
55.17% and 82.5% depending on the tested formulation). 
Once the suitability of NIR spectroscopy to distinguish between freeze-dried samples 
containing different virus states and virus medium volume was demonstrated, a similar 
evaluation (using the same strategy) was examined for FTIR spectroscopy in chapter 6. FTIR 
spectra collected on freeze-dried samples varying in virus medium volume, pre-freeze-drying 
virus treatment or virus dose were analyzed using PCA. Three spectral regions which might 
provide information on the coated proteins of freeze-dried live, attenuated viruses, being (i) 
1700-1600cm-1 (amide I band), 1600-1500cm-1 (amide II band) and 1200-1350cm-1 (amide III 
band), were evaluated. The amide III spectral range, not influenced by water, was the most 
appropriate one to distinguish between the different virus medium volume, pre-freeze-
drying virus treatment and virus dose samples. 
Taking advantage of the findings of chapters 5 and 6, both process analytical spectroscopic 
techniques (NIR and FTIR) were linked to the results of traditional end product analysis tools 
(chapter 7) in order to better understand freeze-dried live, attenuated virus destabilization 
mechanisms during storage. Freeze-dried samples stored during four weeks at 4°C or at 37°C 
were weekly analyzed by NIR and FTIR spectroscopy as well as potency assay, Karl Fischer 
and modulated differential scanning calorimetry (MDSC).  
Stored at 37°C, the virus titer decreased and the relaxation enthalpy increased according a 
two phase pattern, suggesting a link between mobility and virus destabilization. Evaluation 
of the amide A/II band (NIR spectra) revealed that the destabilization of the virus was 
probably linked to a change in the hydrogen bonds strength between trehalose (the 
stabilizer) and the virus proteins. By studying the amide III band (FTIR spectra), it was found 
that the virus destabilization was coupled to a decrease of β-turn and an increase of α-helix. 
Together, NIR and FTIR spectroscopy showed that the relaxation enthalpy (i.e., the molecular 
mobility) increase upon storage played a role in the stability of the viruses by modifying the 
strength of the hydrogen bonds between the virus coated proteins and the amorphous 
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trehalose used as stabilizer. At 4°C, under conditions specified for long term storage, the 
virus titer remained constant and no relaxation enthalpy was observed.  
The aim of chapter 8 was to develop a model able to classify freeze-dried samples according 
to their dose content based on off-line collected NIR spectra. Three different dose 
presentations (i.e., 125, 50, 25) and a placebo were used and 6 batches were freeze-dried. 
Three batches were used to develop the model (i.e., the calibration set), two batches to test 
the model (i.e., test set) and finally, one batch to evaluate the robustness of the model. Soft 
Independent Modelling of Class Analogy (SIMCA) was applied to classify the four dose 
presentations. Spectral range optimization was performed using Orthogonal Partial Least 
Squares (OPLS) regression analysis. The optimized calibration model was able to classify vials 
of an independent test set with a global correct classification rate of 98.5% (test set Zoe 4). 
The optimized model was also characterized for its specificity, sensitivity and accuracy 
following the EMA guidelines. Finally, the robustness study demonstrated that the 
classification of new vials was sensitive to their residual moisture content. 
In chapter 9, the possibility to predict the titer of a freeze-dried live, attenuated virus 
vaccine formulation using NIR spectroscopy was assessed. A calibration data set existing of 
NIR spectra of freeze-dried 125-dose vials, exposed 0, 9, 16, 23 or 30 days to room 
temperature prior to freeze-drying and resulting in different virus titers, was used as 
calibration set and modeled using orthogonal partial least squares (OPLS) and partial least 
squares (PLS) regression. After spectral range and preprocessing optimization, the model 
was able to predict the titer of new independent freeze-dried 125-dose vials exposed 0, 7 
and 11 days to room temperature with a Root Mean Square Error of Prediction (RMSEP) of 
0.19 log10 CCID50. 
Two different live, attenuated virus species were used during this thesis. Species A, 
formulated in monodose was used in chapters 5, 6 and 7 whereas species B, formulated in 
multidose was used in chapter 6, 8 and 9. 
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SAMENVATTING EN ALGEMENE CONCLUSIE 
 
Vriesdrogen (lyofiliseren) is de methode bij uitstek voor de stabilisatie van levend, verzwakte 
virussen in vaccins. Ondanks hun ruime gebruik in de farmaceutische industrie, gebeurt de 
formulatie- en procesontwikkeling die gepaard gaat met het vriesdrogen van levend, 
verzwakte virussen nog steeds via experimentele trial-and-error, wat leidt tot suboptimale 
processen. De stabilisatie en destabilisatie mechanismen voor levend, verzwakte virussen 
tijdens het vriesdroog proces zijn nog niet volledig ontrafeld. De moleculaire complexiteit 
van levend, verzwakte virussen, de verschillende oorzaken van destabilisatie en het gebrek 
aan analytische technieken voor de detectie van fysicochemische veranderingen in de 
antigen structuur tijdens en na lyofilisatie zijn een gedeeltelijke verklaring voor dit gebrek in 
kennis. Omwille van deze reden werd de toepasbaarheid van spectroscopische proces 
analytische technieken, in het bijzonder NIR en FTIR spectroscopie, onderzocht in het kader 
van (i) de evaluatie van levend, verzwakte virussen en hun interactie met cryo- en 
lyoprotectanten, (ii) het begrijpen van destabilisatie mechanismen van virussen tijdens 
langdurige bewaring en (iii) de ontwikkeling van praktische toepassingen, gebruik makende 
van chemometrische modellen, met als doel het voorspellen van kritische 
kwaliteitsparameters van het eindproduct. 
In hoofdstuk 2 van deze thesis wordt het vriesdroog proces en materiaal uitgebreid 
beschreven. Het vriesdroog proces bestaat uit 3 opeenvolgende fases: invriezen, primair 
drogen en secundair drogen. Tijdens de invriesstap wordt het grootste deel van het water 
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omgevormd naar ijs. Daarna wordt het gevormde ijs verwijderd via sublimatie (primair 
drogen) en uiteindelijk wordt het onbevroren water verwijderd via desorptie (secundair 
drogen). Ondanks de hoge kosten, het enorme energieverbruik en de lange procestijd, is 
vriesdrogen het voorkeursproces voor het stabiliseren van biofarmaceutische producten. 
Hoewel, ondanks het wijde gebruik en de vele jaren onderzoek, zijn de stabilisatie en 
destabilisatie mechanismen van levend, verzwakte virussen, de optimale formulatie 
samenstelling en proces instellingen nog steeds een belangrijk onderzoeksonderwerp. 
Hoofdstuk 3 voorziet een overzicht van de huidige kennis over het vriesdrogen van levende, 
verzwakte virus vaccins. De verschillende stress factoren die gepaard gaan met de 
opeenvolgende processtappen en zowel de beschermingsmechanismen als de verschillende 
strategieën voor stabilisatie, formulatie en proces gerelateerd, tijdens vriesdrogen, worden 
besproken. Tijdens het invriezen zijn er verschillende stress factoren (intravirale ijsvorming, 
osmolariteitsveranderingen, pH wijzing, destabilisatie van mantelproteïnen en/of het 
lipidenmembraan) die de stabiliteit van levend, verzwakte virussen kunnen aantasten. Het 
toevoegen van een geschikt cryoprotectant of het aanpassen van de invriessnelheid zijn de 
twee belangrijkste strategieën die worden toegepast om het virus te beschermen tegen deze 
stress factoren. Informatie gerelateerd aan de destabilisatie mechanismen tijdens de 
droogstappen zijn beperkt. Het lipidenmembraan en de eiwitten hierin ingebed zijn het 
meest gevoelig voor degradatie. Beide kunnen beschermd worden door gebruik te maken 
van lyoprotectanten die het virus stabiliseren volgens de vitrificatie theorie of de 
watervervang theorie. 
Met het oog op het verbeteren van de productkwaliteit en de procesprestaties, wordt de 
farmaceutische industrie aangemoedigd door de regelgevende instanties om QbD en PAT te 
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implementeren in de productieprocessen. Hoofdstuk 4 geeft een samenvatting van het 
QbD/PAT concept en wijdt aandacht aan enkele specifieke overwegingen inzake 
biotechnologische processen en producten. De verschillende PAT technologieën zoals 
Tunable Diode Laser Absorption Spectroscopy (TDLAS), manometrische temperatuur 
metingen (MTM), Temperature Remote Interrogation System (TEMPRIS), thermokoppels en 
spectroscopische technieken, die toelaten kritische proces- en productparameters te 
monitoren tijdens het vriesdrogen, worden besproken, inclusief hun voornaamste voor- en 
nadelen. Tot slot wordt een beschrijving gegeven van de meetprincipes van de 
spectroscopische proces analytische technologieën, aangewend in deze thesis (NIR en FTIR 
spectroscopie). Verschillende studies werden reeds gewijd aan het monitoren van product 
karakteristieken, gebruik makende van beide technologieën en deze worden voorgesteld. 
Monitoring van het residuele vochtgehalte en het gedrag van proteïnen, zowel off-line als in-
line, zijn de voornaamste toepassingen van NIR spectroscopie bij vriesdrogen. FTIR 
spectroscopie daarentegen wordt beschouwd als de methode bij uitstek voor de (off-line) 
analyse van de secundaire structuur van proteïnen. 
In hoofdstuk 5 werd geëvalueerd of NIR spectroscopie in staat is een onderscheid te maken 
tussen verschillende gevriesdroogde levend, verzwakte virus formulaties. NIR spectra van 
gevriesdroogde stalen, bereid uit verschillende virus media volumes of gebruik makende van 
verschillende pre-vriesdroog behandelingen van het virus (resulterend in een verschillende 
staat van het virus) werden opgenomen en geanalyseerd via principale componenten 
analyse (PCA). Dit liet toe een onderscheid te maken tussen de formulaties die varieerden in 
zowel de voorbehandeling van het virus als in het virus media volume. Twee specifieke 
spectrale regio’s droegen bij tot dit onderscheid: (1) 7300-4000 cm-1, die de amide A/II regio 
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bevat en (2) 10 000-7500 en 6340-5500 cm-1, die de eerste en tweede overtoon van CH 
vibraties bevatten. De mogelijkheid tot classificatie van nieuwe stalen volgens de pre-
vriesdroog behandeling van het virus gebruik makende van een partiële kleinste kwadraten 
discriminantanalyse (PLSDA) model werd ook onderzocht. Cross-validatie van het model was 
met een correcte classificatiescore van 100% succesvol, de predictie van een externe 
onafhankelijke data set daarentegen was niet optimaal, met correcte classificatie scores van 
55,17% en 82,5%, afhankelijk van de geteste formulatie. 
Eenmaal de geschiktheid van NIR spectroscopie werd aangetoond om een onderscheid te 
maken tussen gevriesdroogde stalen die verschilden in staat van het virus en virus media 
volume, werd een gelijkaardige evaluatie gebaseerd op dezelfde strategie uitgevoerd voor 
FTIR spectroscopie in hoofdstuk 6. Ook hier werden FTIR spectra van gevriesdroogde stalen, 
bereid uit verschillende virus media volumes, gebruik makende van verschillende pre-
vriesdroog behandelingen van het virus (resulterend in een verschillende staat van het virus) 
of virus dosis opgenomen en geanalyseerd via PCA. Hiertoe werden drie spectrale regio’s 
onderzocht die mogelijk informatie zouden bevatten over de mantelproteïnen van 
gevriesdroogde levend, verzwakte virussen, namelijk (i) 1700-1600 cm-1 (amide I band), 
1600-1500 cm-1 (amide II band) en 1200-1350 cm-1 (amide III band). De amide III spectrale 
regio, vrij van storende water signalen, is de meest geschikte regio om een onderscheid te 
maken tussen de stalen met een verschillend virus media volume, pre-vriesdroog 
behandeling en virus dosis. 
Gebruik makende van de bevindingen uit hoofdstuk 5 en 6, werden beide proces analytische 
spectroscopische technieken (NIR en FTIR) gelinkt aan de resultaten van de traditionele 
analysetechnieken op de kwaliteit van het eindproduct (hoofdstuk 7), met als finaal doel een 
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beter inzicht te krijgen in de destabilisatie mechanismen tijdens de bewaring van 
gevriesdroogde levend, verzwakte virussen. Gevriesdroogde stalen die gedurende 4 weken 
werden bewaard bij 4°C of 37°C, werden wekelijks geanalyseerd via NIR en FTIR 
spectroscopie alsook via virale potentie bepalingen, Karl Fischer en gemoduleerde 
differentiële scanning calorimetrie (MDSC). 
Bij de stalen bewaard bij 37°C nam de virus titer af en nam tegelijkertijd de relaxatie 
enthalpie toe volgens een twee fasen patroon, wat een link suggereert tussen mobiliteit en 
virus destabilisatie. Evaluatie van de amide A/II band in de NIR spectra onthulde dat 
destabilisatie van het virus waarschijnlijk is gelinkt aan een verandering in de kracht van de 
waterstofbindingen tussen trehalose, het protectant, en de mantelproteïnen van het virus. 
Onderzoek van de amide III band in de FTIR spectra duidt erop dat virus destabilisatie gelinkt 
is aan een afname van de β turn conformatie en een toename in α helix. De combinatie van 
NIR en FTIR spectroscopie toont aan dat de toename in relaxatie enthalpie tijdens bewaring, 
gelinkt aan de moleculaire mobiliteit, een rol speelt bij het stabiliseren van virussen door het 
modificeren van de kracht van de waterstofbindingen tussen de virale mantelproteïnen en 
het amorfe protectant, trehalose. Bij 4°C, specifieke condities voor bewaring op lange 
termijn, blijft de virus titer constant en werd er geen enthalpie relaxatie vastgesteld. 
Het doel van hoofdstuk 8 was de ontwikkeling van een model dat toelaat om 
gevriesdroogde stalen te classificeren op basis van hun dosis, gebaseerd op off-line gemeten 
NIR spectra. Drie verschillende doses (125, 50 en 25) en een placebo werden gebruikt en 6 
batches werden gevriesdroogd. Drie van deze batches werden gebruikt voor de ontwikkeling 
van het model, de calibratie set, twee batches dienden om het model te testen, de test set, 
en, tot slot, de laatste batch werd gebruikt ter evaluatie van de robuustheid van het model. 
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Soft Independent Modelling of Class Analogy (SIMCA) werd toegepast ter classificatie van de 
vier verschillende doses. Optimalisatie van de spectrale regio werd bekomen via orthogonale 
partiële kleinste kwadratenregressie analyse (OPLS). Het geoptimaliseerde calibratiemodel 
was in staat om stalen van een onafhankelijke test set te classificeren met een globale 
correcte classificatie score van 98,5% (test set Zoe 4). Daarnaast voldeed het 
geoptimaliseerde model aan de richtlijnen van EMA voor zowel specificiteit, sensitiviteit als 
accuraatheid. Tot slot, de robuustheidstudie toonde aan dat de classificatie van nieuwe 
stalen gevoelig is voor hun residuele vochtgehalte. 
In hoofdstuk 9 werd de mogelijkheid onderzocht om de titer te voorspellen van 
gevriesdroogde levend, verzwakte virus vaccin formulaties via NIR spectroscopie. NIR spectra 
werden opgenomen van gevriesdroogde stalen (125 doses), die alvorens het vriesdrogen 
werden blootgesteld aan kamertemperatuur voor  0, 9, 16, 23 of 30 dagen, wat uiteindelijk 
resulteerde in verschillende virus titers. Deze NIR spectra fungeerden als calibratie set en 
werden gemodelleerd via orthogonale partiële kleinste kwadratenregressie (OPLS) en 
partiële kleinste kwadratenregressie (PLS). Na optimalisatie van de spectrale regio en 
preprocessing van de spectra, was het model in staat om de titer te voorspellen van nieuwe, 
onafhankelijke gevriesdroogde stalen (125 doses) die gedurende 0, 3 of 7 dagen werden 
blootgesteld aan kamertemperatuur met een gemiddelde kwadratische fout op de 
voorspelling (RMSEP) van 0,19. 
Tijdens deze thesis werd met twee verschillende levend, verzwakte virussoorten gewerkt. 
Soort A, geformuleerd als monodosis vaccin, werd gebruikt in het kader van hoofdstuk 5, 6 
en 7, soort B, geformuleerd als multidoses, werd gebruikt in het kader van hoofdstuk 6, 8 en 
9. 
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BROADER INTERNATIONAL CONTEXT, 
RELEVANCE, AND FUTURE PERSPECTIVES 
 
The general aim of this thesis was to evaluate the potential of spectroscopic tools as process 
analytical techniques for the evaluation of live, attenuated viruses in freeze-dried vaccine 
formulations.  
The specific objectives of this thesis are listed below: 
 Find out if process analytical techniques can be used to evaluate (and hence 
understand) live, attenuated viruses and their interactions with other compounds 
(i.e., stabilizers), in freeze-dried vaccine formulations;  
 Using process analytical techniques, increase the understanding of virus 
destabilization mechanisms during processing and storage; 
 Develop and validate chemometric models allowing the prediction of the (or some) 
end product quality attributes of live, attenuated virus vaccines from fast 
spectroscopic at-line measurements making some traditional time-consuming off-line 
end product analyses superfluous. 
 
Three important topics are addressed and confer this thesis an international dimension as 
well as evaluating and providing new opportunities for the pharmaceutical industry: (i) 
vaccines (biopharmaceuticals), (ii) freeze-drying and (iii) Process Analytical Technology (PAT).   
 
BROADER INTERNATIONAL CONTEXT 
Biopharmaceuticals are considered the key driver of future growth in the pharmaceutical 
industry [1]. Influential biopharmaceutical companies predict a compound annual growth 
rate of 4.4% for biopharmaceutical products as contrasted to small-molecule products with a 
growth rate below 1% [2].  
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Coming from $33 billion sales in 2005, to $82 billion in 2010 and $109 billion in 2012, IMARC 
(International Market Analysis Research and Consulting) expects the global 
biopharmaceutical market to exceed sales worth $166 billion by 2017. The market is 
currently dominated by monoclonal antibodies (50%), followed by recombinant proteins and 
vaccines. 
The freeze-drying process has become a well-established and preferred stabilization 
technique for biopharmaceuticals since approximately 46% of the biopharmaceuticals that 
are currently on the market are freeze-dried (Figure. 11.1) [3].  
 
Figure 11.1:  FDA-approved biopharmaceuticals grouped according to dosage form. The category 
denoted “other” includes frozen solution, oral forms (tablets and capsules), depots, gels and 
emulsions. Adapted from [3]. 
 
As mentioned in chapter 3, except the oral polio vaccine (OPV) which is stable in aqueous 
solution, all live virus vaccines are freeze-dried, emphasizing the importance of this process 
for the worldwide health.  However, the frequent use of freeze-drying does not mean that 
the processes are optimized. Despite the numerous studies performed, the destabilization 
mechanisms as well as the optimal protection strategies during lyophilization and storage 
are still not well known. The lack of knowledge about the virus destabilization mechanisms is 
attributed to the complex structure of viruses, the multiple degradation routes and the lack 
of analytical techniques allowing the measurement of physicochemical changes in the 
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antigen’s structure during and after freeze-drying. Quality is generally assessed by off-line 
time-consuming and less efficient laboratory testing which do not provide direct information 
to elucidate the mechanisms of destabilization and inactivation of viruses.  
Therefore, in order to better understand the virus destabilization mechanisms and 
consequently improve the formulations and processes, analytical techniques that are able to 
monitor the product behaviour are needed.  
Furthermore, the world of pharmaceutical freeze-drying is entering a new phase and is 
facing new challenges [4]. Indeed, the spectrum of pharmaceutical applications 
manufactured by lyophilization has broadened (e.g., nanoparticles, poorly soluble new 
chemical entities (NCE) or gene delivery systems) allowing for valuable pharmaceutical 
improvements but also resulting in more complex freeze-dried products. In order to develop 
optimized formulations and freeze-drying processes, a fundamental understanding of the 
stabilization mechanisms during the process and during storage is required.  
In addition to the development of new types of drugs (which will result in more complex and 
more challenging freeze-dried products), medicines will also become more personalized, 
requiring more flexible manufacturing processes [5]. Offering the possibility to steer and 
control each vial individually, continuous freeze-drying is a possible solution to meet the 
manufacturing flexibility requirement for personalized medicines.  
Conventional batch-wise freeze-drying suffers from some important inherent disadvantages 
such as:  
 High production cost (high energy consumption, large area of space which is very 
expensive in terms of capital investment and operational/maintenance/exploitation 
costs) [6]; 
 Time consuming and labour intensive setup (the process needs to be optimized and 
validated first at lab-scale, followed by pilot-scale and finally at production scale);  
 End product quality variability (uneven heat transfer in the freeze-drying chamber 
and uncontrolled freezing step at the vial level result in different freeze-drying 
process conditions in each vial, which might lead to uncontrolled vial-to-vial and 
batch-to-batch end product variability [7]); 
 Lack of flexibility (only large batches can be produced); 
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 Slow and hence time-consuming and expensive process (the whole cycle may last 1 
to 7 days (and even more) depending on the product properties and the dimensions 
of the vials). 
 
To overcome these disadvantages, a continuous freeze-drying concept [8] is developed and 
evaluated at the laboratory of Process Analytical Technology where this thesis research was 
performed.  Real-time quality evaluation and control of each freeze-dried vial, using in-line 
process analyzers, is crucial for the successful implementation of continuous freeze-drying. 
Therefore, process analytical methodologies have to be developed allowing the continuous 
monitoring and control of the critical process and product aspects. Furthermore, in-process 
measurement techniques are needed allowing the visualization and hence understanding of 
the formulation behaviour during processing (e.g., monitor the influence of the process 
conditions on the freeze-dried product, visualize the protection ability of stabilizers during 
processing). 
Driven by the needs of the biopharmaceutical industry, the improvement of process 
understanding and control as well as the introduction of novel lyophilisation equipment will 
be subjected to more investigation in the coming years. Several process monitoring 
technologies have been developed for freeze-drying offering the possibility to improve 
process understanding and control. Especially since the introduction of the Quality by Design 
(QbD) and PAT concepts, launched by the regulatory authorities (FDA and EMA).  
In conclusion, pharmaceutical freeze-drying is starting a new chapter with new challenges 
but also with new opportunities to “build quality into (new) products”, one of the most 
important statements of the PAT concept. 
More modestly, this thesis was performed under a close collaboration between Ghent 
University and Zoetis. Formerly Pfizer Animal Health, Zoetis is an international company 
which provides animal health products that prevent and treat diseases in livestock and 
companion animals. Throughout this thesis, the progresses, the obtained results, the 
experiments to be performed and the remaining challenges were discussed every three 
months with Belgian Zoetis colleagues as well as colleagues located at different Zoetis sites 
in the world.  
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RELEVANCE 
Because of the current emphasis on QbD and PAT by the regulatory authorities and the 
increased complexity of freeze-dried products, it is needed to leave the traditional way of 
pharmaceutical freeze-drying and to move towards a risk- and science-based approach of 
freeze-drying process development. 
Mainly product behaviour during freeze-drying is uncomprehended, and is partly due to the 
lack of analytical techniques. Experimental simulations of the in-process product behaviour 
are currently mainly done via differential scanning calorimetry (DSC) and freeze-drying 
microscopy measurements. However, these measurements do not fully represent the real 
process environment and do not reflect all relevant product quality attributes.  
Spectroscopic tools such as NIR and FTIR spectroscopy evaluated in this thesis have gained 
attention as PAT tools in the pharmaceutical industry. Their combination represents a 
valuable tool to enhance lyophilization process understanding and efficiency, study 
formulation behaviour, reduce batch losses, reduce the time and costs for process 
development, reduce the product variability and decrease the time for product release. The 
freeze-drying process is very time-consuming and complex, and constitutes an important 
factor on the product cost. Especially, within animal health, where the margins on products 
are small and therefore any improvement on the cost of goods is crucial to compete in the 
market. Around 50 % of the veterinary vaccines within Zoetis are based on live attenuated 
virus strains and therefore an improvement in the freeze-drying process can have huge 
consequences for all these vaccines. The most important parameters for improvements are 
the yields of the antigen(s) after the freeze-drying process, the process time and the stability 
of the lyophilized product. Significant competitive advantages in the market can be obtained 
by improving these parameters.  
The enumeration below summarizes the most important new findings brought by this thesis: 
1. NIR and FTIR spectroscopy can be used as analytical techniques to evaluate viruses in 
freeze-dried vaccine formulations. The implementation of PAT tools, as stimulated by 
the regulatory bodies (FDA and EMA), to monitor the product behaviour might 
increase the process understanding and knowledge.  
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2. The virus behaviour and its interactions with a stabilizer during storage were studied. 
The obtained results can be used in order to improve the formulations and the 
process (improved yield and better stability).  
 
3. NIR and FTIR spectroscopy analysis of the freeze-dried product might make some 
traditional time-consuming off-line end product analysis superfluous (time gain, 
faster release). The presented applications in this thesis demonstrated that NIR and 
FTIR spectroscopy might be used as fast screening tools at the end of the freeze-
drying process. 
 
FUTURE PERSPECTIVES 
The aim of this thesis was to evaluate the potential of spectroscopic tools as process 
analytical techniques for the evaluation of live, attenuated viruses in freeze-dried vaccine 
formulations. The obtained results pave the way for new investigations and offer new 
interesting perspectives but also highlight the shortcomings of the investigated analytical 
techniques and the need of improvements in order to be able to answer the coming 
challenges. 
The most important needed improvements are listed below: 
 Better detection sensitivity in order to:  
o in-line monitor the virus behaviour during freeze-drying 
o increase knowledge of the virus destabilization mechanisms during processing 
and storage  
o evaluate more complex vaccine products (e.g., containing more than one 
antigen) 
More sensitive new techniques such as; Raman optical activity (ROA), terahertz and 
fluorescence suppression Raman spectroscopy offer new opportunities to address these 
challenges and should be evaluated in the future. 
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 Development of new reference methods for virus characterization in order to: 
o compare the obtained spectra with better reference method than the 
potency assay (e.g., flow cytometry might be able to evaluate virus antigen 
fractions in bulks and lyophilized products and is currently under investigation 
at Zoetis) 
 
However, the possibility to evaluate viruses off-line with NIR and FTIR spectroscopy already 
offers new opportunities listed below: 
 Follow up the accelerated stability study and improve the product stability by: 
o performing an annealing step during secondary drying (i.e., increase the 
product temperature 15 to 20°C below Tg for a short period of time (from 5h 
to 20h depending on the formulation)) in order to achieve the lowest possible 
mobility. Different annealing conditions might be tested (i.e., annealing time 
and temperature) 
o screen new stabilizers by focusing on their mobility properties 
 Implementation of the spectroscopic dose classification application at industrial scale 
 Follow up of the titer prediction preliminary study by: 
o including more batches in the calibration model 
o perform robustness study of the calibration model 
o validate the calibration model using accuracy profiles  
 Evaluation of other virus species (i.e., other vaccine products) 
 Evaluation of the possibility to use NIR and FTIR spectroscopy to evaluate viruses at 
other steps of the vaccine production process 
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